METTL3 inhibitors, compositions and their pharmaceutical applications

Abstract

The present invention relates to compounds according to general formula (I) or their stereoisomers, tautomers, deuterated forms, solvates, prodrugs, metabolites, pharma- ceutically acceptable salts or co-crystals, intermediates thereof, and uses in METTL3-related diseases such as cancer. [Formula 1] TIFF2025505238000128.tif37160

Description

[Technical field]

[0001] The present invention relates to compounds according to general formula (I) or their stereoisomers, tautomers, deuterated forms, solvates, prodrugs, metabolites, pharma-ceutically acceptable salts or co-crystals, intermediates thereof, and uses in METTL3 enzyme-associated diseases such as cancer. [Background technology]

[0002] m6A methylation of mRNA affects almost every aspect of RNA metabolism, including RNA expression, splicing, nuclear export, translation, decay, and RNA-protein interactions, and plays an important role in tumor development and progression, affecting the functions of different proteins and exerting different effects in different cancer types.

[0003] METTL3 is one of the M6A methyltransferases, and forms a complex with METTL14 and WTAP to methylate mRNA, affect protein translation, and deposit m6A modification on key transcripts, thereby promoting the development and progression of various cancers (including hematopoietic malignancies and solid tumors). METTL3 can promote the growth of tumor cells in AML, breast cancer, and HCC. Inhibition of METTL3 is expected to achieve tumor suppression by regulating mRNA methylation.

[0004] AML is characterized by the aggregation of immature myeloid cells in the bone marrow and inhibition of myelopoiesis. CMPD, a chronic myeloproliferative disorder, is often associated with an increased number of undifferentiated myeloid cells, a hyperproliferative bone marrow picture, and an increase in peripheral blood cells. In the United States, the age-adjusted incidence of AML is 3.4 / 100,000, resulting in approximately 10,000 deaths per year. AML accounts for approximately 15%-20% of acute leukemias in children and adolescents and approximately 85% of adult cases. The incidence of AML increases with age, and most patients develop the disease at age 60 or older, with a median age at diagnosis of 67 years. The development of METTL3 inhibitors that can treat AML has important clinical implications. Summary of the Invention [Problem to be solved by the invention]

[0005] The object of the present invention is to provide a compound according to general formula (I) or its stereoisomers, tautomers, deuterated products, solvates, prodrugs, metabolites, pharma- ceutically acceptable salts or cocrystals, intermediates and processes for the preparation thereof, and their application in the manufacture of medicines for the treatment of diseases associated with the activity or expression level of METTL3 enzyme. [Means for solving the problem]

[0006] The compounds of the present invention have good pharmacokinetic properties and bioavailability, oral profile and good safety profile.

[0007] The present invention provides a compound or a stereoisomer, tautomer, deuteride, solvate, prodrug, metabolite, pharma- ceutically acceptable salt, or co-crystal thereof, the compound being selected from compounds represented by general formula (I), wherein: [ka] In some embodiments, the compound of general formula (I) is selected from compounds of general formula (II): [ka] In some embodiments, the compound of general formula (I) is selected from compounds of general formula (III): [ka] In some embodiments, the compound of general formula (II) is selected from compounds of general formula (II-1): [ka] In some embodiments, the compound of general formula (II) is selected from compounds of general formula (II-2): [ka] In some embodiments, ring A is [ka] is selected from In some embodiments, ring A is [ka] is selected from In some embodiments, R an , H, C 1-6 Alkyl group, C 3-12 a carbocyclic group or a 3- to 12-membered heterocyclic group, the alkyl group, the carbocyclic group or the heterocyclic group being optionally selected from H, halogen, OH, =O, a cyano group, NH 2 , C 1-6 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, -C 2-4 Alkynyl-C 3-6 Cycloalkyl groups, halogen-substituted C 1-6 C substituted with alkyl or hydroxy groups 1-6 C substituted with alkyl or cyano groups 1-6 Alkyl group, C 1-6 Alkoxy group, C 3-12 It is further substituted with 0 to 4 substituents selected from a cycloalkyl group, a phenyl group, a 3- to 12-membered heterocycloalkyl group, or a 5- to 12-membered heteroaryl group, and the heterocyclic group, heterocycloalkyl group, or heteroaryl group contains 1 to 3 heteroatoms selected from O, S, and N; In some embodiments, R an , H, C 1-4 Alkyl group, C 3-6 cycloalkyl group, 3- to 6-membered heterocycloalkyl group, wherein the alkyl group, cycloalkyl group or heterocycloalkyl group is optionally selected from H, halogen, OH, =O, cyano group, NH 2 , C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, -C 2-4 Alkynyl-C 3-6Cycloalkyl groups, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group, C 3-6 It is further substituted with 0 to 4 substituents selected from a cycloalkyl group, a phenyl group, a 3- to 6-membered heterocycloalkyl group, or a 5- to 6-membered heteroaryl group, and the heterocycloalkyl group or heteroaryl group contains 1 to 3 heteroatoms selected from O, S, and N; In some embodiments, R an is selected from H, methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclohexyl, cyclopentyl, cyclobutyl, oxetanyl, oxacyclopentyl, oxacyclohexyl, azetidinyl, azacyclopentyl, piperidinyl or piperazinyl, and the methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclohexyl, cyclopentyl, cyclobutyl, oxetanyl, oxacyclopentyl, oxacyclohexyl, azetidinyl, azacyclopentyl, piperidinyl or piperazinyl group is optionally selected from H, F, Cl, Br, I, OH, =O, cyano, NH 2 , C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, -C 2-4 Alkynyl-C 3-6 Cycloalkyl groups, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group, C 3-6 It is further substituted with 0 to 4 substituents selected from a cycloalkyl group, a phenyl group, a 3- to 6-membered heterocycloalkyl group, or a 5- to 6-membered heteroaryl group, and the heterocycloalkyl group or heteroaryl group contains 1 to 3 heteroatoms selected from O, S, and N; In some embodiments, Ran is selected from H, methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, oxacyclopentyl or oxacyclohexyl, and said methyl, ethyl, propyl, isopropyl, cyclopropyl, oxetanyl, oxacyclopentyl or oxacyclohexyl groups are optionally selected from H, F, Cl, Br, I, OH, ═O, cyano, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, -C 2-4 Alkynyl-C 3-6 Cycloalkyl, hydroxyl-substituted C 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group, C 3-6 It is further substituted with 0 to 4 substituents selected from a cycloalkyl group, a phenyl group, a 3- to 6-membered heterocycloalkyl group, or a 5- to 6-membered heteroaryl group, and the heterocycloalkyl group or heteroaryl group contains 1 to 3 heteroatoms selected from O, S, and N; In some embodiments, R an is selected from H, methyl, ethyl, propyl, isopropyl, cyclopropyl, oxetanyl, oxacyclopentyl or oxacyclohexyl, and the methyl, ethyl, propyl, isopropyl, cyclopropyl, oxetanyl, oxacyclopentyl or oxacyclohexyl groups are optionally selected from H, F, Cl, Br, I, OH, ═O, cyano, NH 2 , methyl group, ethyl group, propyl group, isopropyl group, vinyl group, 1-propenyl group, 2-propenyl group, ethynyl group, 1-propynyl group, 2-propynyl group, [ka] is further substituted with 0 to 4 substituents selected from a cyclopropyl group, a methoxy group, an ethoxy group, and a phenyl group; In some embodiments, R an is H, methyl, ethyl, propyl, isopropyl, cyclopropyl, [ka] is selected from In some embodiments, R an is H, a methyl group, an ethyl group, a propyl group, an isopropyl group, a cyclopropyl group, or [ka] is selected from In some embodiments, Ring B is selected from a 5-10 membered heterocyclic group, the heterocyclic group containing 1-5 heteroatoms selected from O, S, and N; In some embodiments, Ring B is selected from a 5,5-membered biheteroaryl group, a 5,6-membered biheteroaryl group, or a 6,6-membered biheteroaryl group, wherein the heteroaryl group contains 1 to 5 heteroatoms selected from O, S, and N; In some embodiments, Ring B is selected from a pyrrolopyrrolyl group, a pyrrolopyrazolyl group, a pyrroloimidazolyl group, a pyrazolopyrazolyl group, a pyrazoloimidazolyl group, an imidazoimidazolyl group, a benzopyrrolyl group, a benzopyrazolyl group, a benzimidazolyl group, a pyridopyrrolyl group, a pyridopyrazolyl group, a pyridoimidazolyl group, a pyrimidopyrrolyl group, a pyrimidopyrazolyl group, a pyrimidopyrazolyl group, a pyrimidopyrazolyl group, a pyrimidopyrazolyl group, a pyrimidopyrazolyl group, a pyrimidopyrazinyl group, a pyrazinopyrrolyl group, a pyrazinopyrazolyl group, a pyrazinoimidazolyl group, a pyridazinopyrrolyl group, a pyridazinopyrazolyl group, a pyridazinoimidazolyl group, a benzopyridyl group, a benzopyrimidinyl group, a benzopyrazinyl group, a benzopyridazinyl group, a pyridopyridyl group, a pyridopyrimidinyl group, a pyridopyrazinyl group, or a pyridopyridazinyl group; In some embodiments, Ring B is selected from a benzopyrrolyl group, a benzopyrazolyl group, a benzimidazolyl group, a pyridopyrrolyl group, a pyridopyrazolyl group, a pyridoimidazolyl group, a pyrimidopyrrolyl group, a pyrimidopyrazolyl group, a pyrimidoimidazolyl group, a pyrazinopyrrolyl group, a pyrazinopyrazolyl group, a pyrazinoimidazolyl group, a pyridazinopyrrolyl group, a pyridazinopyrazolyl group, a pyridazinoimidazolyl group; In some embodiments, Ring B is selected from a benzopyrrolyl group; In some embodiments, Ring B is selected from a thienopyrrolyl group; In some embodiments, L is [ka] or a 5- to 6-membered heteroaryl group, the left side of L being connected to ring A, the heteroaryl group being optionally selected from H, halogen, OH, a cyano group, NH 2 , C 1-6 Alkyl, halogen-substituted C 1-6 C substituted with alkyl or hydroxy groups 1-6 C substituted with alkyl or cyano groups 1-6 Alkyl group, C 1-6 is further substituted with 0 to 3 substituents selected from an alkoxy group, the heteroaryl group containing 1 to 3 heteroatoms selected from O, S and N; In some embodiments, L is [ka] or a 5-membered heteroaryl group, the left side of L being connected to ring A, said heteroaryl group being optionally selected from H, halogen, OH, a cyano group, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4is further substituted with 0 to 2 substituents selected from an alkoxy group, the heteroaryl group containing 1 to 3 heteroatoms selected from O, S and N; In some embodiments, L is [ka] is selected from an oxazolyl group, a thiazolyl group, a thienyl group, a furyl group, a pyrrolyl group, a pyrazolyl group, a triazolyl group, or an imidazolyl group, and the left side of L is connected to ring A, and the oxazolyl group, the thiazolyl group, the thienyl group, the furyl group, the pyrrolyl group, the pyrazolyl group, the triazolyl group, or the imidazolyl group is optionally selected from H, F, Cl, Br, I, OH, a cyano group, NH 2 , further substituted with 0 to 2 substituents selected from a methyl group, an ethyl group, a propyl group, an isopropyl group, a methoxy group, and an ethoxy group; In some embodiments, L is [ka] and its left side is connected to ring A; In some embodiments, R 1 , H, C 1-6 Alkyl group or C 3-6 cycloalkyl groups, said alkyl or cycloalkyl groups being optionally selected from H, halogen, OH, =O, cyano, NH 2 , C 1-6 Alkyl, halogen-substituted C 1-6 C substituted with alkyl or hydroxy groups 1-6 C substituted with alkyl or cyano groups 1-6 Alkyl group, C 1-6 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; In some embodiments, R 1 , H, C 1-4 Alkyl group or C 3-6 cycloalkyl groups, said alkyl or cycloalkyl groups being optionally selected from H, halogen, OH, =O, cyano, NH2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; In some embodiments, R 1 is selected from H, a methyl group, an ethyl group, a propyl group, an isopropyl group or a cyclopropyl group, and the methyl group, the ethyl group, the propyl group, the isopropyl group or the cyclopropyl group is optionally selected from H, F, Cl, Br, I, OH, ═O, a cyano group, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; In some embodiments, R 1 is selected from H, a methyl group, an ethyl group, a propyl group, an isopropyl group or a cyclopropyl group, and the methyl group, the ethyl group, the propyl group, the isopropyl group or the cyclopropyl group is optionally selected from H, F, Cl, Br, I, OH, ═O, a cyano group, NH 2 , further substituted by 0 to 4 substituents selected from a methyl group, an ethyl group, a propyl group, an isopropyl group, a methoxy group, an ethoxy group, or a cyclopropyl group; In some embodiments, R 1 is selected from H, a methyl group, an ethyl group, a propyl group, and an isopropyl group; In some embodiments, R 1 is selected from H, In some embodiments, R a or R b are each independently H, a halogen, a cyano group, OH, =O, or C 1-6Alkyl group, C 1-6 Alkoxy group, C 3-6 cycloalkyl groups, said alkyl, alkoxy or cycloalkyl groups being optionally selected from H, halogen, OH, =O, cyano, NH 2 , C 1-6 Alkyl, halogen-substituted C 1-6 C substituted with alkyl or hydroxy groups 1-6 C substituted with alkyl or cyano groups 1-6 Alkyl group, C 1-6 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; In some embodiments, R a or R b are each independently H, a halogen, a cyano group, OH, =O, or C 1-4 Alkyl group, C 1-4 Alkoxy group, C 3-6 cycloalkyl groups, said alkyl, alkoxy or cycloalkyl groups being optionally selected from H, halogen, OH, =O, cyano, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; In some embodiments, R a or R bare each independently selected from H, F, Cl, Br, I, cyano, OH, =O, methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclohexyl, cyclopentyl, cyclobutyl, azetidinyl, azacyclopentyl, azacyclohexyl, piperidinyl, methoxy or ethoxy, and the methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclohexyl, cyclopentyl, cyclobutyl, azetidinyl, azacyclopentyl, azacyclohexyl, piperidinyl, methoxy or ethoxy groups are optionally selected from H, F, Cl, Br, I, OH, =O, cyano, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; In some embodiments, R a or R b are each independently selected from H, F, Cl, Br, I, cyano, OH, =O, methyl, ethyl, propyl, isopropyl, and cyclopropyl, and the methyl, ethyl, propyl, isopropyl, or cyclopropyl groups are optionally selected from H, F, Cl, Br, I, OH, =O, cyano, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; In some embodiments, R a or R b are each independently H, F, Cl, Br, I, a cyano group, OH, =O, or CF 3, a methyl group, an ethyl group, a propyl group, an isopropyl group, a cyclopropyl group; In some embodiments, R a or R b are each independently selected from H, F, Cl, Br, I, cyano, OH, =O, methyl, ethyl, propyl, isopropyl, and cyclopropyl; In some embodiments, R an and R a form a 5-6 membered heterocycle together with the carbon atom to which they are bonded, said heterocycle optionally being selected from the group consisting of H, halogen, OH, =O, cyano, NH 2 , C 1-6 Alkyl, halogen-substituted C 1-6 C substituted with alkyl or hydroxy groups 1-6 C substituted with alkyl or cyano groups 1-6 Alkyl group, C 1-6 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group, and the heterocycle contains 1 to 3 heteroatoms selected from O, S, and N; In some embodiments, R an and R a form a 5-6 membered heteroaromatic ring together with the carbon atom to which they are attached, said heteroaromatic ring optionally being substituted with H, halogen, OH, =O, a cyano group, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group, the heteroaryl group containing 1 to 3 heteroatoms selected from O, S and N; In some embodiments, R an and R atogether with the carbon atoms bonded thereto form a pyridine, pyrimidine, pyridazine or pyrazine ring, said pyridine, pyrimidine or pyrazine ring optionally being selected from the group consisting of H, F, Cl, Br, I, OH, ═O, a cyano group, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; In some embodiments, R an and R a form a pyridine ring together with the carbon atoms attached thereto, said pyridine ring optionally being selected from the group consisting of H, F, Cl, Br, I, OH, ═O, a cyano group, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; In some embodiments, R an and R a form a pyridine ring together with the carbon atom to which they are attached, In some embodiments, [ka] teeth, [ka] is selected from In some embodiments, R 2a , R 2b , R 3a , R 3b are each independently H, a halogen, a cyano group, OH, =O, or C1-6 Alkyl group, C 1-6 Alkoxy group or C 3-6 cycloalkyl groups, said alkyl, alkoxy or cycloalkyl groups being optionally selected from H, halogen, OH, =O, cyano, NH 2 , C 1-6 Alkyl, halogen-substituted C 1-6 C substituted with alkyl or hydroxy groups 1-6 C substituted with alkyl or cyano groups 1-6 Alkyl group, C 1-6 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; In some embodiments, R 2a , R 2b , R 3a , R 3b are each independently H, a halogen, a cyano group, OH, =O, or C 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 cycloalkyl groups, said alkyl, alkoxy or cycloalkyl groups being optionally selected from H, halogen, OH, =O, cyano, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; In some embodiments, R 2a , R 2b , R 3a , R 3b are each independently selected from H, F, Cl, Br, I, cyano, OH, =O, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy or cyclopropyl, and the methyl, ethyl, propyl, isopropyl, methoxy, ethoxy or cyclopropyl groups are optionally selected from H, F, Cl, Br, I, OH, =O, cyano, NH2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; In some embodiments, R 2a , R 2b , R 3a , R 3b are each independently selected from H, F, Cl, Br, I, cyano, OH, =O, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy or cyclopropyl, and the methyl, ethyl, propyl, isopropyl, methoxy, ethoxy or cyclopropyl groups are optionally selected from H, F, Cl, Br, I, OH, =O, cyano, NH 2 , further substituted by 0 to 4 substituents selected from a methyl group, an ethyl group, a propyl group, an isopropyl group, a methoxy group, an ethoxy group, or a cyclopropyl group; In some embodiments, R 2a , R 2b , R 3a , R 3b are each independently selected from H, F, Cl, Br, I, cyano, OH, =O, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, or cyclopropyl; In some embodiments, R 2a , R 2b , R 3a , R 3b are each independently selected from H; In some embodiments, R 2a and R 2b , R 3a and R 3b are each C along with the carbon atom attached to them. 3-6 A carbocyclic group or a 3- to 6-membered heterocyclic group is formed, and the carbocyclic group or the heterocyclic group may optionally be H, a halogen atom, OH, =O, a cyano group, NH2 , C 1-6 Alkyl, halogen-substituted C 1-6 C substituted with alkyl or hydroxy groups 1-6 C substituted with alkyl or cyano groups 1-6 Alkyl group, C 1-6 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group, the heterocyclic group containing 1 to 3 heteroatoms selected from O, S and N; In some embodiments, R 2a and R 2b , R 3a and R 3b form, together with the carbon atom to which they are attached, a cyclopropyl group or a cyclohexyl group, In some embodiments, R cn1 , R cn2 are each independently H, a halogen, a cyano group, OH, =O, or C 1-6 Alkyl group, C 1-6 Alkoxy group, C 3-10 A carbocyclic group, a 3- to 10-membered heterocyclic group, or [ka] wherein the alkyl, alkoxy, carbocyclic or heterocyclic group is optionally selected from H, halogen, OH, ═O, cyano, NH 2 , C 1-6 Alkyl, halogen-substituted C 1-6 C substituted with alkyl or hydroxy groups 1-6 C substituted with alkyl or cyano groups 1-6 Alkyl group, C 1-6 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group, the heterocyclic group containing 1 to 3 heteroatoms selected from O, S and N; In some embodiments, R cn1 , R cn2 are each independently H, a halogen, a cyano group, OH, =O, or C 1-4 Alkyl group, C 1-4Alkoxy group, C 3-10 Cycloalkyl group, 3-10 membered heterocycloalkyl group, or [ka] wherein the alkyl, alkoxy, cycloalkyl or heterocycloalkyl group is optionally selected from H, halogen, OH, ═O, cyano, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group, said heterocycloalkyl group containing 1 to 3 heteroatoms selected from O, S and N; In some embodiments, R cn1 , R cn2 each independently represents H, F, Cl, Br, I, a cyano group, OH, =O, a methyl group, an ethyl group, a propyl group, an isopropyl group, a cyclopropyl group, a cyclohexyl group, a cyclopentyl group, a cyclobutyl group, an azetidinyl group, an azacyclopentyl group, an azacyclohexyl group, or [ka] wherein the methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclohexyl, cyclopentyl, cyclobutyl, azetidinyl, azacyclopentyl, and azacyclohexyl groups are optionally selected from the group consisting of H, F, Cl, Br, I, OH, ═O, cyano, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; In some embodiments, R cn1 , R cn2 each independently represents H, F, Cl, Br, I, a cyano group, OH, =O, a methyl group, an ethyl group, a propyl group, an isopropyl group, a cyclopropyl group, a cyclohexyl group, a cyclopentyl group, a cyclobutyl group, or [ka] wherein the methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclohexyl, cyclopentyl, and cyclobutyl groups are optionally selected from H, F, Cl, Br, I, OH, ═O, cyano, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; In some embodiments, R cn1 , R cn2 each independently represents H, a methyl group, an ethyl group, a propyl group, an isopropyl group, a cyclopropyl group, a cyclohexyl group, a cyclopentyl group, a cyclobutyl group, or [ka] wherein the methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclohexyl, cyclopentyl, and cyclobutyl groups are optionally selected from H, F, Cl, Br, I, OH, ═O, cyano, NH 2 , C.F. 3 , further substituted by 0 to 4 substituents selected from a methyl group, an ethyl group, a propyl group, an isopropyl group, a cyclopropyl group, a methoxy group, or an ethoxy group; In some embodiments, ring C is C 3-12a carbocyclic group or a 3- to 12-membered heterocyclic group, the heterocyclic group containing 1 to 3 heteroatoms selected from O, S and N; In some embodiments, ring C is C 3-7 Monocycloalkyl groups, C 4-11 Fused cycloalkyl groups, C 5~11 C-membered spirocycloalkyl group 5-12 is selected from a bridged cycloalkyl group, a 4- to 7-membered monoheterocycloalkyl group, a 4- to 11-membered fused heterocycloalkyl group, a 5- to 11-membered spiroheterocycloalkyl group, or a 5- to 12-membered bridged heterocycloalkyl group, wherein the heterocycloalkyl group contains 1 to 3 heteroatoms selected from O, S, and N; In some embodiments, Ring C1 is a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, an oxetanyl group, an oxacyclopentyl group, an oxacyclohexyl group, an azetidinyl group, an azacyclopentyl group, a piperidine, a morpholine, a piperazine, a 1,4-diazepanyl group, a cyclopropyl-fused cyclopentyl, a cyclopentyl-fused cyclobutyl, a cyclopentyl-fused cyclopentyl, a cyclopentyl-fused cyclohexyl, a cyclopropyl-spiro-cyclopentyl, a cyclobutyl-spiro-cyclobutyl, a cyclobutyl-spiro-cyclobutyl, a cyclobutyl-spiro-cyclobutyl, a cyclobutyl-spiro-cyclobutyl, a cyclobutyl-spiro-cyclobutyl, a cyclobutyl-spiro-cyclopentyl ...pentyl-spiro-cyclopentyl, a cyclopentyl-spiro-cyclopentyl, a cyclopentyl-spiro-cyclopentyl, a cyclopentyl-spiro-cyclopentyl, a cyclo pyro-cyclopentyl, cyclopentyl-spiro-cyclopentyl, cyclopentyl-spiro-cyclohexyl, cyclohexyl-spiro-cyclohexyl, cyclopropyl-fused azetidinyl, cyclopropyl-fused azacyclopentyl, cyclopropyl-fused azacyclohexyl, cyclobutyl-fused azetidinyl, cyclobutyl-fused azacyclopentyl, cyclobutyl-fused azacyclohexyl, cyclopentyl-fused azetidinyl, cyclopentyl-fused azacyclopentyl, cyclopentyl-fused azacyclohexyl, cyclohexyl-fused azetidinyl, cyclo hexyl-fused azacyclopentyl, cyclohexyl-fused azacyclohexyl, azetidinyl-fused azetidinyl, azetidinyl-fused azacyclopentyl, azetidinyl-fused azacyclohexyl, azacyclopentyl-fused azetidinyl, azacyclopentyl-fused azacyclopentyl, azacyclopentyl-fused azacyclohexyl, azacyclohexyl-fused azetidinyl, azacyclohexyl-fused azacyclopentyl, azacyclohexyl-fused azacyclohexyl, cyclobutyl-spiro-azetidinyl, cyclobutyl-spiro-azacyclopentyl, cyclo butyl-spiro-azacyclohexyl, cyclopentyl-spiro-azetidinyl, cyclopentyl-spiro-azacyclopentyl, cyclopentyl-spiro-azacyclohexyl, cyclohexyl-spiro-azetidinyl, cyclohexyl-spiro-azacyclopentyl, cyclohexyl-spiro-azacyclohexyl, azetidinyl-spiro-azetidinyl, azetidinyl-spiro-azacyclopentyl, azetidinyl-spiro-azacyclohexyl, azacyclopentyl-spiro-azetidinyl, azacyclopentyl-spiro-azacyclohexyl, azacyclopentyl-spiro-azetidinyl, azacyclopentyl-spiro-azacyclopentyl,azacyclopentyl-spiro-azacyclohexyl, azacyclohexyl-spiro-azetidinyl, azacyclohexyl-spiro-azacyclopentyl, azacyclohexyl-spiro-azacyclohexyl, oxetanyl group, oxacyclopentyl group, oxacyclohexyl group, cyclopropyl fused oxetanyl, cyclopropyl fused oxacyclopentyl, cyclopropyl fused oxacyclohexyl, cyclobutyl fused oxetanyl, cyclobutyl fused oxacyclopentyl, cyclobutyl fused oxacyclohexyl, cyclopentyl fused oxetanyl, Cyclopentyl-fused oxacyclopentyl, cyclopentyl-fused oxacyclohexyl, cyclohexyl-fused oxetanyl, cyclohexyl-fused oxacyclopentyl, cyclohexyl-fused oxacyclohexyl, azetidinyl-fused oxetanyl, azetidinyl-fused oxacyclopentyl, azetidinyl-fused oxacyclohexyl, azacyclopentyl-fused oxetanyl, azacyclopentyl-fused oxacyclopentyl, azacyclopentyl-fused oxacyclohexyl, azacyclohexyl-fused oxetanyl, azacyclohexyl-fused oxacyclopentyl , azacyclohexyl-fused oxacyclohexyl, cyclobutyl-spiro-oxetanyl, cyclobutyl-spiro-oxacyclopentyl, cyclobutyl-spiro-oxacyclohexyl, cyclopentyl-spiro-oxetanyl, cyclopentyl-spiro-oxacyclopentyl, cyclopentyl-spiro-oxacyclohexyl, cyclohexyl-spiro-oxetanyl, cyclohexyl-spiro-oxacyclopentyl, cyclohexyl-spiro-oxacyclohexyl, azetidinyl-spiro-oxetanyl, azetidinyl-spiro-oxacyclo pentyl, azetidinyl-spiro-oxacyclohexyl, azacyclopentyl-spiro-oxetanyl, azacyclopentyl-spiro-oxacyclopentyl, azacyclopentyl-spiro-oxacyclohexyl, azacyclohexyl-spiro-oxetanyl, azacyclohexyl-spiro-oxacyclopentyl, azacyclohexyl-spiro-oxacyclohexyl, bicyclo[2.1.1]hexanyl, bicyclo[2.2.1]heptanyl, bicyclo[3.3.2]decanyl, bicyclo[2.2.2]octyl, bicyclo[3.2.1]octyl,Bicyclo[3.3.3]undecyl, adamantyl group, [ka] is selected from In some embodiments, ring C1 is a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, an oxetanyl group, an oxacyclopentyl group, an oxacyclohexyl group, an azetidinyl group, an azacyclopentyl group, a piperidine, a morpholine, a piperazine, a 1,4-diazepanyl group, a cyclopropyl-fused cyclopentyl, a cyclopentyl-fused cyclobutyl, a cyclopentyl-fused cyclopentyl, a cyclopentyl-fused cyclohexyl, [ka] selected from bicyclo[2.1.1]hexanyl, bicyclo[2.2.1]heptanyl, bicyclo[3.3.2]decanyl, bicyclo[2.2.2]octyl, bicyclo[3.2.1]octyl, bicyclo[3.3.3]undecyl, and adamantyl groups; In some embodiments, Ring C1 is a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cyclopentyl-fused cyclobutyl group, or [ka] is selected from In some embodiments, R c1 are each independently H, a halogen, a cyano group, OH, =O, or C 1-6 Alkyl group, C 1-6 Alkoxy group, C 3-12 a carbocyclic group or a 3- to 12-membered heterocyclic group, and the alkyl, alkoxy, carbocyclic or heterocyclic group is optionally selected from H, halogen, OH, =O, cyano, NH 2 , C 1-6 Alkyl, halogen-substituted C 1-6 C substituted with alkyl or hydroxy groups 1-6 C substituted with alkyl or cyano groups 1-6 Alkyl group, C 1-6Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group, the heterocyclic group containing 1 to 3 heteroatoms selected from O, S and N; In some embodiments, R c1 are each independently H, a halogen, a cyano group, OH, =O, or C 1-4 Alkyl group, C 1-4 Alkoxy group, C 3-6 A cycloalkyl group or a 3- to 6-membered heterocycloalkyl group, wherein the alkyl group, alkoxy group, cycloalkyl group or heterocycloalkyl group is optionally selected from H, halogen, OH, =O, cyano group, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group, said heterocycloalkyl group containing 1 to 3 heteroatoms selected from O, S and N; In some embodiments, R c1 are each independently selected from H, F, Cl, Br, I, cyano, OH, =O, methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclohexyl, cyclopentyl, cyclobutyl, azetidinyl, azacyclopentyl, piperidinyl, piperazinyl, methoxy or ethoxy, and the methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclohexyl, cyclopentyl, cyclobutyl, azetidinyl, azacyclopentyl, piperidinyl, piperazinyl, methoxy or ethoxy groups are optionally selected from H, F, Cl, Br, I, OH, =O, cyano, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; In some embodiments, R c1 are each independently selected from H, F, Cl, Br, I, cyano, OH, =O, methyl, ethyl, propyl, isopropyl, cyclopropyl, methoxy or ethoxy, and the methyl, ethyl, propyl, isopropyl, cyclopropyl, methoxy or ethoxy groups are optionally selected from H, F, Cl, Br, I, OH, =O, cyano, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; In some embodiments, R c1 are each independently selected from H, F, Cl, Br, I, cyano, OH, =O, methyl, ethyl, propyl, isopropyl, and cyclopropyl; In some embodiments, R c1 are each independently selected from H, F, and Cl; In some embodiments, R cn1 and R cn2 together with the carbon atom to which they are bonded form a 3- to 12-membered heterocyclic group, said heterocyclic group optionally being selected from H, halogen, OH, =O, a cyano group, NH 2 , C 1-6 Alkyl, halogen-substituted C 1-6 C substituted with alkyl or hydroxy groups 1-6 C substituted with alkyl or cyano groups 1-6 Alkyl group, C 1-6 Alkoxy group or C 3-6is further substituted with 0 to 4 substituents selected from a cycloalkyl group, the heterocyclic group containing 1 to 3 heteroatoms selected from O, S and N; In some embodiments, R cn1 and R cn2 together with the carbon atom to which they are bonded form a 4- to 7-membered monoheterocycloalkyl group, a 4- to 11-membered fused heterocycloalkyl group, a 5- to 11-membered spiroheterocycloalkyl group, or a 5- to 12-membered bridged heterocycloalkyl group, the heterocycloalkyl group optionally being selected from H, halogen, OH, =O, a cyano group, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group, said heterocycloalkyl group containing 1 to 3 heteroatoms selected from O, S and N; In some embodiments, R cn1 and R cn2together with the carbon atoms bonded thereto, represent a substituted or unsubstituted azetidinyl group, azacyclopentyl group, piperidine, piperazine, azetidinyl-fused cyclopropyl, azetidinyl-fused cyclobutyl, azetidinyl-fused cyclopentyl, azetidinyl-fused cyclohexyl, azacyclopentyl-fused cyclopropyl, azacyclopentyl-fused cyclobutyl, azacyclopentyl-fused cyclopentyl, azacyclopentyl-fused cyclohexyl, azacyclohexyl-fused cyclopropyl, azacyclohexyl-fused cyclobutyl, azacyclohexyl-fused cyclopentyl, azacyclohexyl-fused cyclohexyl, azetidinyl-fused azetidinyl, azetidinyl-fused azacyclopentyl, azetidinyl-fused azacyclohexyl, azacyclopentyl-fused azetidinyl, azacyclopentyl-fused azacyclopentyl, azacyclohexyl-fused aza Cyclohexyl, azacyclohexyl-fused azetidinyl, azacyclohexyl-fused azacyclopentyl, azacyclohexyl-fused azacyclohexyl, azetidinyl-spiro-azetidinyl, azetidinyl-spiro-azacyclopentyl, azetidinyl-spiro-azacyclohexyl, azacyclopentyl-spiro-azetidinyl, azacyclopentyl-spiro-azacyclopentyl, azacyclopentyl-spiro- azacyclohexyl, azacyclohexyl-spiro-azetidinyl, azacyclohexyl-spiro-azacyclopentyl, azacyclohexyl-spiro-azacyclohexyl, azacyclopentyl-spiro-cyclobutyl, azacyclopentyl-spiro-cyclopentyl, azacyclohexyl-spiro-cyclobutyl, azacyclohexyl-spiro-cyclopentyl, azacyclohexyl-spiro-cyclohexyl, [ka] and optionally, when substituted, H, halogen, OH, =O, cyano group, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; In some embodiments, R cn1 and R cn2 together with the carbon atoms bonded thereto form a substituted or unsubstituted azetidinyl group, azacyclopentyl group, piperidine, piperazine, azacyclopentyl-spiro-cyclobutyl, azacyclopentyl-spiro-cyclopentyl, azacyclohexyl-spiro-cyclobutyl, azacyclohexyl-spiro-cyclopentyl, azacyclohexyl-spiro-cyclohexyl, optionally substituted with H, F, Cl, Br, I, OH, ═O, a cyano group, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; In some embodiments, R cn1 and R cn2 together with the carbon atoms bonded thereto form a substituted or unsubstituted azetidinyl group, azacyclopentyl group, piperidine, piperazine, azacyclopentyl-spiro-cyclobutyl, azacyclopentyl-spiro-cyclopentyl, azacyclohexyl-spiro-cyclobutyl, azacyclohexyl-spiro-cyclopentyl, azacyclohexyl-spiro-cyclohexyl, optionally substituted with H, F, Cl, Br, I, OH, ═O, a cyano group, NH 2 , C.F. 3 , further substituted by 0 to 4 substituents selected from a methyl group, an ethyl group, a propyl group, an isopropyl group, a cyclopropyl group, a methoxy group, or an ethoxy group; In some embodiments, R cn1 and R cn2 along with the carbon atoms attached to them [ka] Forming In some embodiments, R cn1 and R cn2 along with the carbon atoms attached to them [ka] Forming In some embodiments, ring C2 is selected from an azetidinyl group, an azacyclopentyl group, piperidine, or piperazine; In some embodiments, R c2 are each independently H, F, Cl, Br, I, OH, =O, a cyano group, or NH 2 , methyl, ethyl, propyl, isopropyl, cyclopropyl, methoxy, and ethoxy groups; In some embodiments, m is selected from 0, 1, 2, or 3; In some embodiments, m is selected from 0, 1, or 2; In some embodiments, m is selected from 0 or 1, In some embodiments, n is selected from 0, 1, 2, 3, 4, 5, 6, or 7; In some embodiments, n is selected from 0, 1, 2, 3, or 4; In some embodiments, n is selected from 0, 1, 2, or 3; In some embodiments, n is selected from 0 or 1, In some embodiments, p is selected from 0, 1, 2, or 3; In some embodiments, p is selected from 0, 1, or 2; In some embodiments, q is selected from 0, 1, 2, or 3; In some embodiments, q is selected from 0, 1, or 2; In some embodiments, s is selected from 0, 1, 2, or 3; In some embodiments, s is selected from 0, 1, or 2; In some embodiments, s is selected from 0 or 1, In some embodiments, t is selected from 0, 1, 2, 3, 4, 5, 6, or 7; In some embodiments, t is selected from 0, 1, 2, 3, or 4; In some embodiments, t is selected from 0, 1, 2, or 3; In some embodiments, t is selected from 0, 1, or 2; In some embodiments, r is selected from 0, 1, 2, or 3.

[0008] In a first embodiment of the present invention, there is provided a compound represented by general formula (I) or a stereoisomer, tautomer, deuteride, solvate, prodrug, metabolite, pharma- ceutically acceptable salt, or co-crystal thereof, [ka] Ring A is [ka] is selected from L is [ka] or a 5- to 6-membered heteroaryl group, the left side of L being connected to ring A, the heteroaryl group being optionally selected from H, halogen, OH, a cyano group, NH 2 , C 1-6 Alkyl, halogen-substituted C 1-6 C substituted with alkyl or hydroxy groups 1-6 C substituted with alkyl or cyano groups 1-6 Alkyl group, C 1-6 is further substituted with 0 to 3 substituents selected from an alkoxy group, the heteroaryl group containing 1 to 3 heteroatoms selected from O, S and N; R an , H, C 1-6 Alkyl group, C 3-12a carbocyclic group or a 3- to 12-membered heterocyclic group, the alkyl group, the carbocyclic group or the heterocyclic group being optionally selected from H, halogen, OH, =O, a cyano group, NH 2 , C 1-6 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, -C 2-4 Alkynyl-C 3-6 Cycloalkyl groups, halogen-substituted C 1-6 C substituted with alkyl or hydroxy groups 1-6 C substituted with alkyl or cyano groups 1-6 Alkyl group, C 1-6 Alkoxy group, C 3-12 It is further substituted with 0 to 4 substituents selected from a cycloalkyl group, a phenyl group, a 3- to 12-membered heterocycloalkyl group, or a 5- to 12-membered heteroaryl group, and the heterocyclic group, heterocycloalkyl group, or heteroaryl group contains 1 to 3 heteroatoms selected from O, S, and N; Ring B is selected from a 5- to 10-membered heterocyclic group, the heterocyclic group containing 1 to 5 heteroatoms selected from O, S, and N; R a or R b are each independently H, a halogen, a cyano group, OH, =O, or C 1-6 Alkyl group, C 1-6 Alkoxy group, C 3-6 cycloalkyl groups, said alkyl, alkoxy or cycloalkyl groups being optionally selected from H, halogen, OH, =O, cyano, NH 2 , C 1-6 Alkyl, halogen-substituted C 1-6 C substituted with alkyl or hydroxy groups 1-6 C substituted with alkyl or cyano groups 1-6 Alkyl group, C 1-6 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; One option is R an and R aform a 5-6 membered heterocycle together with the carbon atom to which they are bonded, said heterocycle optionally being selected from the group consisting of H, halogen, OH, =O, cyano, NH 2 , C 1-6 Alkyl, halogen-substituted C 1-6 C substituted with alkyl or hydroxy groups 1-6 C substituted with alkyl or cyano groups 1-6 Alkyl group, C 1-6 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group, and the heterocycle contains 1 to 3 heteroatoms selected from O, S, and N; R 1 , H, C 1-6 Alkyl group or C 3-6 cycloalkyl groups, said alkyl or cycloalkyl groups being optionally selected from H, halogen, OH, =O, cyano, NH 2 , C 1-6 Alkyl, halogen-substituted C 1-6 C substituted with alkyl or hydroxy groups 1-6 C substituted with alkyl or cyano groups 1-6 Alkyl group, C 1-6 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; R 2a , R 2b , R 3a , R 3b are each independently H, a halogen, a cyano group, OH, =O, or C 1-6 Alkyl group, C 1-6 Alkoxy group or C 3-6 cycloalkyl groups, said alkyl, alkoxy or cycloalkyl groups being optionally selected from H, halogen, OH, =O, cyano, NH 2 , C 1-6 Alkyl, halogen-substituted C 1-6 C substituted with alkyl or hydroxy groups 1-6 C substituted with alkyl or cyano groups 1-6 Alkyl group, C 1-6 Alkoxy group or C 3-6is further substituted with 0 to 4 substituents selected from a cycloalkyl group; One option is R 2a and R 2b , R 3a and R 3b are each C along with the carbon atom attached to them. 3-6 A carbocyclic group or a 3- to 6-membered heterocyclic group is formed, and the carbocyclic group or the heterocyclic group may optionally be H, a halogen atom, OH, =O, a cyano group, NH 2 , C 1-6 Alkyl, halogen-substituted C 1-6 C substituted with alkyl or hydroxy groups 1-6 C substituted with alkyl or cyano groups 1-6 Alkyl group, C 1-6 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group, the heterocyclic group containing 1 to 3 heteroatoms selected from O, S and N; R cn1 , R cn2 are each independently H, a halogen, a cyano group, OH, =O, or C 1-6 Alkyl group, C 1-6 Alkoxy group, C 3-10 A carbocyclic group, a 3- to 10-membered heterocyclic group, or [ka] wherein the alkyl, alkoxy, carbocyclic or heterocyclic group is optionally selected from H, halogen, OH, ═O, cyano, NH 2 , C 1-6 Alkyl, halogen-substituted C 1-6 C substituted with alkyl or hydroxy groups 1-6 C substituted with alkyl or cyano groups 1-6 Alkyl group, C 1-6 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group, the heterocyclic group containing 1 to 3 heteroatoms selected from O, S and N; Ring C1 is C 3-12a carbocyclic group or a 3- to 12-membered heterocyclic group, the heterocyclic group containing 1 to 3 heteroatoms selected from O, S and N; R c1 is H, halogen, cyano group, OH, =O, C 1-6 Alkyl group, C 1-6 Alkoxy group, C 3-12 a carbocyclic group or a 3- to 12-membered heterocyclic group, and the alkyl, alkoxy, carbocyclic or heterocyclic group is optionally selected from H, halogen, OH, =O, cyano, NH 2 , C 1-6 Alkyl, halogen-substituted C 1-6 C substituted with alkyl or hydroxy groups 1-6 C substituted with alkyl or cyano groups 1-6 Alkyl group, C 1-6 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group, the heterocyclic group containing 1 to 3 heteroatoms selected from O, S and N; One option is R cn1 and R cn2 together with the carbon atom to which they are bonded form a 3- to 12-membered heterocyclic group, said heterocyclic group optionally being selected from the group consisting of H, halogen, OH, =O, a cyano group, NH 2 , C 1-6 Alkyl, halogen-substituted C 1-6 C substituted with alkyl or hydroxy groups 1-6 C substituted with alkyl or cyano groups 1-6 Alkyl group, C 1-6 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group, the heterocyclic group containing 1 to 3 heteroatoms selected from O, S and N; m is selected from 0, 1, 2 or 3; n is selected from 0, 1, 2, 3, 4, 5, 6 or 7; p is selected from 0, 1, 2 or 3; q is selected from 0, 1, 2 or 3; s is selected from 0, 1, 2 or 3; t is selected from 0, 1, 2, 3, 4, 5, 6 or 7.

[0009] In a second embodiment of the present invention, there is provided a compound represented by general formula (II) or a stereoisomer, tautomer, deuteride, solvate, prodrug, metabolite, pharma- ceutically acceptable salt or co-crystal thereof, wherein the compound is selected from the group consisting of compounds represented by general formula (II): [ka] R an , H, C 1-6 Alkyl group, C 3-12 a carbocyclic group or a 3- to 12-membered heterocyclic group, and the alkyl, cycloalkyl, carbocyclic or heterocyclic group is optionally selected from H, D, halogen, OH, =O, cyano, NH 2 , C 1-6 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, -C 2-4 Alkynyl-C 3-6 Cycloalkyl groups, halogen-substituted C 1-6 C substituted with alkyl or hydroxy groups 1-6 C substituted with alkyl or cyano groups 1-6 Alkyl group, C 1-6 Alkoxy group, C 3-12 It is further substituted with 0 to 4 substituents selected from a cycloalkyl group, a phenyl group, a 3- to 12-membered heterocycloalkyl group, or a 5- to 12-membered heteroaryl group, and the heterocyclic group, heterocycloalkyl group, or heteroaryl group contains 1 to 3 heteroatoms selected from O, S, and N; Ring B is selected from a 5- to 10-membered heterocyclic group, the heterocyclic group containing 1 to 5 heteroatoms selected from O, S, and N; R a or R b are each independently H, a halogen, a cyano group, OH, =O, or C 1-6 Alkyl group, C 1-6 Alkoxy group, C 3-6cycloalkyl groups, said alkyl, alkoxy or cycloalkyl groups being optionally selected from H, halogen, OH, =O, cyano, NH 2 , C 1-6 Alkyl, halogen-substituted C 1-6 C substituted with alkyl or hydroxy groups 1-6 C substituted with alkyl or cyano groups 1-6 Alkyl group, C 1-6 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; One option is R an and R a form a 5-6 membered heterocycle together with the carbon atom to which they are bonded, said heterocycle optionally being selected from the group consisting of H, halogen, OH, =O, cyano, NH 2 , C 1-6 Alkyl, halogen-substituted C 1-6 C substituted with alkyl or hydroxy groups 1-6 C substituted with alkyl or cyano groups 1-6 Alkyl group, C 1-6 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group, and the heterocycle contains 1 to 3 heteroatoms selected from O, S, and N; R 1 , H, C 1-6 Alkyl group or C 3-6 cycloalkyl groups, said alkyl or cycloalkyl groups being optionally selected from H, halogen, OH, =O, cyano, NH 2 , C 1-6 Alkyl, halogen-substituted C 1-6 C substituted with alkyl or hydroxy groups 1-6 C substituted with alkyl or cyano groups 1-6 Alkyl group, C 1-6 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; R 2a , R 2b , R 3a , R 3bare each independently H, a halogen, a cyano group, OH, =O, or C 1-6 Alkyl group, C 1-6 Alkoxy group or C 3-6 cycloalkyl groups, said alkyl, alkoxy or cycloalkyl groups being optionally selected from H, halogen, OH, =O, cyano, NH 2 , C 1-6 Alkyl, halogen-substituted C 1-6 C substituted with alkyl or hydroxy groups 1-6 C substituted with alkyl or cyano groups 1-6 Alkyl group, C 1-6 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; One option is R 2a and R 2b , R 3a and R 3b are each C along with the carbon atom attached to them. 3-6 A carbocyclic group or a 3- to 6-membered heterocyclic group is formed, and the carbocyclic group or the heterocyclic group may optionally be H, a halogen atom, OH, =O, a cyano group, NH 2 , C 1-6 Alkyl, halogen-substituted C 1-6 C substituted with alkyl or hydroxy groups 1-6 C substituted with alkyl or cyano groups 1-6 Alkyl group, C 1-6 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group, the heterocyclic group containing 1 to 3 heteroatoms selected from O, S and N; R cn1 , R cn2 are each independently H, a halogen, a cyano group, OH, =O, or C 1-6 Alkyl group, C 1-6 Alkoxy group, C 3-10 A carbocyclic group, a 3- to 10-membered heterocyclic group, or [ka] wherein the alkyl, alkoxy, carbocyclic or heterocyclic group is optionally selected from H, halogen, OH, ═O, cyano, NH 2 , C 1-6 Alkyl, halogen-substituted C 1-6 C substituted with alkyl or hydroxy groups 1-6 C substituted with alkyl or cyano groups 1-6 Alkyl group, C 1-6 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group, the heterocyclic group containing 1 to 3 heteroatoms selected from O, S and N; Ring C1 is C 3-12 a carbocyclic group or a 3- to 12-membered heterocyclic group, the heterocyclic group containing 1 to 3 heteroatoms selected from O, S and N; R c1 is H, halogen, cyano group, OH, =O, C 1-6 Alkyl group, C 1-6 Alkoxy group, C 3-12 a carbocyclic group or a 3- to 12-membered heterocyclic group, and the alkyl, alkoxy, carbocyclic or heterocyclic group is optionally selected from H, halogen, OH, =O, cyano, NH 2 , C 1-6 Alkyl, halogen-substituted C 1-6 C substituted with alkyl or hydroxy groups 1-6 C substituted with alkyl or cyano groups 1-6 Alkyl group, C 1-6 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group, the heterocyclic group containing 1 to 3 heteroatoms selected from O, S and N; One option is R cn1 and R cn2 together with the carbon atom to which they are bonded form a 3- to 12-membered heterocyclic group, said heterocyclic group optionally being selected from H, halogen, OH, =O, a cyano group, NH 2 , C 1-6 Alkyl, halogen-substituted C 1-6 C substituted with alkyl or hydroxy groups1-6 C substituted with alkyl or cyano groups 1-6 Alkyl group, C 1-6 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group, the heterocyclic group containing 1 to 3 heteroatoms selected from O, S and N; m is selected from 0, 1, 2 or 3; n is selected from 0, 1, 2, 3, 4, 5, 6 or 7; p is selected from 0, 1, 2 or 3; q is selected from 0, 1, 2 or 3; s is selected from 0, 1, 2 or 3; t is selected from 0, 1, 2, 3, 4, 5, 6 or 7.

[0010] As a third embodiment of the present invention, there is provided a compound represented by the above-mentioned general formula (I) or (II) or a stereoisomer, tautomer, deuteride, solvate, prodrug, metabolite, pharma- ceutically acceptable salt or cocrystal thereof, R an , H, C 1-4 Alkyl group, C 3-6 cycloalkyl group, 3- to 6-membered heterocycloalkyl group, wherein the alkyl group, cycloalkyl group, cycloalkyl group or heterocycloalkyl group is optionally selected from H, D, halogen, OH, =O, cyano group, NH 2 , C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, -C 2-4 Alkynyl-C 3-6 Cycloalkyl groups, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group, C 3-6It is further substituted with 0 to 4 substituents selected from a cycloalkyl group, a phenyl group, a 3- to 6-membered heterocycloalkyl group, or a 5- to 6-membered heteroaryl group, and the heterocycloalkyl group or heteroaryl group contains 1 to 3 heteroatoms selected from O, S, and N; R a or R b are each independently H, a halogen, a cyano group, OH, =O, or C 1-4 Alkyl group, C 1-4 Alkoxy group, C 3-6 cycloalkyl groups, said alkyl, alkoxy or cycloalkyl groups being optionally selected from H, halogen, OH, =O, cyano, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; One option is R an and R a form a 5-6 membered heteroaromatic ring together with the carbon atom to which they are attached, said heteroaromatic ring optionally being substituted with H, halogen, OH, =O, a cyano group, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group, the heteroaryl group containing 1 to 3 heteroatoms selected from O, S and N; R 1 , H, C 1-4 Alkyl group or C 3-6 cycloalkyl groups, said alkyl or cycloalkyl groups being optionally selected from H, halogen, OH, =O, cyano, NH2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; R 2a , R 2b , R 3a , R 3b are each independently H, a halogen, a cyano group, OH, =O, or C 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 cycloalkyl groups, said alkyl, alkoxy or cycloalkyl groups being optionally selected from H, halogen, OH, =O, cyano, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; Ring B is selected from a 5,5-membered biheteroaryl group, a 5,6-membered biheteroaryl group, and a 6,6-membered biheteroaryl group, the heteroaryl group containing 1 to 5 heteroatoms selected from O, S, and N; m is selected from 0, 1 or 2; n is selected from 0, 1, 2, 3 or 4; p is selected from 0, 1 or 2; q is selected from 0, 1 or 2; Other definitions are the same as those in the second embodiment of the present invention.

[0011] As a fourth embodiment of the present invention, there is provided a compound represented by the above-mentioned general formula (I) or (II) or a stereoisomer, tautomer, deuteride, solvate, prodrug, metabolite, pharma- ceutically acceptable salt or cocrystal thereof, R cn1 , R cn2 are each independently H, a halogen, a cyano group, OH, =O, or C 1-4 Alkyl group, C 1-4 Alkoxy group, C 3-10 Cycloalkyl group, 3-10 membered heterocycloalkyl group, or [ka] wherein the alkyl, alkoxy, cycloalkyl or heterocycloalkyl group is optionally selected from H, halogen, OH, ═O, cyano, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group, said heterocycloalkyl group containing 1 to 3 heteroatoms selected from O, S and N; Ring C1 is C 3-7 Monocycloalkyl groups, C 4-11 Fused cycloalkyl groups, C 5~11 C-membered spirocycloalkyl group 5-12 is selected from a bridged cycloalkyl group, a 4- to 7-membered monoheterocycloalkyl group, a 4- to 11-membered fused heterocycloalkyl group, a 5- to 11-membered spiroheterocycloalkyl group, or a 5- to 12-membered bridged heterocycloalkyl group, wherein the heterocycloalkyl group contains 1 to 3 heteroatoms selected from O, S, and N; R c1 is H, halogen, cyano group, OH, =O, C 1-4 Alkyl group, C 1-4 Alkoxy group, C 3-6A cycloalkyl group or a 3- to 6-membered heterocycloalkyl group, wherein the alkyl group, alkoxy group, cycloalkyl group or heterocycloalkyl group is optionally selected from H, halogen, OH, =O, cyano group, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group, said heterocycloalkyl group containing 1 to 3 heteroatoms selected from O, S and N; One option is R cn1 and R cn2 together with the carbon atom to which they are bonded form a 4- to 7-membered monoheterocycloalkyl group, a 4- to 11-membered fused heterocycloalkyl group, a 5- to 11-membered spiroheterocycloalkyl group, or a 5- to 12-membered bridged heterocycloalkyl group, the heterocycloalkyl group optionally being selected from H, halogen, OH, =O, a cyano group, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group, said heterocycloalkyl group containing 1 to 3 heteroatoms selected from O, S and N; s is selected from 0, 1 or 2; t is selected from 0, 0, 1, 2, 3 or 4; Other definitions are the same as in the first, second, third or fourth embodiment of the present invention.

[0012] As a fifth embodiment of the present invention, there is provided a compound represented by the above-mentioned general formula (I) or (II) or a stereoisomer, tautomer, deuteride, solvate, prodrug, metabolite, pharma- ceutically acceptable salt or cocrystal thereof, R an is selected from H, methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclohexyl, cyclopentyl, cyclobutyl, oxetanyl, oxacyclopentyl, oxacyclohexyl, azetidinyl, azacyclopentyl, piperidinyl or piperazinyl, and said methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclohexyl, cyclopentyl, cyclobutyl, oxetanyl, oxacyclopentyl, oxacyclohexyl, azetidinyl, azacyclopentyl, piperidinyl or piperazinyl group is optionally selected from H, D, F, Cl, Br, I, OH, =O, cyano, NH 2 , C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, -C 2-4 Alkynyl-C 3-6 Cycloalkyl groups, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group, C 3-6 It is further substituted with 0 to 4 substituents selected from a cycloalkyl group, a phenyl group, a 3- to 6-membered heterocycloalkyl group, or a 5- to 6-membered heteroaryl group, and the heterocycloalkyl group or heteroaryl group contains 1 to 3 heteroatoms selected from O, S, and N; R a or R bare each independently selected from H, F, Cl, Br, I, cyano, OH, =O, methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclohexyl, cyclopentyl, cyclobutyl, azetidinyl, azacyclopentyl, azacyclohexyl, piperidinyl, methoxy or ethoxy, and the methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclohexyl, cyclopentyl, cyclobutyl, azetidinyl, azacyclopentyl, azacyclohexyl, piperidinyl, methoxy or ethoxy groups are optionally selected from H, F, Cl, Br, I, OH, =O, cyano, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; One option is R an and R a together with the carbon atoms bonded thereto form a pyridine, pyrimidine, pyridazine or pyrazine ring, said pyridine, pyrimidine or pyrazine ring optionally being selected from the group consisting of H, F, Cl, Br, I, OH, ═O, a cyano group, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; R 1 is selected from H, a methyl group, an ethyl group, a propyl group, an isopropyl group or a cyclopropyl group, and the methyl group, the ethyl group, the propyl group, the isopropyl group or the cyclopropyl group is optionally selected from H, F, Cl, Br, I, OH, ═O, a cyano group, NH 2 , C1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; R 2a , R 2b , R 3a , R 3b are each independently selected from H, F, Cl, Br, I, cyano, OH, =O, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy or cyclopropyl, and the methyl, ethyl, propyl, isopropyl, methoxy, ethoxy or cyclopropyl groups are optionally selected from H, F, Cl, Br, I, OH, =O, cyano, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; Ring B is selected from a pyrrolopyrrolyl group, a pyrrolopyrazolyl group, a pyrroloimidazolyl group, a pyrazolopyrazolyl group, a pyrazoloimidazolyl group, an imidazoimidazolyl group, a benzopyrrolyl group, a benzopyrazolyl group, a benzimidazolyl group, a pyridopyrrolyl group, a pyridopyrazolyl group, a pyridoimidazolyl group, a pyrimidopyrrolyl group, a pyrimidopyrazolyl group, a pyrimidopyrazolyl group, a pyrimidopyrazolyl group, a pyrimidopyrazolyl group, a pyrimidopyrazolyl group, a pyrimidopyrazinyl group, a pyrazinopyrrolyl group, a pyrazinopyrazolyl group, a pyrazinoimidazolyl group, a pyridazinopyrrolyl group, a pyridazinopyrazolyl group, a pyridazinoimidazolyl group, a benzopyridyl group, a benzopyrimidinyl group, a benzopyrazinyl group, a benzopyridazinyl group, a pyridopyridyl group, a pyridopyrimidinyl group, a pyridopyrazinyl group, or a pyridopyridazinyl group; R cn1 , R cn2each independently represents H, F, Cl, Br, I, a cyano group, OH, =O, a methyl group, an ethyl group, a propyl group, an isopropyl group, a cyclopropyl group, a cyclohexyl group, a cyclopentyl group, a cyclobutyl group, an azetidinyl group, an azacyclopentyl group, an azacyclohexyl group, or [ka] wherein the methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclohexyl, cyclopentyl, cyclobutyl, azetidinyl, azacyclopentyl, and azacyclohexyl groups are optionally selected from the group consisting of H, F, Cl, Br, I, OH, ═O, cyano, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; Ring C1 is a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, an oxetanyl group, an oxacyclopentyl group, an oxacyclohexyl group, an azetidinyl group, an azacyclopentyl group, a piperidine, a morpholine, a piperazine, a 1,4-diazepanyl group, a cyclopropyl-fused cyclopentyl group, a cyclobutyl-fused cyclopentyl group, a cyclopentyl-fused cyclopentyl group, a cyclopentyl-fused cyclohexyl group, a cyclopropyl-spiro-cyclopentyl group, a cyclobutyl-spiro-cyclobutyl group, a cyclobutyl-spiro-cyclopentyl group, Cyclopentyl-spiro-cyclopentyl, cyclopentyl-spiro-cyclohexyl, cyclohexyl-spiro-cyclohexyl, cyclopropyl-fused azetidinyl, cyclopropyl-fused azacyclopentyl, cyclopropyl-fused azacyclohexyl, cyclobutyl-fused azetidinyl, cyclobutyl-fused azacyclopentyl, cyclobutyl-fused azacyclohexyl, cyclopentyl-fused azetidinyl, cyclopentyl-fused azacyclopentyl, cyclopentyl-fused azacyclohexyl, cyclohexyl-fused azetidinyl, cyclohexyl-fused azacyclopentyl, azacyclopentyl, cyclohexyl-fused azacyclohexyl, azetidinyl-fused azetidinyl, azetidinyl-fused azacyclopentyl, azetidinyl-fused azacyclohexyl, azacyclopentyl-fused azetidinyl, azacyclopentyl-fused azacyclopentyl, azacyclopentyl-fused azacyclohexyl, azacyclohexyl-fused azetidinyl, azacyclohexyl-fused azacyclopentyl, azacyclohexyl-fused azacyclohexyl, cyclobutyl-spiro-azetidinyl, cyclobutyl-spiro-azacyclopentyl, cyclobutyl- spiro-azacyclohexyl, cyclopentyl-spiro-azetidinyl, cyclopentyl-spiro-azacyclopentyl, cyclopentyl-spiro-azacyclohexyl, cyclohexyl-spiro-azetidinyl, cyclohexyl-spiro-azacyclopentyl, cyclohexyl-spiro-azacyclohexyl, azetidinyl-spiro-azetidinyl, azetidinyl-spiro-azacyclopentyl, azetidinyl-spiro-azacyclohexyl, azacyclopentyl-spiro-azetidinyl, azacyclopentyl-spiro-azacyclopentyl, azacyclopentyl-spiro-azacyclopentyl,azacyclopentyl-spiro-azacyclohexyl, azacyclohexyl-spiro-azetidinyl, azacyclohexyl-spiro-azacyclopentyl, azacyclohexyl-spiro-azacyclohexyl, oxetanyl group, oxacyclopentyl group, oxacyclohexyl group, cyclopropyl fused oxetanyl, cyclopropyl fused oxacyclopentyl, cyclopropyl fused oxacyclohexyl, cyclobutyl fused oxetanyl, cyclobutyl fused oxacyclopentyl, cyclobutyl fused oxacyclohexyl, cyclopentyl fused oxetanyl, Cyclopentyl-fused oxacyclopentyl, cyclopentyl-fused oxacyclohexyl, cyclohexyl-fused oxetanyl, cyclohexyl-fused oxacyclopentyl, cyclohexyl-fused oxacyclohexyl, azetidinyl-fused oxetanyl, azetidinyl-fused oxacyclopentyl, azetidinyl-fused oxacyclohexyl, azacyclopentyl-fused oxetanyl, azacyclopentyl-fused oxacyclopentyl, azacyclopentyl-fused oxacyclohexyl, azacyclohexyl-fused oxetanyl, azacyclohexyl-fused oxacyclopentyl , azacyclohexyl-fused oxacyclohexyl, cyclobutyl-spiro-oxetanyl, cyclobutyl-spiro-oxacyclopentyl, cyclobutyl-spiro-oxacyclohexyl, cyclopentyl-spiro-oxetanyl, cyclopentyl-spiro-oxacyclopentyl, cyclopentyl-spiro-oxacyclohexyl, cyclohexyl-spiro-oxetanyl, cyclohexyl-spiro-oxacyclopentyl, cyclohexyl-spiro-oxacyclohexyl, azetidinyl-spiro-oxetanyl, azetidinyl-spiro-oxacyclo pentyl, azetidinyl-spiro-oxacyclohexyl, azacyclopentyl-spiro-oxetanyl, azacyclopentyl-spiro-oxacyclopentyl, azacyclopentyl-spiro-oxacyclohexyl, azacyclohexyl-spiro-oxetanyl, azacyclohexyl-spiro-oxacyclopentyl, azacyclohexyl-spiro-oxacyclohexyl, bicyclo[2.1.1]hexanyl, bicyclo[2.2.1]heptanyl, bicyclo[3.3.2]decanyl, bicyclo[2.2.2]octyl, bicyclo[3.2.1]octyl,Bicyclo[3.3.3]undecyl, adamantyl group, [ka] is selected from R c1 are each independently selected from H, F, Cl, Br, I, cyano, OH, =O, methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclohexyl, cyclopentyl, cyclobutyl, azetidinyl, azacyclopentyl, piperidinyl, piperazinyl, methoxy or ethoxy, and the methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclohexyl, cyclopentyl, cyclobutyl, azetidinyl, azacyclopentyl, piperidinyl, piperazinyl, methoxy or ethoxy groups are optionally selected from H, F, Cl, Br, I, OH, =O, cyano, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; One option is R cn1 and R cn2together with the carbon atom bonded thereto, a substituted or unsubstituted azetidinyl group, azacyclopentyl group, piperidine, piperazine, azetidinyl-fused cyclopropyl, azetidinyl-fused cyclobutyl, azetidinyl-fused cyclopentyl, azetidinyl-fused cyclohexyl, azacyclopentyl-fused cyclopropyl, azacyclopentyl-fused cyclobutyl, azacyclopentyl-fused cyclopentyl, azacyclopentyl-fused cyclohexyl, azacyclohexyl-fused cyclopropyl, azacyclohexyl-fused cyclobutyl, azacyclohexyl-fused cyclopentyl, azacyclohexyl-fused cyclohexyl, azetidinyl-fused azetidinyl, azetidinyl-fused azacyclopentyl, azetidinyl-fused azacyclohexyl azacyclopentyl-fused azetidinyl, azacyclopentyl-fused azacyclopentyl, azacyclopentyl-fused azacyclohexyl, azacyclohexyl-fused azetidinyl, azacyclohexyl-fused azacyclopentyl, azacyclohexyl-fused azacyclohexyl, azetidinyl-spiro-azetidinyl, azetidinyl-spiro-azacyclopentyl, azetidinyl-spiro-azacyclohexyl, azacyclopentyl-spiro-azetidinyl, azacyclopentyl-spiro-azacyclopentyl, azacyclopentyl-spiro-azacyclohexyl, azacyclohexyl-spiro-azetidinyl, azacyclopentyl-spiro-azacyclopentyl, azacyclopentyl-spiro-azacyclohexyl, azacyclohexyl-spiro-azetidinyl, azacyclohexyl-spiro-azacyclopentyl, azacyclohexyl-spiro-azacyclohexyl, [ka] and optionally, when substituted, H, halogen, OH, =O, cyano group, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; Other definitions are the same as in the first, second, third or fourth embodiment of the present invention.

[0013] As a sixth embodiment of the present invention, there is provided a compound represented by the above-mentioned general formula (I) or (II) or a stereoisomer, tautomer, deuteride, solvate, prodrug, metabolite, pharma- ceutically acceptable salt or cocrystal thereof, R an is selected from H, methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, oxacyclopentyl or oxacyclohexyl, and said methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, oxacyclopentyl or oxacyclohexyl groups are optionally selected from H, D, F, Cl, Br, I, OH, ═O, cyano, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, -C 2-4 Alkynyl-C 3-6 Cycloalkyl, hydroxyl-substituted C 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group, C 3-6 It is further substituted with 0 to 4 substituents selected from a cycloalkyl group, a phenyl group, a 3- to 6-membered heterocycloalkyl group, or a 5- to 6-membered heteroaryl group, and the heterocycloalkyl group or heteroaryl group contains 1 to 3 heteroatoms selected from O, S, and N; R a or R b are each independently selected from H, F, Cl, Br, I, cyano, OH, =O, methyl, ethyl, propyl, isopropyl, and cyclopropyl, and the methyl, ethyl, propyl, isopropyl, or cyclopropyl groups are optionally selected from H, F, Cl, Br, I, OH, =O, cyano, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; One option is R an and R a form a pyridine ring together with the carbon atoms attached thereto, said pyridine ring optionally being selected from the group consisting of H, F, Cl, Br, I, OH, ═O, a cyano group, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; Ring B is selected from a benzopyrrolyl group, a benzopyrazolyl group, a benzimidazolyl group, a pyridopyrrolyl group, a pyridopyrazolyl group, a pyridoimidazolyl group, a pyrimidopyrrolyl group, a pyrimidopyrazolyl group, a pyrimidoimidazolyl group, a pyrazinopyrrolyl group, a pyrazinopyrazolyl group, a pyrazinoimidazolyl group, a pyridazinopyrrolyl group, a pyridazinopyrazolyl group, and a pyridazinoimidazolyl group; R cn1 , R cn2 each independently represents H, F, Cl, Br, I, a cyano group, OH, =O, a methyl group, an ethyl group, a propyl group, an isopropyl group, a cyclopropyl group, a cyclohexyl group, a cyclopentyl group, a cyclobutyl group, or [ka] wherein the methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclohexyl, cyclopentyl, and cyclobutyl groups are optionally selected from H, F, Cl, Br, I, OH, ═O, cyano, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; Ring C1 may be a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, an oxetanyl group, an oxacyclopentyl group, an oxacyclohexyl group, an azetidinyl group, an azacyclopentyl group, a piperidine, a morpholine, a piperazine, a 1,4-diazepanyl group, [ka] selected from bicyclo[2.1.1]hexanyl, bicyclo[2.2.1]heptanyl, bicyclo[3.3.2]decanyl, bicyclo[2.2.2]octyl, bicyclo[3.2.1]octyl, bicyclo[3.3.3]undecyl, and adamantyl groups; R c1 are each independently selected from H, F, Cl, Br, I, cyano, OH, =O, methyl, ethyl, propyl, isopropyl, cyclopropyl, methoxy or ethoxy, and the methyl, ethyl, propyl, isopropyl, cyclopropyl, methoxy or ethoxy groups are optionally selected from H, F, Cl, Br, I, OH, =O, cyano, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; One option is R cn1 and R cn2 together with the carbon atom to which they are attached form a substituted or unsubstituted azetidinyl group, azacyclopentyl group, piperidine or piperazine, which, when substituted, may optionally be H, F, Cl, Br, I, OH, =O, a cyano group, NH 2 , C 1-4Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; Other definitions are the same as in the first, second, third, fourth or fifth embodiment of the present invention.

[0014] As a seventh embodiment of the present invention, there is provided a compound represented by the following general formula (II-1) or general formula (II-2), or a stereoisomer, tautomer, deuteride, solvate, prodrug, metabolite, pharma- ceutically acceptable salt, or cocrystal thereof, [ka] R an is H, methyl group, CD 3 , ethyl, propyl, isopropyl, cyclopropyl, oxetanyl, oxacyclopentyl or oxacyclohexyl, said methyl, ethyl, propyl, isopropyl, cyclopropyl, oxetanyl, oxacyclopentyl or oxacyclohexyl groups being optionally selected from H, F, Cl, Br, I, OH, ═O, cyano, NH 2 , methyl group, ethyl group, propyl group, isopropyl group, vinyl group, 1-propenyl group, 2-propenyl group, ethynyl group, 1-propynyl group, 2-propynyl group, [ka] is further substituted with 0 to 4 substituents selected from a cyclopropyl group, a methoxy group, an ethoxy group, and a phenyl group; R a or R b are each independently selected from H, F, Cl, Br, I, cyano, OH, =O, methyl, ethyl, propyl, isopropyl, and cyclopropyl; One option is R an and Ra form a pyridine ring together with the carbon atom to which they are attached, Ring C1 is a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, or [ka] is selected from R c1 are each independently selected from H, F, Cl, Br, I, cyano, OH, =O, methyl, ethyl, propyl, isopropyl, and cyclopropyl; Ring C2 is selected from an azetidinyl group, an azacyclopentyl group, a piperidine or a piperazine; R c2 are each independently H, F, Cl, Br, I, OH, =O, a cyano group, or NH 2 , methyl, ethyl, propyl, isopropyl, cyclopropyl, methoxy, and ethoxy groups; m is selected from 0 or 1; n is selected from 0 or 1; r is selected from 0, 1, 2 or 3; s is selected from 0 or 1; t is selected from 0, 1, 2 or 3; Other definitions are the same as in the first, second, third, fourth, fifth or sixth embodiment of the present invention.

[0015] As an eighth embodiment of the present invention, there is provided a compound represented by the following general formula (III) or a stereoisomer, tautomer, deuterated product, solvate, prodrug, metabolite, pharma- ceutically acceptable salt, or cocrystal thereof, [ka] Ring A is [ka] is selected from L is [ka] or a 5- to 6-membered heteroaryl group, the left side of L being connected to ring A, the heteroaryl group being optionally selected from H, halogen, OH, a cyano group, NH 2 , C 1-6 Alkyl, halogen-substituted C 1-6 C substituted with alkyl or hydroxy groups 1-6 C substituted with alkyl or cyano groups 1-6 Alkyl group, C 1-6 is further substituted with 0 to 3 substituents selected from an alkoxy group, the heteroaryl group containing 1 to 3 heteroatoms selected from O, S and N; R an , H, C 1-6 Alkyl group, C 3-12 a carbocyclic group or a 3- to 12-membered heterocyclic group, the alkyl group, the carbocyclic group or the heterocyclic group being optionally selected from H, halogen, OH, =O, a cyano group, NH 2 , C 1-6 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, -C 2-4 Alkynyl-C 3-6 Cycloalkyl groups, halogen-substituted C 1-6 C substituted with alkyl or hydroxy groups 1-6 C substituted with alkyl or cyano groups 1-6 Alkyl group, C 1-6 Alkoxy group, C 3-12 It is further substituted with 0 to 4 substituents selected from a cycloalkyl group, a phenyl group, a 3- to 12-membered heterocycloalkyl group, or a 5- to 12-membered heteroaryl group, and the heterocyclic group, heterocycloalkyl group, or heteroaryl group contains 1 to 3 heteroatoms selected from O, S, and N; R a or R b are each independently H, a halogen, a cyano group, OH, =O, or C 1-6 Alkyl group, C 1-6 Alkoxy group, C 3-6 cycloalkyl groups, said alkyl, alkoxy or cycloalkyl groups being optionally selected from H, halogen, OH, =O, cyano, NH2 , C 1-6 Alkyl, halogen-substituted C 1-6 C substituted with alkyl or hydroxy groups 1-6 C substituted with alkyl or cyano groups 1-6 Alkyl group, C 1-6 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; R 1 , H, C 1-6 Alkyl group or C 3-6 cycloalkyl groups, said alkyl or cycloalkyl groups being optionally selected from H, halogen, OH, =O, cyano, NH 2 , C 1-6 Alkyl, halogen-substituted C 1-6 C substituted with alkyl or hydroxy groups 1-6 C substituted with alkyl or cyano groups 1-6 Alkyl group, C 1-6 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; R 2a , R 2b , R 3a , R 3b are each independently H, a halogen, a cyano group, OH, =O, or C 1-6 Alkyl group, C 1-6 Alkoxy group or C 3-6 cycloalkyl groups, said alkyl, alkoxy or cycloalkyl groups being optionally selected from H, halogen, OH, =O, cyano, NH 2 , C 1-6 Alkyl, halogen-substituted C 1-6 C substituted with alkyl or hydroxy groups 1-6 C substituted with alkyl or cyano groups 1-6 Alkyl group, C 1-6 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; One option is R 2a and R 2b , R 3aand R 3b are each C along with the carbon atom attached to them. 3-6 A carbocyclic group or a 3- to 6-membered heterocyclic group is formed, and the carbocyclic group or the heterocyclic group may optionally be H, a halogen atom, OH, =O, a cyano group, NH 2 , C 1-6 Alkyl, halogen-substituted C 1-6 C substituted with alkyl or hydroxy groups 1-6 C substituted with alkyl or cyano groups 1-6 Alkyl group, C 1-6 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group, the heterocyclic group containing 1 to 3 heteroatoms selected from O, S and N; R cn1 , R cn2 are each independently H, a halogen, a cyano group, OH, =O, or C 1-6 Alkyl group, C 1-6 Alkoxy group, C 3-10 A carbocyclic group, a 3- to 10-membered heterocyclic group, or [ka] wherein the alkyl, alkoxy, carbocyclic or heterocyclic group is optionally selected from H, halogen, OH, ═O, cyano, NH 2 , C 1-6 Alkyl, halogen-substituted C 1-6 C substituted with alkyl or hydroxy groups 1-6 C substituted with alkyl or cyano groups 1-6 Alkyl group, C 1-6 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group, the heterocyclic group containing 1 to 3 heteroatoms selected from O, S and N; Ring C1 is C 3-12 a carbocyclic group or a 3- to 12-membered heterocyclic group, the heterocyclic group containing 1 to 3 heteroatoms selected from O, S and N; R c1 are each independently H, a halogen, a cyano group, OH, =O, or C1-6 Alkyl group, C 1-6 Alkoxy group, C 3-12 a carbocyclic group or a 3- to 12-membered heterocyclic group, and the alkyl, alkoxy, carbocyclic or heterocyclic group is optionally selected from H, halogen, OH, =O, cyano, NH 2 , C 1-6 Alkyl, halogen-substituted C 1-6 C substituted with alkyl or hydroxy groups 1-6 C substituted with alkyl or cyano groups 1-6 Alkyl group, C 1-6 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group, the heterocyclic group containing 1 to 3 heteroatoms selected from O, S and N; One option is R cn1 and R cn2 together with the carbon atom to which they are bonded form a 3- to 12-membered heterocyclic group, said heterocyclic group optionally being selected from H, halogen, OH, =O, a cyano group, NH 2 , C 1-6 Alkyl, halogen-substituted C 1-6 C substituted with alkyl or hydroxy groups 1-6 C substituted with alkyl or cyano groups 1-6 Alkyl group, C 1-6 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group, the heterocyclic group containing 1 to 3 heteroatoms selected from O, S and N; m is selected from 0, 1, 2 or 3; n is selected from 0, 1, 2 or 3; s is selected from 0, 1, 2 or 3; t is selected from 0, 1, 2, 3 or 4.

[0016] As a ninth embodiment of the present invention, there is provided a compound represented by the above-mentioned general formula (I) or (III), or a stereoisomer, tautomer, deuteride, solvate, prodrug, metabolite, pharma- ceutically acceptable salt, or cocrystal thereof, R an, H, C 1-4 Alkyl group, C 3-6 cycloalkyl group, 3- to 6-membered heterocycloalkyl group, wherein the alkyl group, cycloalkyl group or heterocycloalkyl group is optionally selected from H, halogen, OH, =O, cyano group, NH 2 , C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, -C 2-4 Alkynyl-C 3-6 Cycloalkyl groups, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group, C 3-6 It is further substituted with 0 to 4 substituents selected from a cycloalkyl group, a phenyl group, a 3- to 6-membered heterocycloalkyl group, or a 5- to 6-membered heteroaryl group, and the heterocycloalkyl group or heteroaryl group contains 1 to 3 heteroatoms selected from O, S, and N; R a or R b are each independently H, a halogen, a cyano group, OH, =O, or C 1-4 Alkyl group, C 1-4 Alkoxy group, C 3-6 cycloalkyl groups, said alkyl, alkoxy or cycloalkyl groups being optionally selected from H, halogen, OH, =O, cyano, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; R 1 , H, C 1-4 Alkyl group or C 3-6cycloalkyl groups, said alkyl or cycloalkyl groups being optionally selected from H, halogen, OH, =O, cyano, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; R 2a , R 2b , R 3a , R 3b are each independently H, a halogen, a cyano group, OH, =O, or C 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 cycloalkyl groups, said alkyl, alkoxy or cycloalkyl groups being optionally selected from H, halogen, OH, =O, cyano, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; m is selected from 0, 1 or 2; n is selected from 0, 1 or 2; Other definitions are the same as those in the eighth embodiment of the present invention.

[0017] As a tenth embodiment of the present invention, there is provided a compound represented by the above general formula (I) or (III) or a stereoisomer, tautomer, deuteride, solvate, prodrug, metabolite, pharma- ceutically acceptable salt or cocrystal thereof, L is [ka] or a 5-membered heteroaryl group, the left side of L being connected to ring A, said heteroaryl group being optionally selected from H, halogen, OH, a cyano group, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 is further substituted with 0 to 2 substituents selected from an alkoxy group, the heteroaryl group containing 1 to 3 heteroatoms selected from O, S and N; R 1 is selected from H, a methyl group, an ethyl group, a propyl group, an isopropyl group or a cyclopropyl group, and the methyl group, the ethyl group, the propyl group, the isopropyl group or the cyclopropyl group is optionally selected from H, F, Cl, Br, I, OH, ═O, a cyano group, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; R cn1 , R cn2 are each independently H, a halogen, a cyano group, OH, =O, or C 1-4 Alkyl group, C 1-4 Alkoxy group, C 3-7 Monocycloalkyl groups, C 4-10 Fused cycloalkyl groups, C 5~10 C-membered spirocycloalkyl group 5-10 a bridged cycloalkyl group, a 4- to 7-membered monoheterocycloalkyl group, a 4- to 10-membered condensed heterocycloalkyl group, a 5- to 10-membered spiroheterocycloalkyl group, a 5- to 10-membered bridged heterocycloalkyl group, or [ka] wherein the alkyl, alkoxy, cycloalkyl or heterocycloalkyl group is optionally selected from H, halogen, OH, ═O, cyano, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group, said heterocycloalkyl group containing 1 to 3 heteroatoms selected from O, S and N; Ring C1 is C 3-7 Monocycloalkyl groups, C 4-11 Fused cycloalkyl groups, C 5~11 C-membered spirocycloalkyl group 5-12 is selected from a bridged cycloalkyl group, a 4- to 7-membered monoheterocycloalkyl group, a 4- to 11-membered fused heterocycloalkyl group, a 5- to 11-membered spiroheterocycloalkyl group, or a 5- to 12-membered bridged heterocycloalkyl group, wherein the heterocycloalkyl group contains 1 to 3 heteroatoms selected from O, S, and N; R c1 are each independently H, a halogen, a cyano group, OH, =O, or C 1-4 Alkyl group, C 1-4 Alkoxy group, C 3-6 A cycloalkyl group or a 3- to 6-membered heterocycloalkyl group, wherein the alkyl group, alkoxy group, cycloalkyl group or heterocycloalkyl group is optionally selected from H, halogen, OH, =O, cyano group, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group, said heterocycloalkyl group containing 1 to 3 heteroatoms selected from O, S and N; One option is R cn1 and R cn2 together with the carbon atom to which they are bonded form a 4- to 7-membered monoheterocycloalkyl group, a 4- to 11-membered fused heterocycloalkyl group, a 5- to 11-membered spiroheterocycloalkyl group, or a 5- to 12-membered bridged heterocycloalkyl group, the heterocycloalkyl group optionally being selected from H, halogen, OH, =O, a cyano group, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group, said heterocycloalkyl group containing 1 to 3 heteroatoms selected from O, S and N; s is selected from 0, 1, and 2; t is selected from 0, 1, 2, 3 or 4; Other definitions are the same as those in the eighth or ninth embodiment of the present invention.

[0018] As an eleventh embodiment of the present invention, there is provided a compound represented by the above-mentioned general formula (I) or (III), or a stereoisomer, tautomer, deuterated product, solvate, prodrug, metabolite, pharma- ceutically acceptable salt, or cocrystal thereof, comprising: R an is selected from H, methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclohexyl, cyclopentyl, cyclobutyl, oxetanyl, oxacyclopentyl, oxacyclohexyl, azetidinyl, azacyclopentyl, piperidinyl or piperazinyl, and the methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclohexyl, cyclopentyl, cyclobutyl, oxetanyl, oxacyclopentyl, oxacyclohexyl, azetidinyl, azacyclopentyl, piperidinyl or piperazinyl group is optionally selected from H, F, Cl, Br, I, OH, =O, cyano, NH2 , C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, -C 2-4 Alkynyl-C 3-6 Cycloalkyl groups, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group, C 3-6 It is further substituted with 0 to 4 substituents selected from a cycloalkyl group, a phenyl group, a 3- to 6-membered heterocycloalkyl group, or a 5- to 6-membered heteroaryl group, and the heterocycloalkyl group or heteroaryl group contains 1 to 3 heteroatoms selected from O, S, and N; R a or R b are each independently selected from H, F, Cl, Br, I, cyano, OH, =O, methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclohexyl, cyclopentyl, cyclobutyl, azetidinyl, azacyclopentyl, azacyclohexyl, piperidinyl, methoxy or ethoxy, and the methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclohexyl, cyclopentyl, cyclobutyl, azetidinyl, azacyclopentyl, azacyclohexyl, piperidinyl, methoxy or ethoxy groups are optionally selected from H, F, Cl, Br, I, OH, =O, cyano, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; L is [ka] is selected from an oxazolyl group, a thiazolyl group, a thienyl group, a furyl group, a pyrrolyl group, a pyrazolyl group, a triazolyl group, or an imidazolyl group, and the left side of L is connected to ring A, and the oxazolyl group, the thiazolyl group, the thienyl group, the furyl group, the pyrrolyl group, the pyrazolyl group, the triazolyl group, or the imidazolyl group is optionally selected from H, F, Cl, Br, I, OH, a cyano group, NH 2 , further substituted with 0 to 2 substituents selected from a methyl group, an ethyl group, a propyl group, an isopropyl group, a methoxy group, and an ethoxy group; R 1 is selected from H, a methyl group, an ethyl group, a propyl group, and an isopropyl group; R 2a , R 2b , R 3a , R 3b are each independently selected from H, F, Cl, Br, I, cyano, OH, =O, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy or cyclopropyl, and the methyl, ethyl, propyl, isopropyl, methoxy, ethoxy or cyclopropyl groups are optionally selected from H, F, Cl, Br, I, OH, =O, cyano, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; R cn1 , R cn2 each independently represents H, F, Cl, Br, I, a cyano group, OH, =O, a methyl group, an ethyl group, a propyl group, an isopropyl group, a cyclopropyl group, a cyclohexyl group, a cyclopentyl group, a cyclobutyl group, an azetidinyl group, an azacyclopentyl group, an azacyclohexyl group, or [ka] wherein the methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclohexyl, cyclopentyl, cyclobutyl, azetidinyl, azacyclopentyl, and azacyclohexyl groups are optionally selected from the group consisting of H, F, Cl, Br, I, OH, ═O, cyano, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; Ring C1 is a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, an oxetanyl group, an oxacyclopentyl group, an oxacyclohexyl group, an azetidinyl group, an azacyclopentyl group, a piperidine, a morpholine, a piperazine, a 1,4-diazepanyl group, a cyclopropyl-fused cyclopentyl, a cyclopentyl-fused cyclobutyl, a cyclopentyl-fused cyclopentyl, a cyclopentyl-fused cyclohexyl, a cyclopropyl-spiro-cyclopentyl, a cyclobutyl-spiro-cyclobutyl, a cyclobutyl-spiro-cyclopentyl, Cyclopentyl-spiro-cyclopentyl, cyclopentyl-spiro-cyclohexyl, cyclohexyl-spiro-cyclohexyl, cyclopropyl-fused azetidinyl, cyclopropyl-fused azacyclopentyl, cyclopropyl-fused azacyclohexyl, cyclobutyl-fused azetidinyl, cyclobutyl-fused azacyclopentyl, cyclobutyl-fused azacyclohexyl, cyclopentyl-fused azetidinyl, cyclopentyl-fused azacyclopentyl, cyclopentyl-fused azacyclohexyl, cyclohexyl-fused azetidinyl, cyclohexyl-fused azacyclopentyl, azacyclopentyl, cyclohexyl-fused azacyclohexyl, azetidinyl-fused azetidinyl, azetidinyl-fused azacyclopentyl, azetidinyl-fused azacyclohexyl, azacyclopentyl-fused azetidinyl, azacyclopentyl-fused azacyclopentyl, azacyclopentyl-fused azacyclohexyl, azacyclohexyl-fused azetidinyl, azacyclohexyl-fused azacyclopentyl, azacyclohexyl-fused azacyclohexyl, cyclobutyl-spiro-azetidinyl, cyclobutyl-spiro-azacyclopentyl, cyclobutyl- spiro-azacyclohexyl, cyclopentyl-spiro-azetidinyl, cyclopentyl-spiro-azacyclopentyl, cyclopentyl-spiro-azacyclohexyl, cyclohexyl-spiro-azetidinyl, cyclohexyl-spiro-azacyclopentyl, cyclohexyl-spiro-azacyclohexyl, azetidinyl-spiro-azetidinyl, azetidinyl-spiro-azacyclopentyl, azetidinyl-spiro-azacyclohexyl, azacyclopentyl-spiro-azetidinyl, azacyclopentyl-spiro-azacyclopentyl, azacyclopentyl-spiro-azacyclopentyl,azacyclopentyl-spiro-azacyclohexyl, azacyclohexyl-spiro-azetidinyl, azacyclohexyl-spiro-azacyclopentyl, azacyclohexyl-spiro-azacyclohexyl, oxetanyl group, oxacyclopentyl group, oxacyclohexyl group, cyclopropyl fused oxetanyl, cyclopropyl fused oxacyclopentyl, cyclopropyl fused oxacyclohexyl, cyclobutyl fused oxetanyl, cyclobutyl fused oxacyclopentyl, cyclobutyl fused oxacyclohexyl, cyclopentyl fused oxetanyl, Cyclopentyl-fused oxacyclopentyl, cyclopentyl-fused oxacyclohexyl, cyclohexyl-fused oxetanyl, cyclohexyl-fused oxacyclopentyl, cyclohexyl-fused oxacyclohexyl, azetidinyl-fused oxetanyl, azetidinyl-fused oxacyclopentyl, azetidinyl-fused oxacyclohexyl, azacyclopentyl-fused oxetanyl, azacyclopentyl-fused oxacyclopentyl, azacyclopentyl-fused oxacyclohexyl, azacyclohexyl-fused oxetanyl, azacyclohexyl-fused oxacyclopentyl , azacyclohexyl-fused oxacyclohexyl, cyclobutyl-spiro-oxetanyl, cyclobutyl-spiro-oxacyclopentyl, cyclobutyl-spiro-oxacyclohexyl, cyclopentyl-spiro-oxetanyl, cyclopentyl-spiro-oxacyclopentyl, cyclopentyl-spiro-oxacyclohexyl, cyclohexyl-spiro-oxetanyl, cyclohexyl-spiro-oxacyclopentyl, cyclohexyl-spiro-oxacyclohexyl, azetidinyl-spiro-oxetanyl, azetidinyl-spiro-oxacyclo pentyl, azetidinyl-spiro-oxacyclohexyl, azacyclopentyl-spiro-oxetanyl, azacyclopentyl-spiro-oxacyclopentyl, azacyclopentyl-spiro-oxacyclohexyl, azacyclohexyl-spiro-oxetanyl, azacyclohexyl-spiro-oxacyclopentyl, azacyclohexyl-spiro-oxacyclohexyl, bicyclo[2.1.1]hexanyl, bicyclo[2.2.1]heptanyl, bicyclo[3.3.2]decanyl, bicyclo[2.2.2]octyl, bicyclo[3.2.1]octyl,Bicyclo[3.3.3]undecyl, adamantyl group, [ka] is selected from R c1 are each independently selected from H, F, Cl, Br, I, cyano, OH, =O, methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclohexyl, cyclopentyl, cyclobutyl, azetidinyl, azacyclopentyl, piperidinyl, piperazinyl, methoxy or ethoxy, and the methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclohexyl, cyclopentyl, cyclobutyl, azetidinyl, azacyclopentyl, piperidinyl, piperazinyl, methoxy or ethoxy groups are optionally selected from H, F, Cl, Br, I, OH, =O, cyano, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; One option is R cn1 and R cn2together with the carbon atoms bonded thereto, represent a substituted or unsubstituted azetidinyl group, azacyclopentyl group, piperidine, piperazine, azetidinyl-fused cyclopropyl, azetidinyl-fused cyclobutyl, azetidinyl-fused cyclopentyl, azetidinyl-fused cyclohexyl, azacyclopentyl-fused cyclopropyl, azacyclopentyl-fused cyclobutyl, azacyclopentyl-fused cyclopentyl, azacyclopentyl-fused cyclohexyl, azacyclohexyl-fused cyclopropyl, azacyclohexyl-fused cyclobutyl, azacyclohexyl-fused cyclopentyl, azacyclohexyl-fused cyclohexyl, azetidinyl-fused azetidinyl, azetidinyl-fused azacyclopentyl, azetidinyl-fused azacyclohexyl, azacyclopentyl-fused azetidinyl, azacyclopentyl-fused azacyclopentyl, azacyclohexyl-fused aza Cyclohexyl, azacyclohexyl-fused azetidinyl, azacyclohexyl-fused azacyclopentyl, azacyclohexyl-fused azacyclohexyl, azetidinyl-spiro-azetidinyl, azetidinyl-spiro-azacyclopentyl, azetidinyl-spiro-azacyclohexyl, azacyclopentyl-spiro-azetidinyl, azacyclopentyl-spiro-azacyclopentyl, azacyclopentyl-spiro- azacyclohexyl, azacyclohexyl-spiro-azetidinyl, azacyclohexyl-spiro-azacyclopentyl, azacyclohexyl-spiro-azacyclohexyl, azacyclopentyl-spiro-cyclobutyl, azacyclopentyl-spiro-cyclopentyl, azacyclohexyl-spiro-cyclobutyl, azacyclohexyl-spiro-cyclopentyl, azacyclohexyl-spiro-cyclohexyl, [ka] and optionally, when substituted, H, halogen, OH, =O, cyano group, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; Other definitions are the same as in the eighth, ninth or tenth embodiment of the present invention.

[0019] As a twelfth embodiment of the present invention, there is provided a compound represented by the above general formula (I) or (III) or a stereoisomer, tautomer, deuteride, solvate, prodrug, metabolite, pharma- ceutically acceptable salt, or cocrystal thereof, comprising: R an is selected from H, methyl, ethyl, propyl, isopropyl, and cyclopropyl groups, and the methyl, ethyl, propyl, isopropyl, and cyclopropyl groups are optionally selected from H, F, Cl, Br, I, OH, ═O, cyano, NH 2 , methyl group, ethyl group, propyl group, isopropyl group, vinyl group, 1-propenyl group, 2-propenyl group, ethynyl group, 1-propynyl group, 2-propynyl group, [ka] is further substituted with 0 to 4 substituents selected from a cyclopropyl group, a methoxy group, an ethoxy group, and a phenyl group; R a or R b are each independently selected from H, F, Cl, Br, I, cyano, OH, =O, methyl, ethyl, propyl, isopropyl, and cyclopropyl, and the methyl, ethyl, propyl, isopropyl, or cyclopropyl groups are optionally selected from H, F, Cl, Br, I, OH, =O, cyano, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; R cn1 , R cn2each independently represents H, F, Cl, Br, I, a cyano group, OH, =O, a methyl group, an ethyl group, a propyl group, an isopropyl group, a cyclopropyl group, a cyclohexyl group, a cyclopentyl group, a cyclobutyl group, or [ka] wherein the methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclohexyl, cyclopentyl, and cyclobutyl groups are optionally selected from H, F, Cl, Br, I, OH, ═O, cyano, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; Ring C1 is a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, an oxetanyl group, an oxacyclopentyl group, an oxacyclohexyl group, an azetidinyl group, an azacyclopentyl group, piperidine, morpholine, piperazine, 1,4-diazepanyl group, a cyclopropyl-fused cyclopentyl, a cyclopentyl-fused cyclobutyl, a cyclopentyl-fused cyclopentyl, a cyclopentyl-fused cyclohexyl, [ka] selected from bicyclo[2.1.1]hexanyl, bicyclo[2.2.1]heptanyl, bicyclo[3.3.2]decanyl, bicyclo[2.2.2]octyl, bicyclo[3.2.1]octyl, bicyclo[3.3.3]undecyl, and adamantyl groups; R c1are each independently selected from H, F, Cl, Br, I, cyano, OH, =O, methyl, ethyl, propyl, isopropyl, cyclopropyl, methoxy or ethoxy, and the methyl, ethyl, propyl, isopropyl, cyclopropyl, methoxy or ethoxy groups are optionally selected from H, F, Cl, Br, I, OH, =O, cyano, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; One option is R cn1 and R cn2 together with the carbon atoms bonded thereto form a substituted or unsubstituted azetidinyl group, azacyclopentyl group, piperidine, piperazine, azacyclopentyl-spiro-cyclobutyl, azacyclopentyl-spiro-cyclopentyl, azacyclohexyl-spiro-cyclobutyl, azacyclohexyl-spiro-cyclopentyl, azacyclohexyl-spiro-cyclohexyl, optionally substituted with H, F, Cl, Br, I, OH, =O, a cyano group, NH 2 , C 1-4 Alkyl, halogen-substituted C 1-4 C substituted with alkyl or hydroxy groups 1-4 C substituted with alkyl or cyano groups 1-4 Alkyl group, C 1-4 Alkoxy group or C 3-6 is further substituted with 0 to 4 substituents selected from a cycloalkyl group; Other definitions are the same as in the eighth, ninth, tenth or eleventh embodiment of the present invention.

[0020] As a thirteenth embodiment of the present invention, there is provided a compound represented by the above general formula (I) or (III) or a stereoisomer, tautomer, deuteride, solvate, prodrug, metabolite, pharma- ceutically acceptable salt, or cocrystal thereof, comprising: Ring A is [ka] is selected from L is [ka] and its left side is connected to ring A; R a or R b are each independently H, F, Cl, Br, I, a cyano group, OH, =O, or CF 3 , a methyl group, an ethyl group, a propyl group, an isopropyl group, a cyclopropyl group; R 2a , R 2b , R 3a , R 3b are each independently selected from H; R cn1 , R cn2 each independently represents H, a methyl group, an ethyl group, a propyl group, an isopropyl group, a cyclopropyl group, a cyclohexyl group, a cyclopentyl group, a cyclobutyl group, or [ka] wherein the methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclohexyl, cyclopentyl, and cyclobutyl groups are optionally selected from H, F, Cl, Br, I, OH, ═O, cyano, NH 2 , C.F. 3 , further substituted by 0 to 4 substituents selected from a methyl group, an ethyl group, a propyl group, an isopropyl group, a cyclopropyl group, a methoxy group, or an ethoxy group; Ring C1 is a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cyclopentyl-fused cyclobutyl group, or [ka] is selected from R c1 are each independently selected from H, F, and Cl; One option is R cn1 and R cn2 together with the carbon atoms bonded thereto form a substituted or unsubstituted azetidinyl group, azacyclopentyl group, piperidine, piperazine, azacyclopentyl-spiro-cyclobutyl, azacyclopentyl-spiro-cyclopentyl, azacyclohexyl-spiro-cyclobutyl, azacyclohexyl-spiro-cyclopentyl, azacyclohexyl-spiro-cyclohexyl, optionally substituted with H, F, Cl, Br, I, OH, ═O, a cyano group, NH 2 , C.F. 3 , further substituted by 0 to 4 substituents selected from a methyl group, an ethyl group, a propyl group, an isopropyl group, a cyclopropyl group, a methoxy group, or an ethoxy group; m is selected from 0 or 1; n is selected from 0 or 1; s is selected from 0 or 1; t is selected from 0, 1 or 2; Other definitions are the same as in the eighth, ninth, tenth, eleventh or twelfth embodiment of the present invention.

[0021] The present invention relates to the following compound or a stereoisomer, tautomer, deuterated form, solvate, prodrug, metabolite, pharma- ceutically acceptable salt or co-crystal thereof, wherein the compound is listed in Table S-1 or Table S-2 below:

[0022] [Table 1-1] [Table 1-2] [Table 1-3]

[0023] [Table 2-1] [Table 2-2] The structure is selected from one of the structures shown in

[0024] The present invention provides pharmaceutical compositions, comprising the aforementioned compounds or stereoisomers, tautomers, deuterated forms, solvates, prodrugs, metabolites, pharma- ceutically acceptable salts, or co-crystals thereof, and a pharma- ceutically acceptable carrier.

[0025] The present invention relates to a pharmaceutical composition comprising a therapeutically effective amount of the compound of the present invention described above or a stereoisomer, deuterated form, solvate, prodrug, metabolite, pharma- ceutically acceptable salt or co-crystal thereof, and a pharma- ceutically acceptable carrier.

[0026] In some embodiments, the pharmaceutical compositions of the invention may be in the form of a unit dosage form (the amount of active ingredient in a unit dosage form is also referred to as the "formulation specification").

[0027] An "effective amount" or "therapeutically effective amount" as used herein includes administering a sufficient amount of a compound disclosed herein that relieves to some extent one or more symptoms of the disease or condition being treated (e.g., a METTL3 enzyme-related disease, such as cancer). In some embodiments, the result is a reduction and / or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. For example, an "effective amount" for therapeutic use is the amount of a composition comprising a compound disclosed herein that is required to provide a clinically significant reduction in a disease symptom.Examples of therapeutically effective amounts include 1-1500 mg, 1-1400 mg, 1-1200 mg, 1-1000 mg, 1-900 mg, 1-800 mg, 1-700 mg, 1-600 mg, 2-600 mg, 3-600 mg, 4-600 mg, 5-600 mg, 6-600 mg, 10-600 mg, 20-600 mg, 25-600 mg, 30-600 mg, 40-600 mg, 50-600 mg, 60-600 mg, 70-600 mg, 75-600 mg, 80-600 mg, 90-600 mg, 100-600 mg, 200-600 mg, 1-500 mg, 2~500mg, 3~500mg, 4~500mg, 5~500mg, 6~500mg, 10~500mg, 20~500mg, 25~500mg, 30~500mg, 40~500mg, 50~500mg, 60~500mg, 70~500mg, 75~500mg, 8 0~500mg, 90~500mg, 100~500mg, 125~500mg, 150~500mg, 200~500mg, 250~500mg, 300~500mg, 400~500mg, 5~400mg, 10~400mg, 20~400mg, 25~400mg, 3 0~400mg, 40~400mg, 50~400mg, 60~400mg, 70~400mg, 75~400mg, 80~400mg, 90~400mg, 100~400mg, 125~400mg, 150~400mg, 200~400mg, 250~400mg, 3 00~400mg, 1~300mg, 2~300mg, 5~300mg, 10~300mg, 20~300mg, 25~300mg, 30~300mg, 40~300mg, 50~300mg, 60~300mg, 70~300mg, 75~300mg, 80~300mg , 90-300mg, 100-300mg, 125-300mg, 150-300mg, 200-300mg, 250-300mg, 1-200mg, 2-200mg, 5-200mg, 10-200mg, 20-200mg, 25-200mg, 30-200mg, 40-200mg, 50-200mg, 60-200mg, 70-200mg, 75-200mg, 80-200mg, 90-200mg, 100-200mg, 125-200mg, 150-200mg, 80-1000mg, and 80-800mg.

[0028] In some embodiments, the pharmaceutical composition contains 1-1500 mg, 1-1400 mg, 1-1200 mg, 1-1000 mg, 20-800 mg, 40-800 mg, 40-400 mg, 25-200 mg, 1 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 110 mg, 120 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, 190 mg, 200 mg, 210 mg, 220 mg, 230 mg, 240 mg, 250 mg, 300 mg, 350 mg, 40 mg, 45 mg, 50 mg, 55 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 110 mg, 120 mg, 250 mg, 260 mg, 270 mg, 280 mg, 290 mg, 300 mg, 310 mg, 320 mg, 330 mg, 340 mg, 350 mg, 360 mg, 370 mg, 380 mg, 390 mg, 400 mg, 410 mg, 420 mg, 430 mg, 440 mg, 450 mg, 50 mg, 55 mg, 65 mg, 70 mg, 75 mg, 80 mg, g, 125 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, 190 mg, 200 mg, 210 mg, 220 mg, 230 mg, 240 mg, 250 mg, 300 mg, 320 mg, 400 mg, 480 mg, 500 mg, 600 mg, 640 mg, 840 mg of a compound of the present invention or a stereoisomer, deuterated form, solvate, prodrug, metabolite, pharma- ceutically acceptable salt, or co-crystal thereof.

[0029] A method for treating a disease in a mammal, the method comprising administering to a subject a therapeutically effective amount of a compound of the present invention or a stereoisomer, deuterated form, solvate, prodrug, metabolite, pharma- ceutically acceptable salt, or co-crystal thereof, wherein the therapeutically effective amount is preferably 1-1500 mg, and the disease is (e.g., a METTL3 enzyme-associated disease such as cancer).

[0030] A method for treating a disease in a mammal, the method comprising administering to a subject a pharmaceutical compound of the present invention or a stereoisomer, deuterated form, solvate, prodrug, metabolite, pharma- ceutically acceptable salt, or co-crystal thereof in a daily dose of 1-1500 mg / day, the daily dose may be a single dose or a divided dose, and in some embodiments, the daily dose is 10-1500 mg / day, 10-1000 mg / day, 10-800 mg / day, 25-800 mg / day, 50-800 mg / day, 100-800 mg / day, 200-800 mg / day, 200-2 ... In some embodiments, the daily dose includes, but is not limited to, 10 mg / day, 20 mg / day, 25 mg / day, 50 mg / day, 80 mg / day, 100 mg / day, 125 mg / day, 150 mg / day, 160 mg / day, 200 mg / day, 300 mg / day, 320 mg / day, 400 mg / day, 480 mg / day, 600 mg / day, 640 mg / day, 800 mg / day, 1000 mg / day, 1200 mg / day, and 1400 mg / day.

[0031] The present invention relates to a kit, which may comprise a composition in the form of a single dose or multiple doses, comprising a compound of the present invention or a stereoisomer, deuterated form, solvate, prodrug, metabolite, pharma- ceutically acceptable salt or co-crystal thereof, wherein the amount of the compound of the present invention or a stereoisomer, deuterated form, solvate, prodrug, metabolite, pharma- ceutically acceptable salt or co-crystal thereof is the same as that amount in said pharmaceutical composition.

[0032] The present invention further provides the application of the aforementioned compound or a stereoisomer, tautomer, deuteride, solvate, prodrug, metabolite, pharma- ceutically acceptable salt or cocrystal thereof, or said pharmaceutical composition, in the manufacture of a medicament for treating a disease associated with inhibition of METTL3 enzyme, wherein said disease is selected from cancer.

[0033] The amounts of the compounds of the invention or of their stereoisomers, deuterated forms, solvates, prodrugs, metabolites, pharma- ceutically acceptable salts or co-crystals are in each case calculated in terms of the free base form.

[0034] Unless stated to the contrary, terms used in the specification and claims of this application have the following meanings.

[0035] Carbon, hydrogen, oxygen, sulfur, nitrogen, or F, Cl, Br, I in the groups and compounds described in the present invention include their isotopic status, and carbon, hydrogen, oxygen, sulfur, or nitrogen in the groups and compounds described in the present invention are optionally further replaced by one or more corresponding isotopes, where the isotope of carbon is: 12 C and 13 C and 14 C; isotopes of hydrogen include protium (H), deuterium (D, also called heavy hydrogen), and tritium (T, also called tritium); isotopes of oxygen include 16 O and 17 O and 18 The isotopes of sulfur include 32 S and 33 S and 34 S and 36 S and the nitrogen isotopes are 14 N and 15 N and the fluorine isotope is 17 F and 19 F and the chlorine isotope is 35 Cl and 37 The isotopes of bromine include Cl and 79 Br and 81 Includes Br.

[0036] “Halogen” refers to F, Cl, Br or I.

[0037] "Halogen substitution" refers to F, Cl, Br or I substitution, including, but not limited to, substitution with 1 to 10 substituents selected from F, Cl, Br or I, substitution with 1 to 6 substituents selected from F, Cl, Br or I, substitution with 1 to 4 substituents selected from F, Cl, Br or I. "Halogen substitution" is abbreviated as "halogenation".

[0038] "Alkyl group" refers to a substituted or unsubstituted straight or branched chain saturated aliphatic hydrocarbon group, including, but not limited to, alkyl groups of 1 to 20 carbon atoms, alkyl groups of 1 to 8 carbon atoms, alkyl groups of 1 to 6 carbon atoms, and alkyl groups of 1 to 4 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, neobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, and various branched chain isomers thereof, and the definition of alkyl group described herein is consistent with this definition. The alkyl group may be monovalent, divalent, trivalent, or tetravalent.

[0039] An "alkylene group" is a substituted or unsubstituted straight-chain or branched-chain divalent saturated hydrocarbon group, -(CH 2 ) v - (where v is an integer from 1 to 10), and examples of alkylene groups include, but are not limited to, methylene, ethylene, propylene, and butylene groups.

[0040] "Cycloalkyl group" refers to a substituted or unsubstituted saturated carbocyclic hydrocarbon group, typically having 3 to 10 carbon atoms, non-limiting examples of which include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl. The definition of cycloalkyl group as described herein is as described above. Cycloalkyl group may be monovalent, divalent, trivalent, or tetravalent.

[0041] "Heterocycloalkyl group" refers to a substituted or unsubstituted saturated heteroatom-containing cyclic hydrocarbon group, containing 3-10 atoms, 3-8 atoms, but not limited to, 1-3 heteroatoms selected from N, O, or S, and optionally substituted N, S in the ring of the heterocycloalkyl group can be oxidized to various oxidation states. Heterocycloalkyl groups can be linked on heteroatoms or carbon atoms, heterocycloalkyl groups can be linked on aromatic or non-aromatic rings, and heterocycloalkyl groups can be linked to bridged or spiro rings, non-limiting examples include oxiranyl, azacyclopropyl, oxetanyl, azetidinyl, tetrahydrofuranyl, tetrahydro-2H-pyranyl, dioxolanyl, dioxanyl, pyrrolidinyl, piperidinyl, imidazolidinyl, oxazolidinyl, oxazinanyl, morpholinyl, hexahydropyrimidinyl, and piperazinyl groups. The heterocycloalkyl group may be monovalent, divalent, trivalent or tetravalent.

[0042] An "alkenyl group" is a substituted or unsubstituted straight and branched chain unsaturated hydrocarbon group that has at least one, and typically one, two or three, carbon-carbon double bonds and a backbone that contains 2 to 10, 2 to 6 or 2 to 4 carbon atoms, including, but not limited to, examples of alkenyl groups include vinyl, allyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-methyl-1-butenyl, 2-methyl-1-butenyl, 2-methyl-3-butenyl, and the like. The definition of alkenyl as described herein is consistent with this definition, including, but not limited to, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-methyl-1-pentenyl, 2-methyl-1-pentenyl, 1-heptenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 1-octenyl, 3-octenyl, 1-nonenyl, 3-nonenyl, 1-decenyl, 4-decenyl, 1,3-butadiene, 1,3-pentadiene, 1,4-pentadiene, and 1,4-hexadiene. The alkenyl group may be monovalent, divalent, trivalent, or tetravalent.

[0043] "Alkynyl group" refers to a substituted or unsubstituted straight and branched chain unsaturated hydrocarbon group that has at least one, and typically one, two or three, carbon-carbon triple bonds and a main chain containing 2 to 10 carbon atoms, including those having 2 to 6 carbon atoms in the main chain, and those having 2 to 4 carbon atoms in the main chain. Examples of alkynyl groups include, but are not limited to, ethynyl, propargyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pent ... Alkynyl groups may be monovalent, divalent, trivalent or tetravalent, including, but not limited to, methyl-1-butynyl, 2-methyl-1-butynyl, 2-methyl-3-butynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, 1-methyl-1-pentynyl, 2-methyl-1-pentynyl, 1-heptynyl, 2-heptynyl, 3-heptynyl, 4-heptynyl, 1-octynyl, 3-octynyl, 1-nonynyl, 3-nonynyl, 1-decynyl, 4-decynyl and the like.

[0044] "Alkoxy" refers to a substituted or unsubstituted -O-alkyl group. Non-limiting examples include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, n-pentyloxy, n-hexyloxy, cyclopropoxy, and cyclobutoxy.

[0045] A "carbocyclic group" or "carbocycle" refers to a substituted or unsubstituted, saturated or unsaturated, aromatic or non-aromatic ring, which may be a 3- to 8-membered monocyclic, 4- to 12-membered bicyclic, or 10- to 15-membered tricyclic system, and which may be linked to an aromatic or non-aromatic ring, which may optionally be a monocyclic, bridged, or spirocyclic ring. Non-limiting examples include cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, 1-cyclopentyl-1-alkenyl, 1-cyclopentyl-2-alkenyl, 1-cyclopentyl-3-alkenyl, cyclohexyl group, 1-cyclohexyl-2-alkenyl, 1-cyclohexyl-3-alkenyl, cyclohexenyl group, benzene ring, naphthalene ring, bicyclo[1.1.1]pentanyl, bicyclo[2.1.1]hexanyl, bicyclo[2.2.1]heptanyl, bicyclo[3.3.2]decanyl, bicyclo[2.2.2]octyl, bicyclo[3.2.1]octyl, bicyclo[3.3.3]undecyl, adamantyl group, [ka] A "carbocyclic group" or "carbocycle" may be monovalent, divalent, trivalent or tetravalent.

[0046] A "heterocyclic group" or "heterocycle" refers to a substituted or unsubstituted, saturated or unsaturated, aromatic or non-aromatic ring, which may be a 3- to 8-membered monocyclic, 4- to 12-membered bicyclic, or 10- to 15-membered tricyclic system, containing one or more (including but not limited to 2, 3, 4, or 5) heteroatoms selected from N, O, or S, and wherein the optionally substituted N, S in the ring of the heterocyclic group may be oxidized to various oxidation states. Heterocyclic groups may be attached at a heteroatom or carbon atom, heterocyclic groups may be attached at an aromatic or non-aromatic ring, and heterocyclic groups may be attached to bridged or spiro rings, non-limiting examples of which are oxiranyl, azacyclopropyl, oxetanyl, azetidinyl, 1,3-dioxolanyl, 1,4-dioxolanyl, 1,3-dioxanyl, azacycloheptyl, pyridyl, furyl, thienyl, pyranyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazolyl, piperidinyl, morpholinyl, thiomorpholinyl, 1,3-dithianyl, dihydrofuryl, dihydropyranyl, dithiolanyl, and tetrahydrofuranyl. , tetrahydropyrrolyl group, tetrahydroimidazolyl group, tetrahydrothiazolyl group, tetrahydropyranyl group, benzimidazolyl group, benzopyridyl group, pyrrolopyridyl group, benzodihydrofuryl group, pyrrolyl group, pyrazolyl group, thiazolyl group, oxazolyl group, pyrazinyl group, indazolyl group, benzothienyl group, benzofuryl group, benzopyrrolyl group, benzimidazolyl group, benzothiazolyl group, benzoxazolyl group, benzopyridyl group, benzopyrimidinyl group, benzopyrazinyl group, piperazinyl group, azabicyclo[3.2.1]octyl group, azabicyclo[5.2.0]nonyl group, oxatricyclo[5.3.1.1]dodecyl group, azaadamantyl group, oxaspiro[3.3]heptyl group, [ka] The "heterocyclic group" or "heterocycle" may be monovalent, divalent, trivalent or tetravalent.

[0047] "Spiro ring" or "spirocyclic group" refers to a polycyclic group that shares one atom (called a spiro atom) between substituted or unsubstituted monocyclic rings, where the number of ring atoms in the spiro ring system can be, but is not limited to, 5-20, 6-14, 6-12, or 6-10, and where one or more of the rings can contain zero or more (including but not limited to, 1, 2, 3, or 4) double bonds and optionally contain N, O, or S(=O). n It may contain 0 to 5 heteroatoms selected from: [ka] A "spiro ring" or "spiro ring group" may be monovalent, divalent, trivalent, or tetravalent.

[0048] "Fused ring" or "fused ring group" refers to a polycyclic group in which each ring in the system shares an adjacent pair of atoms with another ring in the system, where one or more of the rings may contain zero or more (including but not limited to 1, 2, 3 or 4) double bonds, may be substituted or unsubstituted, and each ring in the fused ring system may contain 0-5 heteroatoms or groups containing heteroatoms (N, S(=O) n or O, where n is 0, 1 or 2. The number of ring atoms in the fused ring system may include, but is not limited to, 5 to 20, 5 to 14, 5 to 12, 5 to 10. Non-limiting examples include: [ka] The "fused ring" or "fused ring group" may be monovalent, divalent, trivalent, or tetravalent.

[0049] "Bridged ring" or "bridged ring group" refers to a substituted or unsubstituted polycyclic group containing two atoms that are not directly linked, which may contain zero or more double bonds, and any ring in the fused ring system may contain zero to five groups selected from or containing heteroatoms, including but not limited to N, S(=O)n, or O, where n is 0, 1, 2. The number of ring atoms includes, but is not limited to, 5-20, 5-14, 5-12, or 5-10. Non-limiting examples include: [ka] cubane, adamantane. A "bridged ring" or "bridged ring group" may be monovalent, divalent, trivalent, or tetravalent.

[0050] "Carbospirocycle", "spirocyclic carbocyclic group", "spirocarbocyclic group" or "carbospirocyclic group" refers to a "spirocycle" whose ring system consists only of carbon atoms. The definition of "carbospirocycle", "spirocyclic carbocyclic group", "spirocarbocyclic group" or "carbospirocyclic group" as used herein is consistent with spirocycle.

[0051] "Carbocyclic ring", "fused ring carbocyclic group", "fused carbocyclic group" or "carbocyclic fused ring group" refers to a "fused ring" whose ring system consists only of carbon atoms. The definition of "carbocyclic ring", "fused ring carbocyclic group", "fused carbocyclic group" or "carbocyclic fused ring group" as used herein is consistent with fused ring.

[0052] A "carbon bridged ring", "bridged ring carbocyclic group", "bridged carbocyclic group" or "carbon bridged ring group" refers to a "bridged ring" whose ring system consists only of carbon atoms. The definition of "carbon bridged ring", "bridged ring carbocyclic group", "bridged carbocyclic group" or "carbon bridged ring group" as described herein is consistent with a bridged ring.

[0053] The terms "heteromonocyclic", "monocyclic heterocyclic group" and "heteromonocyclic group" refer to a monocyclic "heterocyclic group" or "heterocycle", and the definitions of the heterocyclic group, "monocyclic heterocyclic group" and "heteromonocyclic group" described herein are consistent with the definition of a heterocycle.

[0054] A "heterofused ring", "heterofused ring group", "fused ring heterocyclic group" or "heterofused ring group" refers to a "fused ring" containing a heteroatom. The definition of a heterofused ring, "heterofused ring group", "fused ring heterocyclic group" or "heterofused ring group" described herein is consistent with the definition of a fused ring.

[0055] A "heterospiro ring", a "heterospiro ring group", a "spirocyclic heterocyclic group" or a "heterospiro ring group" refers to a "spiro ring" containing a heteroatom. The definition of a heterospiro ring, a "heterospiro ring group", a "spirocyclic heterocyclic group" or a "heterospiro ring group" as described herein is consistent with a spiro ring.

[0056] A "hetero bridged ring", "hetero bridged ring group", "bridged ring heterocyclic group" or "hetero bridged ring group" refers to a "bridged ring" containing a heteroatom. The definition of a hetero bridged ring, "hetero bridged ring group", "bridged ring heterocyclic group" or "hetero bridged ring group" described herein is consistent with the bridged ring.

[0057] An "aryl group" or "aromatic ring" refers to a substituted or unsubstituted aromatic hydrocarbon group having a single ring or fused rings, the number of ring atoms in the aromatic ring including, but not limited to, 6 to 18, 6 to 12, or 6 to 10 carbon atoms. The aryl ring can be fused to a saturated or unsaturated carbocyclic or heterocyclic ring, where the ring connected to the base skeleton is an aryl ring, non-limiting examples of which include a benzene ring, a naphthalene ring, [ka] The "aryl group" or "aromatic ring" may be monovalent, divalent, trivalent or tetravalent. When divalent, trivalent or tetravalent, the linking site is on the aryl ring.

[0058] A "heteroaryl group" or "heteroaromatic ring" refers to a substituted or unsubstituted aromatic hydrocarbon group containing 1-5 groups selected from or containing heteroatoms (including but not limited to N, O, or S(=O)n, where n is 0, 1, or 2), and the number of ring atoms in the heteroaromatic ring includes, but is not limited to, 5-15, 5-10, or 5-6. Non-limiting examples of heteroaryl groups include, but are not limited to, pyridyl, furyl, thienyl, pyridyl, pyranyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazolyl, benzopyrazole, benzimidazole, benzopyridine, pyrrolopyridine, and the like. The heteroaryl ring can be fused to a saturated or unsaturated carbocyclic or heterocyclic ring, where the ring connected to the base skeleton is a heteroaryl ring, and non-limiting examples include [ka] The definition of the heteroaryl group described herein is consistent with this definition. The heteroaryl group may be monovalent, divalent, trivalent or tetravalent. When divalent, trivalent or tetravalent, the linking site is on the heteroaryl ring.

[0059] "Five-membered fused five-membered heteroaromatic ring" refers to five fused five-membered heteroaromatic rings, in which in two fused rings, at least one ring contains one or more heteroatoms (including, but not limited to, O, S, or N), and the entire group has aromatic character; non-limiting examples include a pyrrolopyrrole ring, a pyrazolopyrrole ring, a pyrazolopyrazole ring, a pyrrolofuran ring, a pyrazolofuran ring, a pyrrolothiophene ring, and a pyrazolothiophene ring.

[0060] "Five-fused six-membered heteroaromatic ring" refers to five-fused six-membered heteroaromatic rings, where in two fused rings, at least one ring contains one or more heteroatoms (including but not limited to O, S or N) and the entire group has aromatic character; non-limiting examples include benzo five-membered heteroaryl groups, six-membered heteroaromatic rings fused five-membered heteroaromatic rings.

[0061] "Substituted" or "unsubstituted" refers to substitution with one or more (including, but not limited to, 2, 3, 4, or 5) substituents, which can be any of the following: H, F, Cl, Br, I, alkyl, cycloalkyl, alkoxy, halogenated alkyl, thiol, hydroxy, nitro, mercapto, amino, cyano, isocyano, aryl, heteroaryl, heterocyclic, bridged ring, spirocyclic, fused ring, hydroxyalkyl, =O, carbonyl, aldehyde, carboxylic acid, formate, -(CH 2 ) m -C(=O)-R a , -O-(CH 2 ) m -C(=O)-R a , -(CH 2 ) m -C(=O)-NR b R c , -(CH 2 ) m S(=O) n R a , -(CH 2 ) m -Alkenyl-R a , OR d or -(CH 2 ) m -Alkynyl-R a (wherein m and n are 0, 1, or 2), an arylthio group, a thiocarbonyl group, a silyl group, or -NR b R c and the like, where R b and R c are independently selected from H, a hydroxy group, an amino group, a carbonyl group, an alkyl group, an alkoxy group, a cycloalkyl group, a heterocyclic group, an aryl group, a heteroaryl group, a sulfonyl group, and a trifluoromethanesulfonyl group; b and R c R can form a five- or six-membered cycloalkyl group or a heterocyclic group. a and R dEach is independently selected from an aryl group, a heteroaryl group, an alkyl group, an alkoxy group, a cycloalkyl group, a heterocyclic group, a carbonyl group, an ester group, a bridged ring group, a spiro ring group or a fused ring group.

[0062] "Containing 1 to 5 heteroatoms selected from O, S, N" means containing 1, 2, 3, 4 or 5 heteroatoms selected from O, S, N.

[0063] "Substituted with 0 to X substituents" means substituted with 0, 1, 2, 3…X substituents, where X is selected from any integer from 1 to 10. For example, "substituted with 0 to 4 substituents" means substituted with 0, 1, 2, 3 or 4 substituents. For example, "substituted with 0 to 5 substituents" means substituted with 0, 1, 2, 3, 4 or 5 substituents. For example, "the hetero-bridged ring is optionally further substituted with 0 to 4 substituents selected from H or F" means the hetero-bridged ring is optionally further substituted with 0, 1, 2, 3 or 4 substituents selected from H or F.

[0064] A ring of X to Y members (3 ≤ X < Y, Y is selected from any integer from 4 to 12) includes rings of X, X + 1, X + 2, X + 3, X + 4…Y members. The ring includes a heterocyclic ring, a carbocyclic ring, an aromatic ring, an aryl group, a heteroaryl group, a cycloalkyl group, a heteromonocyclic ring, a hetero-fused ring, a heterospiro ring or a hetero-bridged ring. For example, "4 to 7-membered heteromonocyclic ring" means a 4-membered, 5-membered, 6-membered or 7-membered heteromonocyclic ring, and "5 to 10-membered hetero-fused ring" means a 5-membered, 6-membered, 7-membered, 8-membered, 9-membered or 10-membered hetero-fused ring.

[0065] "Optionally" or "optionally" means that the subsequently described event or circumstance may, but does not necessarily, occur, and the description includes both cases where the event or circumstance occurs and cases where it does not occur. For example, "an alkyl group optionally substituted with F" means that the alkyl group may, but does not necessarily, be substituted with F, and indicates that the alkyl group is substituted with F and the alkyl group is not substituted with F.

[0066] "Pharmaceutically acceptable salts" or "a pharma-ceutically acceptable salt thereof" refers to salts in which the compounds of the present invention retain the biological effectiveness and properties of the free acids or free bases and which are obtained by reaction of said free acids with non-toxic inorganic or organic bases, or by reaction of said free bases with non-toxic inorganic or organic acids.

[0067] "Pharmaceutical composition" refers to a mixture of one or more compounds according to the present invention, or a stereoisomer, tautomer, deuteride, solvate, prodrug, metabolite, pharma- ceutically acceptable salt, or co-crystal thereof, and other chemical components, where "other chemical components" refers to a pharma- ceutically acceptable carrier, excipient, and / or one or more other therapeutic agents.

[0068] "Formulation specifications" refers to the weight of the active ingredient contained in one unit dosage form, one tablet unit dosage form, or each other unit dosage form.

[0069] A "carrier" refers to a material that does not cause significant irritation to an organism and does not destroy the biological activity and properties of the administered compound.

[0070] "Excipient" refers to an inert substance added to a pharmaceutical composition to facilitate administration of a compound. Non-limiting examples include calcium carbonate, calcium phosphate, sugars, starches, cellulose derivatives (including microcrystalline cellulose), gelatin, vegetable oils, polyethylene glycols, diluents, granulating agents, lubricants, adhesives, and disintegrating agents.

[0071] "Prodrug" refers to a compound that can be converted to a biologically active compound of the present invention through metabolism in vivo. The prodrug of the present invention is prepared by modifying an amino or carboxyl group in the compound of the present invention, which can be removed by conventional manipulation or in vivo to yield the parent compound. When a prodrug of the present invention is administered to a mammalian individual, the prodrug splits to form a free amino or carboxyl group.

[0072] "Cocrystal" refers to a crystalline body formed by the association of an active pharmaceutical ingredient (API) and a cocrystal former (CCF) through the action of hydrogen bonds or other non-covalent bonds, where the API and CCF are both solids in their pure state at room temperature, and there is a fixed stoichiometric ratio between each component. Cocrystals are multi-component crystalline bodies, and include not only binary cocrystals formed between two neutral solids, but also multi-component cocrystals formed between a neutral solid and a salt or solvate.

[0073] "Animal" includes mammals such as humans, companion animals, zoo animals, and farm animals, and is preferably a human, horse, or dog.

[0074] "Stereoisomer" refers to isomers that result from different ways in which atoms are arranged in molecules, and includes cis-trans isomers, enantiomers and conformational isomers.

[0075] "Tautomer" refers to a functional isomer produced when an atom in a molecule rapidly shifts between two positions, for example, keto-enol isomers and amide-imido alcohol isomers.

[0076] "I C 50 " is the concentration of a drug or inhibitor required to inhibit a specified biological process (or some component in that process, e.g., enzyme, receptor, cell, etc.) by half. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0077] The following examples are provided to illustrate the technical solutions of the present invention in detail, and the protection scope of the present invention includes but is not limited to these.

[0078] The structures of the compounds were confirmed by nuclear magnetic resonance (NMR) and / or mass spectrometry (MS). The NMR displacements (δ) are 10 -6 The NMR measurements were performed using nuclear magnetometers (Bruker Avance III 400 and Bruker Avance 300) and the measurement solvent was deuterated dimethyl sulfoxide (DMSO-d 6 ), deuterated chloroform (CDCl 3 ), deuterated methanol (CD 3 OD) and the internal standard is tetramethylsilane (TMS). The MS measurements were performed using Agilent 6120B (ESI) and Agilent 6120B (APCI). HPLC measurements were performed using an Agilent 1260DAD high pressure liquid chromatograph (Zorbax SB-C18 100 × 4.6 mm, 3.5 μM). Thin layer chromatography silica gel plate is Yantai Yellow Sea HSGF 254 Or Qingdao GF 254 Silica gel plates are used. Silica gel plates used for thin layer chromatography (TLC) are 0.15mm to 0.20mm in diameter. For the separation and purification of products by thin layer chromatography, 0.4mm to 0.5mm diameter plates are used. Column chromatography generally uses Yantai Yellow Sea silica gel with a mesh size of 200-300 as the carrier. Boc: tert-butoxycarbonyl group, Ts: p-toluenesulfonyl group, CDI: N,N-carbonyldiimidazole, Cbz: benzyloxycarbonyl group, TMS: trimethylsilyl group, DDQ: 2,3-dichloro-5,6-dicyanobenzoquinone, DMAP: 4-dimethylaminopyridine, TBTU: CAS 125700-67-6, DIPEA: N,N-diisopropylethylamine, DMF: N,N-dimethylformamide, THF: tetrahydrofuran, HATU: CAS: 148893-10-1.

[0079] Example 1: Preparation of Compound 1 [ka] Step 1: Fabrication of 1b Compound 1a (2.0 g, 20.59 mmol) was dissolved in 100 mL of water, 1a-1 (3.83 g, 26.96 mmol) was added, the reaction solution was maintained at room temperature and stirred for 16 hours, 100 mL of dichloromethane was added, extraction and separation was performed, the aqueous phase was further extracted once with dichloromethane (100 mL × 1), the organic phase was combined, the organic phase was washed once with saturated saline (100 mL × 1), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography to obtain 1b (1.2 g, yield 28.1%). LC-MS: m / z(ESI): 208.1 [M+H] +

[0080] Step 2: Fabrication of 1c Under nitrogen gas protection, 1b (1.20 g, 5.79 mmol) was dissolved in anhydrous THF (20 mL), potassium trimethylsilanolate (1.49 g, 11.58 mmol) was added, and the mixture was reacted at 70° C. for 3 h. The reaction solution was cooled to room temperature, and 4 M hydrochloric acid-dioxane solution (3.2 mL) was added, followed by filtration. The resulting solid was filtered, washed with ether, and dried to obtain the target compound (1c) (0.75 g, 67.0%). LC-MS: m / z(ESI): 194.1 [M+H] +

[0081] Step 3: Preparation of Compound 1 Compound 1c (58 mg, 0.3 mmol) was dissolved in 5 mL of ultra-dehydrated DMF, and then 1c-1 (100 mg, 0.41 mmol), HATU (171 mg, 0.45 mmol), and DIPEA (0.25 mL) were added to the reaction vessel in that order. The reaction solution was kept at room temperature and stirred for 16 h, and then the mixture was diluted with 10 mL of ethyl acetate and 10 mL of saturated NaHCO 3An aqueous solution was added, extraction and separation were performed, the aqueous phase was further extracted once with ethyl acetate (10 mL × 1), the organic phase was combined, the organic phase was washed once with saturated saline (10 mL × 1), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was then subjected to prep-HPLC to obtain the trifluoroacetate salt of compound 1 (43 mg, yield 34.2%). Preparation conditions: Instrument: SHIMADZU LC-20AP, Chromatography column: Phenomenex C18, Mobile phase: A is 0.1% TFA aqueous solution, B is acetonitrile, Gradient: Mobile phase B increases from 10% to 40% within 15 min, Flow rate: 25 mL / min, Column temperature: Room temperature, Detection wavelength: 210 nm, Sample treatment: Sample concentration is 100 mg / ml, Solvent is acetonitrile and water. Injection volume: 1 milliliter per injection. Post-treatment: After separation, the mixture was freeze-dried to obtain a solid powder. 1 H NMR (400MHz, DMSO-d 6 )δ 11.06(s,1H)9.25-9.17(m,1H),8.83-8.68(m,2H),7.74-7.69(m,2H),7 .53-7.48(m,1H),7.41-7.37(m,1H),7.07-7.02(m,1H),6.57-6.53(m,1 H),6.46(s,1H),4.61-4.54(m,2H),4.29-4.20(m,2H),3.78(s,3H),3.0 4-2.95(m,2H),2.65-2.55(m,1H),2.10-2.01(m,2H),1.93-1.70(m,4H). LC-MS: m / z=419.2[M+H] +

[0082] Example 2: Preparation of Compound 2 [ka] Step 1: Fabrication of 2b Compound 2a (2.0 g, 24.07 mmol) was dissolved in 100 mL of water, 1a-1 (3.42 g, 24.07 mmol) was added, the reaction solution was maintained at room temperature and stirred for 16 hours, 100 mL of dichloromethane was added, extraction and separation was performed, the aqueous phase was further extracted once with dichloromethane (100 mL × 1), the organic phase was combined, the organic phase was washed once with saturated saline (100 mL × 1), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography to obtain 2b (0.6 g, yield 12.9%). LC-MS: m / z(ESI): 194.1 [M+H] +

[0083] Step 2: Fabrication of 2c Under nitrogen gas protection, 2b (0.60 g, 3.11 mmol) was dissolved in anhydrous THF (20 mL) and potassium trimethylsilanolate (0.80 g, 6.22 mmol) was added. The mixture was stirred at 70° C. for 3 h. The reaction mixture was cooled to room temperature and 4 M hydrochloric acid-dioxane solution (0.5 mL) was added. The mixture was then filtered. The solid obtained was filtered, washed with ether, and dried to obtain the target compound (2c) (0.45 g, 80.7%).

[0084] Step 3: Preparation of Compound 2 Compound 2c (54 mg, 0.3 mmol) was dissolved in 5 mL of ultra-dehydrated DMF, and then 1c-1 (100 mg, 0.41 mmol), HATU (171 mg, 0.45 mmol), and DIPEA (0.15 mL) were added to the reaction vessel in that order. The reaction solution was kept at room temperature and stirred for 16 h, and then the reaction mixture was diluted with 10 mL of ethyl acetate and 10 mL of saturated NaHCO 3 An aqueous solution was added, extraction and separation were performed, the aqueous phase was further extracted once with ethyl acetate (10 mL × 1), the organic phase was combined, the organic phase was washed once with saturated saline (10 mL × 1), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was then subjected to prep-HPLC to obtain the trifluoroacetate salt of compound 2 (18 mg, yield 14.83%). The preparation conditions are as follows: Instrument: SHIMADZU LC-20AP, Chromatography column: Phenomenex C18, Mobile phase: A is 0.1% TFA aqueous solution, B is acetonitrile, Gradient: Mobile phase B increases from 8% to 38% within 15 min, Flow rate: 25 mL / min, Column temperature: Room temperature, Detection wavelength: 210 nm, Sample treatment: Sample concentration is 100 mg / ml, Solvent is acetonitrile and water, Injection volume: 1 milliliter per injection. Post-treatment: After separation, the mixture was freeze-dried to obtain a solid powder. 1 H NMR (400MHz, DMSO-d 6 )δ 12.91(s,1H),11.07(s,1H),8.85-8.70(m,3H),7.71-7.68(m,1H),7.67 -7.62(m,1H),7.53-7.48(m,1H),7.41-7.37(m,1H),7.06-7.01(m,1H),6 .58-6.52(m,1H),6.45(s,1H),4.59-4.53(m,2H),4.29-4.22(m,2H),3.0 3-2.95(m,2H),2.67-2.55(m,1H),2.11-1.99(m,2H),1.92-1.68(m,4H). LC-MS: m / z=405.2[M+H] + .

[0085] Example 3: Preparation of Compound 3 [ka] Step 1: Manufacturing 3b Compound 1c (200 mg, 1.04 mmol), TBTU (500 mg, 1.56 mmol), and DIPEA (0.52 mL) were dissolved in 5 mL of ultra-dehydrated DMF, and the reaction solution was reacted at room temperature for 1 hour. Then, 3a-1 (260 mg, 1.05 mmol) was added to the reaction vessel and reacted at room temperature for 16 hours. 10 mL of ethyl acetate and 10 mL of saturated NaHCO 3An aqueous solution was added, extraction and separation were performed, the organic phase was taken out, and then the aqueous phase was extracted with ethyl acetate (10 mL), the organic phase was combined, the organic phase was washed with saturated saline (10 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was then purified by column chromatography to obtain compound 3b (300 mg, yield 68.1%).

[0086] Step 2: Manufacturing 3c Under nitrogen gas protection, 3b (300 mg, 0.71 mmol) was dissolved in anhydrous THF (5 mL), water (1 mL) and acetic acid (1 mL) were added, and the mixture was reacted at room temperature for 2 hours. The reaction solution was concentrated, 10 mL of water was added, and after the solid precipitated, it was filtered. The obtained solid was filtered, washed with ether, and dried to obtain the target compound (3c) (220 mg, 88.70%). 1 H NMR (400MHz, DMSO-d 6 ):δ 11.88(s,1H),9.81(s,1H),9.33-9.25(m,1H),7.75-7.66(m,3H),7.43-7. 33(m,2H),7.15-7.08(m,1H),6.46(s,1H),4.62-4.57(m,2H),3.79(s,3H).

[0087] Step 3: Preparation of compound 3 Compound 3c (120 mg, 0.34 mmol) was added to a round-bottom flask containing 4 mL of ultra-dehydrated DMSO at room temperature, followed by 3c-1 (103 mg, 0.68 mmol) and AcOH (0.1 mL) in sequence. The reaction mixture was kept at room temperature and allowed to react for 2 h, after which sodium triacetoxyborohydride (216 mg, 1.02 mmol) was added to the reaction mixture and allowed to react overnight. 10 mL of organic solvent (dichloromethane / methanol = 10 / 1) and 10 mL of saturated NaHCO 3An aqueous solution was added, extraction and separation were performed to obtain an organic phase, and then the aqueous phase was extracted once with 10 mL of an organic solvent (dichloromethane / methanol = 10 / 1). The organic phases were combined, washed with saturated saline (10 mL x 2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was separated and purified using a silica gel chromatography column to obtain compound 3 (46 mg, 30.1%). LC-MS: m / z(ESI): 449.3[M+1] + 1 H NMR (400MHz, DMSO-d 6 ):δ 10.83(s,1H),9.17-9.07(m,1H),7.77-7.67(m,2H),7.41-7.33(m,1H),7.28(s,1H),6.98-6.91(m,1 H),6.47(s,1H),6.20(s,1H),4.55(d,2H),3.80(s,2H),3.77(s,3H),2.76(s,2H),1.95-1.90(m,6H).

[0088] Example 4: Preparation of Compound 4 [ka] Step 1: Fabrication of 4b Compound 2b (500 mg, 2.59 mmol) was dissolved in 10 mL of ultra-dehydrated DMF, and sodium hydride (204 mg, 5.10 mmol) was added under ice bath conditions. After reacting for 1 hour, deuterated iodomethane (750 mg, 5.18 mmol) was added to the reaction vessel and reacted at room temperature for 16 hours. After the reaction was completed, 1N hydrochloric acid was added to adjust the pH to 7, and 10 mL of dichloromethane and 10 mL of saturated NaHCO 3 An aqueous solution was added, extraction and separation was performed, and the organic phase was taken out. The aqueous phase was then extracted once with dichloromethane (10 mL × 1), and the organic phases were combined, washed once with saturated saline (10 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was then purified by column chromatography to obtain compound 4b (200 mg, yield 36.7%). LC-MS: m / z(ESI): 211.1 [M+H] +

[0089] Step 2: Manufacturing 4c Under nitrogen gas protection, 4b (200 mg, 0.95 mmol) was dissolved in anhydrous THF (5 mL) and potassium trimethylsilanolate (243 mg, 1.90 mmol) was added. The mixture was reacted at 70° C. for 1 h. The reaction mixture was cooled to room temperature and 4 M hydrochloric acid-dioxane solution (0.75 mL) was added. The mixture was then filtered. The resulting solid was filtered, washed with ether, and dried to give the desired compound (4c) (160 mg, 85.8%). LC-MS: m / z(ESI): 197.1 [M+H] +

[0090] Step 3: 4D Manufacturing Compound 4c (160 mg, 0.82 mmol) and CDI (133 mg, 0.82 mmol) were dissolved in 5 mL of ultra-dehydrated DMF, and the reaction solution was reacted at 70 degrees for 3 hours, then cooled to room temperature, and 3a-1 (203 mg, 0.82 mmol) was added to the reaction vessel and reacted at room temperature for 16 hours. After the reaction was completed, 10 mL of ethyl acetate and 10 mL of water were added, extraction and separation were performed, and the organic phase was taken out, and then the aqueous phase was extracted once with ethyl acetate (10 mL), and the organic phase was combined, and the organic phase was washed once with saturated saline (10 mL x 1), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound 4d (330 mg, yield 94.3%).

[0091] Step 4: Manufacturing 4e Under nitrogen gas protection, 4d (330 mg, 0.77 mmol) was dissolved in anhydrous THF (10 mL), water (1 mL) and acetic acid (1 mL) were added, and the mixture was reacted at room temperature for 2 h. After concentration under reduced pressure, 10 mL of water was added, and after the solid precipitated, it was filtered. The obtained solid was filtered, washed with ether, and dried to obtain the target compound (4e) (270 mg, 99.5%). LC-MS: m / z(ESI): 353.0 [M+H] +

[0092] Step 5: Preparation of compound 4 Compound 4e (270 mg, 0.77 mmol) was added to a round-bottom flask containing 8 mL of ultra-dehydrated DMSO at room temperature, followed by 3c-1 (175 mg, 1.16 mmol) and AcOH (0.5 mL) in sequence. The reaction mixture was kept at 70°C for 2 h, after which sodium triacetoxyborohydride (489 mg, 2.31 mmol) was added to the reaction mixture and reacted overnight. After the reaction was completed, 10 mL of dichloromethane / methanol (v:v=10:1) and 10 mL of saturated NaHCO were added. 3 An aqueous solution was added, extraction and separation were performed, and then the aqueous phase was extracted once with 10 mL of dichloromethane / methanol (v:v=10:1), and the organic phases were combined and washed twice with saturated saline (10 mL×2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was separated and purified using a silica gel chromatography column to obtain compound 4 (160 mg, 46.0%). LC-MS: m / z(ESI): 452.3 [M+H] + 1 H NMR (400MHz, DMSO-d 6 ):δ 10.83(s,1H),9.15-9.07(m,1H),7.73-7.67(m,2H),7.39-7.33(m,1H),7.29(s,1H),6.98-6.9 1(m,1H),6.47(s,1H),6.21(s,1H),4.55(d,2H),3.81(s,2H),2.76(s,2H),1.95-1.89(m,6H).

[0093] Example 5: Preparation of Compound 5 [ka] Step 1: Fabrication of 5b 2b (500 mg, 2.6 mmol), 5a (1.04 g, 7.8 mmol), sodium iodide (40 mg, 0.26 mmol) and potassium carbonate (1.07 g, 7.8 mmol) were added to acetone (20 mL), and the reaction was stirred at 70°C for 12 hours. The reaction solution was then cooled to room temperature and concentrated under reduced pressure. The residue was separated and purified using a silica gel column to obtain 5b (360 mg, 54% yield). LC-MS: m / z(ESI): 248.1 [M+H] +

[0094] Step 2: Fabrication of 5c 5b (99 mg, 0.4 mmol) and lithium hydroxide monohydrate (84 mg, 2.0 mmol) were added to a mixed solvent of tetrahydrofuran (5 mL) and water (1.5 mL), and the mixture was stirred at room temperature for 1 hour. The reaction solution was adjusted to pH=6 with 0.5 M hydrochloric acid, and the resulting mixture was concentrated under reduced pressure to dryness to obtain crude 5c. LC-MS: m / z(ESI): 234.1 [M+H] +

[0095] Step 3: Preparation of compound 5 The crude 5c obtained in the previous step and carbonyldiimidazole (73 mg, 0.45 mmol) were added to DMF (7 mL) and stirred at 70° C. for 5 h, the reaction was allowed to stand at room temperature, 1c-1 (121 mg, 0.5 mmol) was added to the system, and the reaction was allowed to continue stirring at room temperature for 10 h. The reaction was then concentrated to dryness under reduced pressure, and the residue was separated by HPLC to give the trifluoroacetate salt of compound 5 (15 mg). HPLC preparative conditions: Instrument: Waters 2767 preparative liquid, chromatographic column: XBridge@Prep C18 (19mm x 250mm). The sample was dissolved in DMF and filtered through a 0.45uM filter to prepare the sample liquid. Preparative chromatographic conditions: a. Mobile phase A: acetonitrile, b. Water (containing 0.1% trifluoroacetic acid), the content of mobile phase A is 10% to 50% gradient elution, the flow rate is 12mL / min, and the elution time is 20 minutes. LC-MS: m / z(ESI): 459.3 [M+H] + 1 H NMR (400MHz, DMSO-d 6):δ 11.09(s,1H),9.26(t,1H),8.81(s,2H),7.83(d,1H),7.76(d,1H),7.50 (d,1H),7.38(s,1H),7.04(d,1H),6.55(s,1H),6.47(s,1H),4.58(d,2H) ),4.25(t,2H),4.10(d,2H),3.04-2.94(m,2H),2.66-2.56(m,1H),2.11 -2.00(m,2H),1.92-1.69(m,4H),1.38-1.26(m,1H),0.59-0.44(m,4H).

[0096] Example 6: Preparation of Compound 6 [ka] Starting from intermediates 2b and 6a, the trifluoroacetate salt of compound 6 was obtained according to the synthesis method of Example 5. HPLC preparative conditions: Instrument: Waters 2767 preparative liquid, chromatographic column: XBridge@Prep C18 (19mm x 250mm). The sample was dissolved in DMF and filtered through a 0.45uM filter to prepare the sample liquid. Preparative chromatographic conditions: a. Mobile phase A: acetonitrile, b. Water (containing 0.1% trifluoroacetic acid), the content of mobile phase A is 10% to 50% gradient elution, the flow rate is 12mL / min, and the elution time is 20 minutes. LC-MS: m / z(ESI): 447.3 [M+H] +

[0097] Example 7: Preparation of Compound 7 [ka] Step 1: Fabrication of 7b Compound 7a (500 mg, 2.59 mmol) was dissolved in ultra-dehydrated DMF (20 mL), cesium carbonate (1.50 g, 4.62 mmol) was added, and the mixture was heated to 110 degrees. Then, sodium chlorodifluoroacetate (770 mg, 5.05 mmol) was added to the reaction vessel and reacted for 20 minutes. After the reaction was completed, the mixture was cooled to room temperature, and 20 mL of dichloromethane and 20 mL of water were added to perform extraction and separation. The aqueous phase was then extracted once with dichloromethane (20 mL), and the dichloromethane layers were combined, washed once with saturated saline (30 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound 7b (570 mg, yield 90.5%). LC-MS: m / z(ESI): 244.1 [M+H] +

[0098] Step 2: Fabrication of 7c Under nitrogen gas protection, 7b (570 mg, 2.34 mmol) was dissolved in anhydrous THF (10 mL) and potassium trimethylsilanolate (450 mg, 3.51 mmol) was added and reacted at 70°C for 1 h. The reaction solution was cooled to room temperature and a 4 M hydrogen chloride-dioxane solution (1.2 mL) was added, followed by filtration. The resulting solid was filtered, washed with ether, and dried to give the desired compound 7c (500 mg, 93.2%). LC-MS: m / z(ESI): 230.1 [M+H] +

[0099] Step 3: Manufacturing 7d Compound 7c (100 mg, 0.44 mmol) and CDI (70 mg, 0.43 mmol) were dissolved in ultra-dehydrated DMF (4 mL), and the reaction solution was reacted at 70 ° C for 3 hours, then cooled to room temperature, and 3a-1 (100 mg, 0.40 mmol) was added to the reaction vessel and reacted at room temperature for 16 hours. After the reaction was completed, ethyl acetate (10 mL) and water (10 mL) were added, and extraction and separation were performed. Then, the aqueous phase was extracted once with ethyl acetate (10 mL), and the organic phase was combined, and the organic phase was washed once with saturated saline (10 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was purified by column chromatography to obtain compound 7d (180 mg, yield 89.0%).

[0100] Step 4: Manufacturing 7e Under nitrogen gas protection, 7d (180 mg, 0.39 mmol) was dissolved in anhydrous THF (5 mL) solution, and water (1 mL) and acetic acid (1 mL) were added. The mixture was reacted at room temperature for 2 h. Tetrahydrofuran was removed by rotation, water (10 mL) was added, and after the solid precipitated, it was filtered. The obtained solid was filtered, washed with ether, and dried to obtain the target compound 7e (157 mg, 97.8%). LC-MS: m / z(ESI): 386.0 [M+H] +

[0101] Step 5: Preparation of compound 7 Compound 7e (120 mg, 0.31 mmol) was added to a round-bottom flask containing ultra-dehydrated DMSO (4 mL) at room temperature, followed by 3c-1 (70 mg, 0.46 mmol) and AcOH (0.1 mL) in sequence. The reaction mixture was kept at 70°C for 2 h, after which sodium triacetoxyborohydride (190 mg, 0.90 mmol) was added to the reaction mixture and the reaction was allowed to proceed overnight. After the reaction was completed, the reaction mixture was diluted with dichloromethane / methanol (v:v=10 / 1, 5 mL) and saturated NaHCO 3(5 mL) aqueous solution was added, extraction and separation were performed, and then the aqueous phase was extracted once with dichloromethane / methanol (v:v=10 / 1, 5 mL). The organic layers were combined, washed twice with saturated saline (5 mL x 2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was then subjected to column chromatography using a silica gel chromatography column to obtain compound 7 (82 mg, 54.6%). LC-MS: m / z(ESI): 485.3 [M+H] + 1 H NMR (400MHz, DMSO-d 6 ):δ 10.84(s,1H),9.30-9.23(m,1H),8.37-8.04(m,2H),7.92-7.88(m,1H),7.41-7.34(m,1H),7.28(s,1H),6.97-6.90(m,1H) ),6.62(s,1H),6.23-6.17(m,1H),4.60-4.54(m,2H),3.80(s,2H),2.75(s,2H),2.08-1.96(br.s,1H),1.90-1.94(m,6H).

[0102] Example 8: Preparation of Compound 8 [ka] The reaction conditions and procedures were the same as in Example 4 to obtain compound 8 (21.0 mg). LC-MS: m / z(ESI): 463.3 [M+H] + . 1 H NMR(400MHz,DMSO-d6):δ 11.03(s,1H),9.22(t,1H),9.03-8.86(m,2H),7.80(d,1H),7.75(d,1H),7.51(d,1H),7.40(s,1H),7. 08-7.03(m,1H),6.57(s,1H),6.46(s,1H),4.58(d,2H),4.34-4.21(m,4H),2.11(d,6H),1.40(t,3H).

[0103] Example 9: Preparation of Compound 9 [ka] The reaction conditions and procedures were the same as in Example 5 to obtain compound 9 (12.0 mg). LC-MS: m / z(ESI): 433.3 [M+H] + . 1 H NMR(400MHz,DMSO-d6):δ 11.03(s,1H),9.27-9.18(m,1H),8.28-8.67(m,2H),7.81(d,1H),7.75(d,1H),7.50(d,1H),7.39(s,1H),7.08-7.01(m,1H),6.56(s,1H) ,6.46(s,1H),4.58(d,2H),4.33-4.19(m,4H),3.08-2.93(m,2H),2.66-2.57(m,1H),2.11-2.00(m,2H),1.93-1.70(m,4H),1.40(t,3H).

[0104] Example 10: Preparation of Compound 10 [ka] The reaction conditions and procedures were the same as in Example 5 to obtain compound 10 (4.0 mg). LC-MS: m / z(ESI): 443.3 [M+H] + . 1 H NMR(400MHz,DMSO-d6):δ 11.03(s,1H),9.35(t,1H),8.84-8.62(m,2H),7.81-7.76(m,2H),7.50(d,1H),7.39(s,1H),7.07-7.02(m,1H),6.55(s,1H),6.50( s,1H),5.16(d,2H),4.58(d,2H),4.24(s,2H),3.58(t,1H),2.99(d,2H),2.64-2.54(m,1H),2.11-2.00(m,2H),1.91-1.69(m,4H).

[0105] Example 11: Preparation of Compound 11 [ka] The reaction conditions and procedures were the same as in Example 5, and the trifluoroacetate of compound 11 was obtained (6 mg). HPLC preparative conditions for the final product: Instrument: Waters 2767 Preparative Chromatography Column: SunFire@Prep C18 (19 mm x 150 mm), Mobile phase composition: Mobile phase A: acetonitrile, Mobile phase B: water (containing 0.1% TFA). LC-MS: m / z(ESI): 445.3 [M+H] + 1 H NMR(400MHz,DMSO-d6):δ 11.08(s,1H),9.01(t,1H),8.78(s,2H),7.70(d,1H),7.65(d,1H),7.51(d,1H),7.40(s,1H),7.05(d,1H),6.56(s,1H),6.49(s,1H),4.6 0(d,2H),4.25(s,2H),3.82-3.69(m,1H),3.04-2.95(m,2H),2.69-2.55(m,1H),2.09-2.01(m,2H),2.89-1.69(m,4H),1.15-1.05(m,4H).

[0106] Example 12: Preparation of Compound 12 [ka] Step 1: Fabrication of 12b 12a (3.81 g, 21.0 mmol) and carbonyldiimidazole (3.41 g, 21.0 mmol) were added to DMF (40 mL), and the reaction was stirred at room temperature for 1 hour, after which cyclobutylmethylamine hydrochloride (3.06 g, 25.2 mmol) was added to the system, and the reaction was continued to be stirred at room temperature for 18 hours. Water (400 mL) was added to the reaction system to quench the reaction, and a large amount of solid precipitated. The filter cake was filtered, washed with water (35 mL x 2), and the filter cake was collected, reduced pressure, and dried in vacuum to obtain 12b (4.6 g, 88% yield). LC-MS: m / z(ESI): 249.1 [M+H] +

[0107] Step 2: Fabrication of 12c 12b (1.15 g, 4.63 mmol) and DDQ (1.58 g, 6.95 mmol) were added to a mixed solvent of methanol (100 mL) and water (20 mL), and the mixture was stirred at 45° C. for 4 hours. The reaction solution was cooled to room temperature, poured into saturated aqueous sodium bicarbonate solution (200 mL) and stirred thoroughly to precipitate a solid. After filtration with diatomaceous earth, the filter cake was removed, and the resulting mother liquor was concentrated and purified by a silica gel column to obtain product 12c (600 mg, yield 49%). LC-MS: m / z(ESI): 263.1 [M+H] +

[0108] Step 3: Fabrication of 12d 12c (500 mg, 1.91 mmol) and hydroxylamine hydrochloride (140 mg, 2.02 mmol) were added to a mixture of tetrahydrofuran (5 mL), ethanol (15 mL) and water (2 mL) and stirred at room temperature for 2 h. The reaction was then directly concentrated and spun to dryness to give crude compound 12d, which was used directly in the next step. LC-MS: m / z(ESI): 278.1 [M+H] +

[0109] Step 4: Fabrication of 12e. The crude 12d obtained in the previous step was added to 1,4-dioxane (30 mL) and stirred homogeneously at room temperature, then lithium aluminum hydride (2.5 M in toluene) (6 mL, 15 mmol) was slowly added dropwise to the system, and the reaction was stirred at 100° C. for 2 hours. The reaction solution was cooled to room temperature, and water (15 mL) was slowly added dropwise to the reaction solution, and then 15% aqueous sodium hydroxide solution (15 mL) was added dropwise, and after stirring for 5 minutes, water (45 mL) was further added dropwise, and the mixture was stirred for 10 minutes, filtered, and the filtrate was spin-dried to obtain the crude compound 12e, which was used directly in the next step.

[0110] Step 5: Preparation of compound 12. 12f (152 mg, 0.8 mmol) and carbonyldiimidazole (130 mg, 0.8 mmol) were added to DMF (5 mL) and stirred at room temperature for 3 h, then the crude 12e obtained in the previous step was added to the system and stirred at room temperature for 3 h. The reaction solution was directly concentrated and spin-dried, and then separated by HPLC to give the trifluoroacetate salt of compound 12 (72 mg, 10% overall yield for the three-step reaction). HPLC separation conditions: Instrument: Waters 2767 separation liquid, chromatographic column: XBridge@Prep C18 (19mm x 250mm). The sample was dissolved in DMF and filtered through a 0.45uM filter to prepare the sample solution. The preparation chromatography conditions were: a. Mobile phase A: acetonitrile, b. Water (containing 0.1% trifluoroacetic acid), the content of mobile phase A was gradient eluted from 10% to 50%, the flow rate was 12mL / min, and the elution time was 20 minutes. LC-MS: m / z(ESI): 420.1 [MH] - 1 H NMR(400MHz,DMSO-d6):δ 11.12(s,1H),9.32(t,1H),9.02(d,1H),8.64(s,2H),8.13-7.98(m,1H),7.76(d,1H),7.51-7.40(m,1H),7.03(s,1H),6.89 (s,1H),6.47(s,1H),4.65(d,2H),4.16(t,2H),2.99-2.86(m,2H),2.62-2.54(m,1H),2.10-1.97(m,2H),1.89-1.68(m,4H).

[0111] Example 13: Preparation of Compound 13 [ka] Step 1: Fabrication of 13b. 13a (1.95 g, 10.0 mmol), DMAP (122 mg, 1.0 mmol) and di-tert-butyl dicarbonate (2.61 g, 12.0 mmol) were added to acetonitrile (50 mL), and the reaction was stirred at 45° C. for 2 hours. The reaction solution was then concentrated, and the residue was separated and purified by silica gel column chromatography to obtain 13b (2.9 g, 98% yield). LC-MS: m / z(ESI): 240.1 [M-55] +

[0112] Step 2: Fabrication of 13c. 13b (2.8g, 9.5mmol) was added to tetrahydrofuran (100mL) and stirred at -30°C for 10 minutes, then DIBAL (15.8mL, 23.7mmol) was slowly added dropwise to the system, and the reaction was continued with stirring at the same temperature for 3 hours. The reaction solution was poured into 0.5M hydrochloric acid (50mL) and stirred thoroughly, then extracted with ethyl acetate (50mL x 3), the organic phase was dried over anhydrous sodium sulfate, filtered, concentrated, and the residue was separated and purified by silica gel column to obtain product 13c (1.3g, yield 51%). LC-MS: m / z(ESI): 250.1 [M-17] +

[0113] Step 3: Fabrication of 13d. 13c (900 mg, 3.37 mmol) and activated manganese dioxide (2.93 g, 33.7 mmol) were added to dichloromethane (20 mL) and stirred at room temperature for 5 hours. The reaction solution was filtered through diatomaceous earth, and the filtrate was concentrated. The residue was separated and purified using a silica gel column to obtain product 13d (830 mg, 93% yield). LC-MS: m / z(ESI): 210.1 [M-55] +

[0114] Step 4: Fabrication of 13f. 13d (830 mg, 3.13 mmol) and 8f-1 (709 mg, 4.7 mmol) were added to N,N-dimethylacetamide (20 mL), then glacial acetic acid (0.1 mL) was added dropwise, and the reaction was stirred at 65 ° C for 3 hours, then the reaction was cooled to room temperature, and sodium triacetoxyborohydride (1.66 g, 7.82 mmol) was added to the system, and the reaction was stirred at room temperature for 10 hours. 0.5 M hydrochloric acid (20 mL) was slowly added dropwise to the reaction, and after stirring for 5 minutes, it was extracted with ethyl acetate (50 mL × 3), the organic phase was dried over anhydrous sodium sulfate, filtered, the filtrate was concentrated, and the residue was separated and purified by silica gel column to give product 13f (911 mg, yield 80%).

[0115] Step 5: Production of 13g. 13f (911 mg, 2.5 mmol), di-tert-butyl dicarbonate (610 mg, 2.8 mmol) and DMAP (30 mg, 0.25 mmol) were added to dichloromethane (30 mL), the reaction was stirred at room temperature for 1 h, and then the reaction solution was concentrated, after which the residue was separated and purified by silica gel column to give product 13g (1.1 g, 94% yield).

[0116] Step 6: Manufacture for 13 h. 13g (1.1 g, 2.37 mmol) and DDQ (681 mg, 3.0 mmol) were added to a mixed solvent of methanol (30 mL) and water (5 mL), and the reaction was stirred at room temperature for 3 hours. The reaction solution was then added to a saturated aqueous sodium bicarbonate solution (100 mL) and stirred for 5 minutes, after which it was extracted with ethyl acetate (50 mL x 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The residue was separated and purified by a silica gel column to obtain product 13h (550 mg, yield 48%). LC-MS: m / z(ESI): 479.1 [M+H] +

[0117] Step 7: Manufacturing of 13i. 13h (550 mg, 1.15 mmol) and hydroxylamine hydrochloride (159 mg, 2.3 mmol) were added to a mixture of tetrahydrofuran (50 mL), ethanol (15 mL) and water (1.5 mL), and the reaction was stirred at room temperature for 3 hours. Water (50 mL) was added to the system and stirred thoroughly to precipitate a solid. The resulting solid was filtered and dried to obtain product 13i (450 mg, 79% yield). LC-MS: m / z(ESI): 494.1 [M+H] +

[0118] Step 8: Fabrication of 13j. 13i (100 mg, 0.2 mmol) and zinc powder (66 mg, 1.02 mmol) were added to glacial acetic acid (5 mL), the reaction was stirred at room temperature for 6 h, then the reaction was filtered through diatomaceous earth, the filtrate was concentrated and spun to dryness to give the acetate salt of 2j, which was then extracted with dichloromethane (50 mL x 3), the organic phase was washed with saturated aqueous potassium carbonate, the organic phase was dried over anhydrous sodium sulfate, then filtered and the filtrate was concentrated to give product 13j (50 mg, 51% yield).

[0119] Step 9: Manufacturing 13k. 13j (50 mg, 0.1 mmol) and 12f (19 mg, 0.1 mmol) were added to N,N-dimethylacetamide (4 mL), HATU (38 mg, 0.1 mmol) and DIPEA (26 mg, 0.2 mmol) were added, and the reaction was stirred at room temperature for 1 hour. Then, water (20 mL) was added to the system, and the mixture was extracted with ethyl acetate (50 mL x 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The residue was separated and purified by silica gel column to give product 13k (50 mg, 73% yield).

[0120] Step 10: Preparation of compound 13. 13k (50 mg, 0.076 mmol) was added to a mixed solvent of dichloromethane (3 mL) and trifluoroacetic acid (0.6 mL), stirred at room temperature for 24 hours, concentrated, and the residue was separated and purified by silica gel preparative thin layer chromatography to obtain compound 13 (6 mg, yield 17%). LC-MS: m / z(ESI): 450.0 [MH] - 1 H NMR (400MHz, CD 3 OD):δ 8.97(d,1H),7.92-7.85(m,1H),7.73(d,1H),7.33-7.26(m,1H),7.00(s,1H), 6.85(s,1H),6.15(s,1H),4.65(s,2H),3.79(s,2H),2.82(s,2H),1.88(d,6H). Preparation of the trifluoroacetate salt of compound 13: Compound 13 (4 mg, 0.00887 mmol) was added to DCM (1 mL), followed by trifluoroacetic acid (0.01 mL), and stirred at room temperature for 5 min before concentrating to dryness under reduced pressure to give the trifluoroacetate salt of compound 13 (5 mg, 99% yield).

[0121] Example 14: Preparation of Compound 14 [ka] Step 1: Fabrication of 14a 13j (0.5 g, 1.04 mmol) was added to dichloromethane (10 mL), and 4 M hydrogen chloride in 1,4-dioxane solution (10 mL) was slowly added dropwise to the system. The reaction was stirred at room temperature for 12 hours, and the reaction solution was concentrated. The residue was separated and purified by silica gel column chromatography to give 14a (195 mg, 60.4%).

[0122] Step 2: Preparation of compound 14 Substrate 7c (23 mg, 0.1 mmol) and carbonyldiimidazole (18 mg, 0.11 mmol) were added to DMF (1 mL) and stirred at 70° C. for 4 hours, then the reaction was placed at room temperature, 14a (28 mg, 0.1 mmol) was added to the system, and the reaction was continued at room temperature overnight. After concentrating the reaction, the trifluoroacetate salt of compound 14 was obtained by HPLC separation (10 mg, 20% yield). HPLC preparative conditions: Instrument: Waters 2767 preparative liquid, chromatographic column: XBridge@Prep C18 (19mm x 250mm). The sample was dissolved in DMF and filtered through a 0.45uM filter to prepare the sample liquid. Preparative chromatographic conditions: a. Mobile phase A: acetonitrile, b. Water (containing 0.1% trifluoroacetic acid), the content of mobile phase A is 10% to 50% gradient elution, the flow rate is 12mL / min, and the elution time is 20 minutes. LC-MS: m / z(ESI): 489.5[MH] - 1 H NMR(400MHz,DMSO-d6):δ 11.10(s,1H),9.37(t,1H),8.82(br,2H),8.17(t,1H),8.10(d,1H),7.91(d,1H),7.02( s,1H),6.60(s,1H),6.48(s,1H),4.65(d,2H),4.20(br,2H),3.25(br,2H),2.10(d,6H).

[0123] Example 15: Preparation of Compound 15 [ka] The reaction conditions and procedures were the same as in Example 12 to obtain compound 15 (110.0 mg). LC-MS: m / z(ESI): 376.0 [M+H] + . 1 H NMR(400MHz,DMSO-d6)δ 11.16(s,1H),9.38(t,1H),8.34-8.03(m,2H),7.92(d,1H),7.02(s,1H),6.60(s,1H),6.48 -6.45(m,1H),4.65(d,2H),4.14(s,2H),2.91(d,2H),2.09-1.98(m,2H),1.90-1.71(m,4H).

[0124] Example 16: Preparation of Compound 16 [ka] The reaction conditions and procedures were the same as in Example 1, and the trifluoroacetate salt of compound 16 was obtained (26.0 mg). HPLC preparative conditions for the final product: Instrument: Waters 2767 Preparative Chromatography Column: SunFire@Prep C18 (19 mm x 150 mm), Mobile phase composition: Mobile phase A: acetonitrile, Mobile phase B: water (containing 0.1% TFA). LC-MS: m / z(ESI): 440.1 [M+H] + 1 H NMR(400MHz,DMSO-d6):δ 11.11-11.06(m,1H),9.37-9.30(m,1H),9.04-8.99(m,1H),8.68-8.5 3(m,2H),8.23-8.16(m,1H),7.87-7.80(m,1H),7.03(s,1H),6.91(s, 1H),6.49-6.45(m,1H),4.68-4.62(m,2H),4.19-4.11(m,2H),2.97-2 .89(m,2H),2.63-2.53(m,1H),2.08-1.99(m,2H),1.90-1.68(m,4H).

[0125] Example 17: Preparation of Compound 17 [ka] The reaction conditions and procedures were the same as in Example 1, and the trifluoroacetate salt of compound 17 was obtained (17.0 mg). HPLC preparative conditions for the final product: Instrument: Waters 2767 Preparative Chromatography Column: SunFire@Prep C18 (19 mm x 150 mm), Mobile phase composition: Mobile phase A: acetonitrile, Mobile phase B: water (containing 0.1% TFA). LC-MS: m / z(ESI): 462.2 [M+H] + 1H NMR(400MHz,DMSO-d6):δ 11.09(s,1H),9.25-9.14(m,1H),8.90-8.83(m,1H),8.71-8.50(m,2H),7.48-7. 43(m,1H),7.20-7.13(m,1H),7.03(s,1H),6.77(s,1H),6.47(s,1H),4.68-4.59 (m,2H),4.19-4.12(m,2H),2.98-2.88(m,2H),2.64-2.53(m,1H),2.26-2.15(m, 1H),2.09-1.98(m,2H),1.92-1.68(m,4H),1.28-1.19(m,2H),1.03-0.95(m,2H).

[0126] Example 18: Preparation of Compound 18 [ka] The reaction conditions and procedures were the same as in Example 1, and compound 18 was obtained (15.0 mg). LC-MS: m / z(ESI): 440.1 [M+H] + 1 H NMR(400MHz,DMSO-d6):δ 10.85(s,1H),9.15-9.07(m,1H),8.84-8.77(m,1H),8.01-7.92(m,1H),7.44-7.34(m,1H),6.96(s,1H),6.92(s,1H),6.10(s, 1H),4.67-4.59(m,2H),3.67(s,2H),2.48(s,2H),2.41-2.30(m,1H),2.00-1.90(m,2H),1.87-1.71(m,2H),1.66-1.54(m,2H).

[0127] Example 19: Preparation of Compound 19 [ka]

[0128] The reaction conditions and procedures were the same as in Example 1, and compound 19 was obtained (5.0 mg). LC-MS: m / z(ESI): 490.2 [M+H]+ 1 H NMR(400MHz,DMSO-d6):δ 10.89(s,1H),9.88-9.81(m,1H),8.45-8.37(m,1H),7.62(s,1H),7.24-7.18(m,1H),6.96(s,1H),6.60(s,1H),6.14(s,1H) ,4.67-4.62(m,2H),3.69(s,2H),2.47(s,2H),2.42-2.35(m,1H),2.02-1.90(m,2H),1.86-1.71(m,2H),1.68-1.55(m,2H).

[0129] Example 20: Preparation of Compound 20 [ka] The reaction conditions and procedures were the same as in Example 12 to obtain compound 20 (30.0 mg).

[0130] LC-MS: m / z(ESI): 436.1 [M+H] + 1 H NMR (400MHz, DMSO-d6): δ 10.83(s,1H),9.24-9.17(m,1H),9.03-8.97(m,1H),8.09-8.02(m,1H),7. 80-7.74(m,1H),7.48-7.40(m,1H),6.92(s,1H),6.89(s,1H),6.10(s,1H) ,4.65-4.58(m,2H),3.73(s,2H),2.39-2.29(m,1H),1.84-1.75(m,2H),1. 68-1.58(m,2H),1.55-1.46(m,1H),1.25-1.07(m,3H),1.06-0.94(m,2H).

[0131] Example 21: Preparation of Compound 21 [ka] The reaction conditions and procedures were the same as in Example 12, and compound 21 was obtained (179.0 mg): LC-MS: m / z(ESI): 337.3 [M+H]+ . 1 H NMR(400MHz,DMSO-d6):δ 10.86(s,1H),9.23(t,1H),9.01(d,1H),8.10-8.02(m,1H),7.77(d,1H),7.48-7.40(m,1H),6.92(s,1H),6.89(s,1H) ,6.12(s,1H),4.63(d,2H),3.69(s,2H),3.02-2.92(m,1H),1.74-1.56(m,4H),1.49-1.37(m,2H),1.35-1.25(m,2H).

[0132] Example 22: Preparation of Compound 22 [ka] The reaction conditions and procedures were the same as in Example 12 to obtain compound 22 (110.0 mg). LC-MS: m / z(ESI): 337.3 [M+H] + . 1 H NMR(400MHz,DMSO-d6):δ 10.84(s,1H),9.22(t,1H),9.01(d,1H),8.09-8.02(m,1H),7.77(d,1H),7.47-7.42(m,1H),6.94( s,1H),6.89(s,1H),6.13(s,1H),4.63(d,2H),3.73(s,1H),2.24(s,2H),1.24(s,2H),0.85(s,9H).

[0133] Biological Test Example 1: Cell:MOLM-13 Cell Line Cell culture medium: RPMI-1640 + 10% FBS + 1% P / S Cryopreservation solution: 50%RPMI-1640, 40%FBS, 10%(V / V)DMSO

[0134] Experimental steps Cell culture: RPMI-1640 + 10% FBS + 1% P / S, culture the cells at 37°C CO 2 The cells were cultured in an incubator at 37 °C and passaged once every 3 to 4 days.

[0135] Cell plating: Cell plating was performed when the cells had grown to logarithmic growth phase. Cells were harvested and the cell density was adjusted to 6×10 4 The cell suspension was adjusted to 50 cells / mL, and then placed in the sample addition tank and added to a 96-well cell culture plate at 50 μL / well (3000 live cells / well). The cells in the sample addition tank were plated carefully to mix evenly, and the cell information and plating date were written on the 96-well plate. NC wells (control wells) and BG wells (background wells) were placed.

[0136] Cell dosing: Compounds were gradient diluted using RPMI-1640 + 10% FBS + 1% P / S + 0.2% DMSO + 100 ng / mL IFN-r, with the highest detection concentration being 10 μM. Compounds were added at 50 μL / well to the 96-well plate where cells were plated. Incubate at 37° C., 5% CO 2 The cells were cultured for a certain period of time under the above conditions.

[0137] Detection of cell proliferation: Cellriter-Glo Reagent was added at 50 μL / well to a cell culture plate that had been incubated in an incubator for a certain period of time.

[0138] The mixture was incubated at room temperature with shaking (500 rpm) in the dark for 10 minutes, and the absorbance was detected using a microplate reader.

[0139] Data Processing The average background value was calculated. The inhibition rate was calculated as [(control well absorbance-experimental well absorbance) / (control well absorbance-background well absorbance)]×100%.

[0140] statistical analysis All results were calculated as mean and standard error (Mean ± SEM) and statistical analysis was performed using Graphpad Prism software to determine the IC of the samples. 50Values ​​are calculated and specific data is displayed in the form of a graph. The biological tests are as follows in Table 1:

[0141] [Table 3] Conclusion: The compounds of the present invention have good inhibitory effects on MOLM-13 cells, and the IC of trifluoroacetate of Compound 3, Compound 4, Compound 7, and Compound 13 are shown in Table 1. 50 are 0.23 μM, 0.16 μM, 0.61 μM, and 0.56 μM, respectively.

[0142] Biological Test Example 2: Pharmacokinetic studies in mice 2.1 Test animals: Male C57 mice, 18-20 g, 6 mice / compound or 12 mice / compound. 2.2 Study design: C57 mice were randomly divided into groups according to weight. They were fasted for 12-14 h without water restriction one day before administration, and fed 4 h after administration.

[0143] [Table 4] Vehicle for intravenous administration: 5% DMA + 5% Solutol + 90% Saline, Vehicle for oral gavage administration: 0.5% MC, (DMA: dimethylacetamide, Solutol: polyethylene glycol-15-hydroxyhydroxystearate, Saline: physiological saline, MC: methylcellulose solution,)

[0144] Before and after administration, 0.06 mL of blood was collected from the orbit under isoflurane anesthesia, placed in an EDTAK2 centrifuge tube, and centrifuged at 5000 rpm at 4°C for 10 min to collect plasma. Blood was collected at 0, 5, 15, 30 min, 1, 2, 4, 7, and 24 h after intravenous and intragastric administration. All samples were stored at -80°C before analysis.

[0145] [Table 5]

[0146] Control compound: compound 23 in WO2021111124, the structure of which is as follows: [ka] . Conclusion: The compounds of the present invention have good pharmacokinetic properties in mice, e.g., AUC 0-t and bioavailability (F) are both superior to the reference compound.

[0147] Biological test example 3: hERG potassium ion channel activity test Experimental platform: electrophysiological manual patch clamp system Cell line: Chinese hamster ovary (CHO) cell line stably expressing the hERG potassium ion channel

[0148] Experimental Method: hERG potassium channel currents were recorded using the whole-cell patch clamp technique at room temperature in CHO (Chinese Hamster Ovary) cells stably expressing the hERG potassium channel. Glass microelectrodes were formed by pulling glass electrode blanks with a (BF150-86-10, Sutter) puller. The tip resistance after filling with the electrode internal solution was approximately 2-5 MΩ, and the glass microelectrode was inserted into the amplifier probe to connect to a patch clamp amplifier. Clamping voltage and data recording were recorded under computer control with pClamp 10 software, the sampling frequency was 10 kHz, and the filter frequency was 2 kHz. After obtaining whole-cell recordings, the cells were clamped to -80 mV, and the hERG potassium current (I hERGThe step voltage to induce hERG was -80 mV, depolarized to +20 mV for 2 s, repolarized to -50 mV, and sustained for 1 s before returning to -80 mV. Stimulation was performed in this manner every 10 s, and hERG potassium currents were confirmed to be stable (for at least 1 min) before starting the dosing process. Compounds were allowed to sit for at least 1 min for each test concentration, and at least two cells were tested for each concentration (n≧2).

[0149] Data processing: Data analysis and processing were carried out using pClamp 10, GraphPad Prism 5 and Excel software. The inhibition degree of hERG potassium current (hERG tail current peak evoked at -50 mV) at different compound concentrations was calculated by the following formula: Inhibition %=[1-(I / Io)]×100% Here, Inhibition % represents the percentage of inhibition of the hERG potassium current by the compound, and I and Io represent the amplitude of the hERG potassium current after administration and before administration, respectively.

[0150] Compound IC 50 was calculated by fitting the following equation using GraphPad Prism 5 software: Y=Bottom+(Top-Bottom) / (1+10^((LogIC 50 -X)*HillSlope)) where X is the Log value of the sample detection concentration, Y is the percentage inhibition at the corresponding concentration, and Bottom and Top are the minimum and maximum percentage inhibition, respectively.

[0151] Experimental results: IC of the inhibitory effect of test compounds on hERG potassium channel current 50 The values ​​are as shown in Table 4 below:

[0152] [Table 6] Conclusion: The compounds of the present invention have weak hERG inhibition.

[0153] Biological Test Example 4: CYP450 Enzyme Inhibition Test The purpose of this study was to evaluate the effects of test substances on the activity of five types of cytochrome P450 (CYP) isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4) in human liver microsomes using an in vitro test system. Specific probe substrates for CYP450 isoenzymes were incubated with human liver microsomes and different concentrations of test substances, and reduced nicotinamide adenine dinucleotide phosphate (NADPH) was added to start the reaction. After the reaction was completed, the metabolites generated by the specific substrates were quantitatively detected by treating the samples and using a liquid chromatography-tandem mass spectrometry (LC-MS / MS) method to measure the changes in the activity of CYP enzymes, calculate IC50 values, and evaluate the potential inhibitory ability of the test substances against each CYP enzyme subtype.

[0154] Experimental conclusion: The compounds of the present invention have weak inhibitory activity against CYP enzymes.

Claims

1. A compound or a stereoisomer, tautomer, deuteride, solvate, prodrug, metabolite, pharma- ceutically acceptable salt, or co-crystal thereof, wherein the compound is selected from the compounds represented by general formula (I): 【Chemistry 1】 Ring A is 【Chemistry 2】 is selected from L is, 【Chemistry 3】 or a 5- to 6-membered heteroaryl group, the left side of L being connected to ring A, said heteroaryl group being optionally selected from H, halogen, OH, a cyano group, NH ２ , C １－６ Alkyl group, halogen-substituted C １－６ C substituted with alkyl or hydroxyl groups １－６ C substituted with alkyl or cyano groups １－６ Alkyl group, C １－６ and wherein the heteroaryl group contains 1 to 3 heteroatoms selected from O, S, and N; R ａｎ is H, C １－６ Alkyl group, C ３－１２ a carbocyclic group or a 3- to 12-membered heterocyclic group, said alkyl group, carbocyclic group or heterocyclic group optionally being selected from H, halogen, OH, ═O, a cyano group, NH ２ , C １－６ Alkyl group, C ２－４ Alkenyl group, C ２－４ Alkynyl group, -C ２－４ Alkynyl-C ３－６ Cycloalkyl groups, halogen-substituted C １－６ C substituted with alkyl or hydroxyl groups １－６ C substituted with alkyl or cyano groups １－６ Alkyl group, C １－６ Alkoxy group, C ３－１２ is further substituted with 0-4 substituents selected from a cycloalkyl group, a phenyl group, a 3- to 12-membered heterocycloalkyl group, or a 5- to 12-membered heteroaryl group, said heterocyclic group, heterocycloalkyl group, or heteroaryl group containing 1-3 heteroatoms selected from O, S, and N; Ring B is selected from a 5- to 10-membered heterocyclic group, said heterocyclic group containing 1 to 5 heteroatoms selected from O, S, and N; R ａ Or R ｂ are each independently H, a halogen, a cyano group, OH, ═O, or C １－６ Alkyl group, C １－６ Alkoxy group, C ３－６ cycloalkyl groups, wherein the alkyl, alkoxy or cycloalkyl groups are optionally selected from H, halogen, OH, ═O, cyano, NH ２ , C １－６ Alkyl group, halogen-substituted C １－６ C substituted with alkyl or hydroxyl groups １－６ C substituted with alkyl or cyano groups １－６ Alkyl group, C １－６ Alkoxy group or C ３－６ is further substituted with 0 to 4 substituents selected from cycloalkyl groups; One option is R ａｎ and R ａ form a 5-6 membered heterocycle together with the carbon atom to which they are attached, said heterocycle optionally being selected from the group consisting of H, halogen, OH, ═O, a cyano group, NH ２ , C １－６ Alkyl group, halogen-substituted C １－６ C substituted with alkyl or hydroxyl groups １－６ C substituted with alkyl or cyano groups １－６ Alkyl group, C １－６ Alkoxy group or C ３－６ is further substituted with 0-4 substituents selected from cycloalkyl groups, said heterocycle containing 1-3 heteroatoms selected from O, S, N; R １ is H, C １－６ Alkyl group or C ３－６ cycloalkyl groups, said alkyl or cycloalkyl groups being optionally selected from H, halogen, OH, ═O, cyano, NH ２ , C １－６ Alkyl group, halogen-substituted C １－６ C substituted with alkyl or hydroxyl groups １－６ C substituted with alkyl or cyano groups １－６ Alkyl group, C １－６ Alkoxy group or C ３－６ is further substituted with 0 to 4 substituents selected from cycloalkyl groups; R ２ａ , R ２ｂ , R ３ａ , R ３ｂ are each independently H, a halogen, a cyano group, OH, ═O, or C １－６ Alkyl group, C １－６ Alkoxy group or C ３－６ cycloalkyl groups, wherein the alkyl, alkoxy or cycloalkyl groups are optionally selected from H, halogen, OH, ═O, cyano, NH ２ , C １－６ Alkyl group, halogen-substituted C １－６ C substituted with alkyl or hydroxyl groups １－６ C substituted with alkyl or cyano groups １－６ Alkyl group, C １－６ Alkoxy group or C ３－６ is further substituted with 0 to 4 substituents selected from cycloalkyl groups; One option is R ２ａ and R ２ｂ , R ３ａ and R ３ｂ Each of them, together with the carbon atom bonded thereto, is C ３－６ Forms a carbocyclic or 3- to 6-membered heterocyclic group, said carbocyclic or heterocyclic group optionally being selected from H, halogen, OH, ═O, cyano, NH ２ , C １－６ Alkyl group, halogen-substituted C １－６ C substituted with alkyl or hydroxyl groups １－６ C substituted with alkyl or cyano groups １－６ Alkyl group, C １－６ Alkoxy group or C ３－６ is further substituted with 0-4 substituents selected from a cycloalkyl group, said heterocyclic group containing 1-3 heteroatoms selected from O, S, and N; R ｃｎ１ , R ｃｎ２ are each independently H, a halogen, a cyano group, OH, ═O, or C １－６ Alkyl group, C １－６ Alkoxy group, C ３－１０ a carbocyclic group, a 3- to 10-membered heterocyclic group, or 【Chemistry 4】 wherein the alkyl, alkoxy, carbocyclic or heterocyclic group is optionally selected from H, halogen, OH, ═O, cyano, NH ２ , C １－６ Alkyl group, halogen-substituted C １－６ C substituted with alkyl or hydroxyl groups １－６ C substituted with alkyl or cyano groups １－６ Alkyl group, C １－６ Alkoxy group or C ３－６ is further substituted with 0-4 substituents selected from a cycloalkyl group, said heterocyclic group containing 1-3 heteroatoms selected from O, S, and N; Ring C1 is C ３－１２ a carbocyclic group or a 3- to 12-membered heterocyclic group, said heterocyclic group containing 1 to 3 heteroatoms selected from O, S and N; R ｃ１ is H, halogen, cyano group, OH, =O, C １－６ Alkyl group, C １－６ Alkoxy group, C ３－１２ a carbocyclic group or a 3- to 12-membered heterocyclic group, said alkyl, alkoxy, carbocyclic or heterocyclic group optionally being selected from H, halogen, OH, ═O, cyano, NH ２ , C １－６ Alkyl group, halogen-substituted C １－６ C substituted with alkyl or hydroxyl groups １－６ C substituted with alkyl or cyano groups １－６ Alkyl group, C １－６ Alkoxy group or C ３－６ is further substituted with 0-4 substituents selected from a cycloalkyl group, said heterocyclic group containing 1-3 heteroatoms selected from O, S, and N; One option is R ｃｎ１ and R ｃｎ２ together with the carbon atom to which they are attached form a 3- to 12-membered heterocyclic group, said heterocyclic group optionally being selected from H, halogen, OH, ═O, a cyano group, NH ２ , C １－６ Alkyl group, halogen-substituted C １－６ C substituted with alkyl or hydroxyl groups １－６ C substituted with alkyl or cyano groups １－６ Alkyl group, C １－６ Alkoxy group or C ３－６ is further substituted with 0-4 substituents selected from a cycloalkyl group, said heterocyclic group containing 1-3 heteroatoms selected from O, S, and N; m is selected from 0, 1, 2 or 3; n is selected from 0, 1, 2, 3, 4, 5, 6 or 7; p is selected from 0, 1, 2 or 3; q is selected from 0, 1, 2 or 3; s is selected from 0, 1, 2 or 3; t is selected from 0, 1, 2, 3, 4, 5, 6, or 7; or a stereoisomer, tautomer, deuteride, solvate, prodrug, metabolite, pharma- ceutically acceptable salt, or co-crystal thereof.

2. The compound has the general formula (II) 【Chemistry 5】 2. The compound of claim 1, selected from the group consisting of the compounds shown in:

3. R ａｎ is H, C １－４ Alkyl group, C ３－６ cycloalkyl group, 3- to 6-membered heterocycloalkyl group, wherein the alkyl group, cycloalkyl group, cycloalkyl group or heterocycloalkyl group is optionally selected from H, D, halogen, OH, ═O, cyano group, NH ２ , C １－４ Alkyl group, C ２－４ Alkenyl group, C ２－４ Alkynyl group, -C ２－４ Alkynyl-C ３－６ Cycloalkyl groups, halogen-substituted C １－４ C substituted with alkyl or hydroxyl groups １－４ C substituted with alkyl or cyano groups １－４ Alkyl group, C １－４ Alkoxy group, C ３－６ is further substituted with 0-4 substituents selected from a cycloalkyl group, a phenyl group, a 3- to 6-membered heterocycloalkyl group, or a 5- to 6-membered heteroaryl group, said heterocycloalkyl group or heteroaryl group containing 1-3 heteroatoms selected from O, S, and N; R ａ Or R ｂ are each independently H, a halogen, a cyano group, OH, ═O, or C １－４ Alkyl group, C １－４ Alkoxy group, C ３－６ cycloalkyl groups, wherein the alkyl, alkoxy or cycloalkyl groups are optionally selected from H, halogen, OH, ═O, cyano, NH ２ , C １－４ Alkyl group, halogen-substituted C １－４ C substituted with alkyl or hydroxyl groups １－４ C substituted with alkyl or cyano groups １－４ Alkyl group, C １－４ Alkoxy group or C ３－６ is further substituted with 0 to 4 substituents selected from cycloalkyl groups; One option is R ａｎ and R ａ form a 5-6 membered heteroaromatic ring together with the carbon atom to which they are attached, said heteroaromatic ring optionally being selected from the group consisting of H, halogen, OH, ═O, a cyano group, NH ２ , C １－４ Alkyl group, halogen-substituted C １－４ C substituted with alkyl or hydroxyl groups １－４ C substituted with alkyl or cyano groups １－４ Alkyl group, C １－４ Alkoxy group or C ３－６ is further substituted with 0-4 substituents selected from a cycloalkyl group, said heteroaryl group containing 1-3 heteroatoms selected from O, S, N; R １ is H, C １－４ Alkyl group or C ３－６ cycloalkyl groups, said alkyl or cycloalkyl groups being optionally selected from H, halogen, OH, ═O, cyano, NH ２ , C １－４ Alkyl group, halogen-substituted C １－４ C substituted with alkyl or hydroxyl groups １－４ C substituted with alkyl or cyano groups １－４ Alkyl group, C １－４ Alkoxy group or C ３－６ is further substituted with 0 to 4 substituents selected from cycloalkyl groups; R ２ａ , R ２ｂ , R ３ａ , R ３ｂ are each independently H, a halogen, a cyano group, OH, ═O, or C １－４ Alkyl group, C １－４ Alkoxy group or C ３－６ cycloalkyl groups, wherein the alkyl, alkoxy or cycloalkyl groups are optionally selected from H, halogen, OH, ═O, cyano, NH ２ , C １－４ Alkyl group, halogen-substituted C １－４ C substituted with alkyl or hydroxyl groups １－４ C substituted with alkyl or cyano groups １－４ Alkyl group, C １－４ Alkoxy group or C ３－６ is further substituted with 0 to 4 substituents selected from cycloalkyl groups; Ring B is selected from a 5,5-membered biheteroaryl group, a 5,6-membered biheteroaryl group, or a 6,6-membered biheteroaryl group, the heteroaryl group containing 1 to 5 heteroatoms selected from O, S, and N; m is selected from 0, 1 or 2; n is selected from 0, 1, 2, 3 or 4; p is selected from 0, 1 or 2; 3. The compound of claim 2, or a stereoisomer, tautomer, deuteride, solvate, prodrug, metabolite, pharma- ceutically acceptable salt, or co-crystal thereof, wherein q is selected from 0, 1, or 2.

4. R ｃｎ１ , R ｃｎ２ are each independently H, a halogen, a cyano group, OH, ═O, or C １－４ Alkyl group, C １－４ Alkoxy group, C ３－１０ a cycloalkyl group, a 3- to 10-membered heterocycloalkyl group, or 【Chemistry 6】 wherein the alkyl, alkoxy, cycloalkyl or heterocycloalkyl group is optionally selected from H, halogen, OH, ═O, cyano, NH ２ , C １－４ Alkyl group, halogen-substituted C １－４ C substituted with alkyl or hydroxyl groups １－４ C substituted with alkyl or cyano groups １－４ Alkyl group, C １－４ Alkoxy group or C ３－６ is further substituted with 0-4 substituents selected from a cycloalkyl group, said heterocycloalkyl group containing 1-3 heteroatoms selected from O, S, N; Ring C1 is C ３－７ Monocycloalkyl group, C ４－１１ Fused cycloalkyl group, C ５～１１ C-membered spirocycloalkyl group ５－１２ a 4- to 7-membered bridged cycloalkyl group, a 4- to 11-membered monoheterocycloalkyl group, a 4- to 11-membered fused heterocycloalkyl group, a 5- to 11-membered spiroheterocycloalkyl group, or a 5- to 12-membered bridged heterocycloalkyl group, said heterocycloalkyl group containing 1 to 3 heteroatoms selected from O, S, and N; R ｃ１ is H, halogen, cyano group, OH, =O, C １－４ Alkyl group, C １－４ Alkoxy group, C ３－６ cycloalkyl group or 3-6 membered heterocycloalkyl group, said alkyl group, alkoxy group, cycloalkyl group or heterocycloalkyl group optionally being selected from H, halogen, OH, ═O, cyano group, NH ２ , C １－４ Alkyl group, halogen-substituted C １－４ C substituted with alkyl or hydroxyl groups １－４ C substituted with alkyl or cyano groups １－４ Alkyl group, C １－４ Alkoxy group or C ３－６ is further substituted with 0-4 substituents selected from a cycloalkyl group, said heterocycloalkyl group containing 1-3 heteroatoms selected from O, S, N; One option is R ｃｎ１ and R ｃｎ２ together with the carbon atoms to which they are attached form a 4- to 7-membered monoheterocycloalkyl group, a 4- to 11-membered fused heterocycloalkyl group, a 5- to 11-membered spiroheterocycloalkyl group, or a 5- to 12-membered bridged heterocycloalkyl group, said heterocycloalkyl group optionally being selected from H, halogen, OH, ═O, a cyano group, NH ２ , C １－４ Alkyl group, halogen-substituted C １－４ C substituted with alkyl or hydroxyl groups １－４ C substituted with alkyl or cyano groups １－４ Alkyl group, C １－４ Alkoxy group or C ３－６ is further substituted with 0-4 substituents selected from a cycloalkyl group, said heterocycloalkyl group containing 1-3 heteroatoms selected from O, S, N; s is selected from 0, 1 or 2; 4. The compound of claim 3, or a stereoisomer, tautomer, deuteride, solvate, prodrug, metabolite, pharma- ceutically acceptable salt, or co-crystal thereof, wherein t is selected from 0, 0, 1, 2, 3, or 4.

5. R ａｎ is selected from H, methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclohexyl, cyclopentyl, cyclobutyl, oxetanyl, oxacyclopentyl, oxacyclohexyl, azetidinyl, azacyclopentyl, piperidinyl or piperazinyl, and said methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclohexyl, cyclopentyl, cyclobutyl, oxetanyl, oxacyclopentyl, oxacyclohexyl, azetidinyl, azacyclopentyl, piperidinyl or piperazinyl group is optionally selected from H, D, F, Cl, Br, I, OH, ═O, cyano, NH ２ , C １－４ Alkyl group, C ２－４ Alkenyl group, C ２－４ Alkynyl group, -C ２－４ Alkynyl-C ３－６ Cycloalkyl groups, halogen-substituted C １－４ C substituted with alkyl or hydroxyl groups １－４ C substituted with alkyl or cyano groups １－４ Alkyl group, C １－４ Alkoxy group, C ３－６ is further substituted with 0-4 substituents selected from a cycloalkyl group, a phenyl group, a 3- to 6-membered heterocycloalkyl group, or a 5- to 6-membered heteroaryl group, said heterocycloalkyl group or heteroaryl group containing 1-3 heteroatoms selected from O, S, and N; R ａ Or R ｂ are each independently selected from H, F, Cl, Br, I, cyano, OH, =0, methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclohexyl, cyclopentyl, cyclobutyl, azetidinyl, azacyclopentyl, azacyclohexyl, piperidinyl, methoxy or ethoxy, and the methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclohexyl, cyclopentyl, cyclobutyl, azetidinyl, azacyclopentyl, azacyclohexyl, piperidinyl, methoxy or ethoxy groups are optionally selected from H, F, Cl, Br, I, OH, =0, cyano, NH ２ , C １－４ Alkyl group, halogen-substituted C １－４ C substituted with alkyl or hydroxyl groups １－４ C substituted with alkyl or cyano groups １－４ Alkyl group, C １－４ Alkoxy group or C ３－６ is further substituted with 0 to 4 substituents selected from cycloalkyl groups; One option is R ａｎ and R ａ form a pyridine, pyrimidine, pyridazine or pyrazine ring together with the carbon atom bonded thereto, said pyridine, pyrimidine or pyrazine ring optionally being selected from the group consisting of H, F, Cl, Br, I, OH, ═O, a cyano group, NH ２ , C １－４ Alkyl group, halogen-substituted C １－４ C substituted with alkyl or hydroxyl groups １－４ C substituted with alkyl or cyano groups １－４ Alkyl group, C １－４ Alkoxy group or C ３－６ is further substituted with 0 to 4 substituents selected from cycloalkyl groups; R １ is selected from H, a methyl group, an ethyl group, a propyl group, an isopropyl group, or a cyclopropyl group, and the methyl group, the ethyl group, the propyl group, the isopropyl group, or the cyclopropyl group is optionally selected from H, F, Cl, Br, I, OH, ═O, a cyano group, NH ２ , C １－４ Alkyl group, halogen-substituted C １－４ C substituted with alkyl or hydroxyl groups １－４ C substituted with alkyl or cyano groups １－４ Alkyl group, C １－４ Alkoxy group or C ３－６ is further substituted with 0 to 4 substituents selected from cycloalkyl groups; R ２ａ , R ２ｂ , R ３ａ , R ３ｂ are each independently selected from H, F, Cl, Br, I, cyano, OH, =0, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy or cyclopropyl, and the methyl, ethyl, propyl, isopropyl, methoxy, ethoxy or cyclopropyl groups are optionally selected from H, F, Cl, Br, I, OH, =0, cyano, NH ２ , C １－４ Alkyl group, halogen-substituted C １－４ C substituted with alkyl or hydroxyl groups １－４ C substituted with alkyl or cyano groups １－４ Alkyl group, C １－４ Alkoxy group or C ３－６ is further substituted with 0 to 4 substituents selected from cycloalkyl groups; Ring B is selected from a pyrrolopyrrolyl group, a pyrrolopyrazolyl group, a pyrroloimidazolyl group, a pyrazolopyrazolyl group, a pyrazoloimidazolyl group, an imidazoimidazolyl group, a benzopyrrolyl group, a benzopyrazolyl group, a benzimidazolyl group, a pyridopyrrolyl group, a pyridopyrazolyl group, a pyridoimidazolyl group, a pyrimidopyrrolyl group, a pyrimidopyrazolyl group, a pyrimidopyrazolyl group, a pyrimidopyrazolyl group, a pyrimidopyrazolyl group, a pyrimidopyrazolyl group, a pyrimidopyrazinyl group, a pyrazinopyrrolyl group, a pyrazinopyrazolyl group, a pyrazinoimidazolyl group, a pyridazinopyrrolyl group, a pyridazinopyrazolyl group, a pyridazinoimidazolyl group, a benzopyridyl group, a benzopyrimidinyl group, a benzopyrazinyl group, a benzopyridazinyl group, a pyridopyridyl group, a pyridopyrimidinyl group, a pyridopyrazinyl group, or a pyridopyridazinyl group; R ｃｎ１ , R ｃｎ２ each independently represents H, F, Cl, Br, I, a cyano group, OH, =O, a methyl group, an ethyl group, a propyl group, an isopropyl group, a cyclopropyl group, a cyclohexyl group, a cyclopentyl group, a cyclobutyl group, an azetidinyl group, an azacyclopentyl group, an azacyclohexyl group, or 【Chemistry 7】 wherein the methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclohexyl, cyclopentyl, cyclobutyl, azetidinyl, azacyclopentyl, and azacyclohexyl groups are optionally selected from H, F, Cl, Br, I, OH, ═O, cyano, NH ２ , C １－４ Alkyl group, halogen-substituted C １－４ C substituted with alkyl or hydroxyl groups １－４ C substituted with alkyl or cyano groups １－４ Alkyl group, C １－４ Alkoxy group or C ３－６ is further substituted with 0 to 4 substituents selected from cycloalkyl groups; Ring C1 is a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, an oxetanyl group, an oxacyclopentyl group, an oxacyclohexyl group, an azetidinyl group, an azacyclopentyl group, piperidine, morpholine, piperazine, 1,4-diazepanyl group, a cyclopropyl-fused cyclopentyl group, a cyclobutyl-fused cyclopentyl group, a cyclopentyl-fused cyclopentyl group, a cyclopentyl-fused cyclohexyl group, a cyclopropyl-spiro-cyclopentyl group, a cyclobutyl-spiro-cyclobutyl group, a cyclobutyl-spiro-cyclopentyl group, Cyclopentyl-spiro-cyclopentyl, cyclopentyl-spiro-cyclohexyl, cyclohexyl-spiro-cyclohexyl, cyclopropyl-fused azetidinyl, cyclopropyl-fused azacyclopentyl, cyclopropyl-fused azacyclohexyl, cyclobutyl-fused azetidinyl, cyclobutyl-fused azacyclopentyl, cyclobutyl-fused azacyclohexyl, cyclopentyl-fused azetidinyl, cyclopentyl-fused azacyclopentyl, cyclopentyl-fused azacyclohexyl, cyclohexyl-fused azetidinyl, cyclohexyl-fused azacyclopentyl, azacyclopentyl, cyclohexyl-fused azacyclohexyl, azetidinyl-fused azetidinyl, azetidinyl-fused azacyclopentyl, azetidinyl-fused azacyclohexyl, azacyclopentyl-fused azetidinyl, azacyclopentyl-fused azacyclopentyl, azacyclopentyl-fused azacyclohexyl, azacyclohexyl-fused azetidinyl, azacyclohexyl-fused azacyclopentyl, azacyclohexyl-fused azacyclohexyl, cyclobutyl-spiro-azetidinyl, cyclobutyl-spiro-azacyclopentyl, cyclobutyl- spiro-azacyclohexyl, cyclopentyl-spiro-azetidinyl, cyclopentyl-spiro-azacyclopentyl, cyclopentyl-spiro-azacyclohexyl, cyclohexyl-spiro-azetidinyl, cyclohexyl-spiro-azacyclopentyl, cyclohexyl-spiro-azacyclohexyl, azetidinyl-spiro-azetidinyl, azetidinyl-spiro-azacyclopentyl, azetidinyl-spiro-azacyclohexyl, azacyclopentyl-spiro-azetidinyl, azacyclopentyl-spiro-azacyclopentyl, azacyclopentyl-spiro-azacyclopentyl,azacyclopentyl-spiro-azacyclohexyl, azacyclohexyl-spiro-azetidinyl, azacyclohexyl-spiro-azacyclopentyl, azacyclohexyl-spiro-azacyclohexyl, oxetanyl group, oxacyclopentyl group, oxacyclohexyl group, cyclopropyl-fused oxetanyl, cyclopropyl-fused oxacyclopentyl, cyclopropyl-fused oxacyclohexyl, cyclobutyl-fused oxetanyl, cyclobutyl-fused oxacyclopentyl, cyclobutyl-fused oxacyclohexyl, cyclopentyl-fused oxetaniyl cyclopentyl-fused oxacyclopentyl, cyclopentyl-fused oxacyclohexyl, cyclohexyl-fused oxetanyl, cyclohexyl-fused oxacyclopentyl, cyclohexyl-fused oxacyclohexyl, azetidinyl-fused oxetanyl, azetidinyl-fused oxolanyl, azetidinyl-fused oxacyclohexyl, azacyclopentyl-fused oxetanyl, azacyclopentyl-fused oxacyclopentyl, azacyclopentyl-fused oxacyclohexyl, azacyclohexyl-fused oxetanyl, azacyclohexyl-fused oxetanyl, azacyclohexyl-fused oxacyclopentyl , azacyclohexyl-fused oxacyclohexyl, cyclobutyl-spiro-oxetanyl, cyclobutyl-spiro-oxacyclopentyl, cyclobutyl-spiro-oxacyclohexyl, cyclopentyl-spiro-oxetanyl, cyclopentyl-spiro-oxacyclopentyl, cyclopentyl-spiro-oxacyclohexyl, cyclohexyl-spiro-oxetanyl, cyclohexyl-spiro-oxacyclopentyl, cyclohexyl-spiro-oxacyclohexyl, azetidinyl-spiro-oxetanyl, azetidinyl-spiro-oxacyclopentyl, clopentyl, azetidinyl-spiro-oxacyclohexyl, azacyclopentyl-spiro-oxetanyl, azacyclopentyl-spiro-oxacyclopentyl, azacyclopentyl-spiro-oxacyclohexyl, azacyclohexyl-spiro-oxetanyl, azacyclohexyl-spiro-oxacyclopentyl, azacyclohexyl-spiro-oxanyl, bicyclo[2.1.1]hexanyl, bicyclo[2.2.1]heptanyl, bicyclo[3.3.2]decanyl, bicyclo[2.2.2]octyl, bicyclo[3.2.1]octyl,bicyclo[3.3.3]undecyl, adamantyl group, 【Chemistry 8】 is selected from R ｃ１ are each independently selected from H, F, Cl, Br, I, cyano, OH, =0, methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclohexyl, cyclopentyl, cyclobutyl, azetidinyl, azacyclopentyl, piperidinyl, piperazinyl, methoxy or ethoxy, and the methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclohexyl, cyclopentyl, cyclobutyl, azetidinyl, azacyclopentyl, piperidinyl, piperazinyl, methoxy or ethoxy groups are optionally selected from H, F, Cl, Br, I, OH, =0, cyano, NH ２ , C １－４ Alkyl group, halogen-substituted C １－４ C substituted with alkyl or hydroxyl groups １－４ C substituted with alkyl or cyano groups １－４ Alkyl group, C １－４ Alkoxy group or C ３－６ is further substituted with 0 to 4 substituents selected from cycloalkyl groups; One option is R ｃｎ１ and R ｃｎ２ together with the carbon atom bonded thereto, a substituted or unsubstituted azetidinyl group, azacyclopentyl group, piperidine, piperazine, azetidinyl-fused cyclopropyl, azetidinyl-fused cyclobutyl, azetidinyl-fused cyclopentyl, azetidinyl-fused cyclohexyl, azacyclopentyl-fused cyclopropyl, azacyclopentyl-fused cyclobutyl, azacyclopentyl-fused cyclopentyl, azacyclopentyl-fused cyclohexyl, azacyclohexyl-fused cyclopropyl, azacyclohexyl-fused cyclobutyl, azacyclohexyl-fused cyclopentyl, azacyclohexyl-fused cyclohexyl, azetidinyl-fused azetidinyl, azetidinyl-fused azacyclopentyl, azetidinyl-fused azacyclohexyl azacyclopentyl-fused azetidinyl, azacyclopentyl-fused azacyclopentyl, azacyclopentyl-fused azacyclohexyl, azacyclohexyl-fused azetidinyl, azacyclohexyl-fused azacyclopentyl, azacyclohexyl-fused azacyclohexyl, azetidinyl-spiro-azetidinyl, azetidinyl-spiro-azacyclopentyl, azetidinyl-spiro-azacyclohexyl, azacyclopentyl-spiro-azetidinyl, azacyclopentyl-spiro-azacyclopentyl, azacyclopentyl-spiro-azacyclohexyl, azacyclohexyl-spiro-azetidinyl, azacyclopentyl-spiro-azacyclopentyl, azacyclopentyl-spiro-azacyclohexyl, azacyclohexyl-spiro-azetidinyl, azacyclohexyl-spiro-azacyclopentyl, azacyclohexyl-spiro-azacyclohexyl, 【Chemistry 9】 and optionally, when substituted, H, halogen, OH, =O, cyano group, NH ２ , C １－４ Alkyl group, halogen-substituted C １－４ C substituted with alkyl or hydroxyl groups １－４ C substituted with alkyl or cyano groups １－４ Alkyl group, C １－４ Alkoxy group or C ３－６ 5. The compound of claim 4, or a stereoisomer, tautomer, deuteride, solvate, prodrug, metabolite, pharma- ceutically acceptable salt, or co-crystal thereof, further substituted with 0 to 4 substituents selected from cycloalkyl groups.

6. R ａｎ is selected from H, methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, oxacyclopentyl or oxacyclohexyl, and said methyl, ethyl, propyl, isopropyl, cyclopropyl, oxetanyl, oxacyclopentyl or oxacyclohexyl groups are optionally selected from H, D, F, Cl, Br, I, OH, ═O, cyano, NH ２ , C １－４ Alkyl group, halogen-substituted C １－４ Alkyl group, C ２－４ Alkenyl group, C ２－４ Alkynyl group, -C ２－４ Alkynyl-C ３－６ Cycloalkyl groups, hydroxyl-substituted C １－４ C substituted with alkyl or cyano groups １－４ Alkyl group, C １－４ Alkoxy group, C ３－６ is further substituted with 0-4 substituents selected from a cycloalkyl group, a phenyl group, a 3- to 6-membered heterocycloalkyl group, or a 5- to 6-membered heteroaryl group, said heterocycloalkyl group or heteroaryl group containing 1-3 heteroatoms selected from O, S, and N; R ａ Or R ｂ are each independently selected from H, F, Cl, Br, I, cyano, OH, =O, methyl, ethyl, propyl, isopropyl, and cyclopropyl, and the methyl, ethyl, propyl, isopropyl, or cyclopropyl groups are optionally selected from H, F, Cl, Br, I, OH, =O, cyano, NH ２ , C １－４ Alkyl group, halogen-substituted C １－４ C substituted with alkyl or hydroxyl groups １－４ C substituted with alkyl or cyano groups １－４ Alkyl group, C １－４ Alkoxy group or C ３－６ is further substituted with 0 to 4 substituents selected from cycloalkyl groups; One option is R ａｎ and R ａ form a pyridine ring together with the carbon atom to which they are attached, said pyridine ring optionally being selected from the group consisting of H, F, Cl, Br, I, OH, ═O, a cyano group, NH ２ , C １－４ Alkyl group, halogen-substituted C １－４ C substituted with alkyl or hydroxyl groups １－４ C substituted with alkyl or cyano groups １－４ Alkyl group, C １－４ Alkoxy group or C ３－６ is further substituted with 0 to 4 substituents selected from cycloalkyl groups; Ring B is selected from a benzopyrrolyl group, a benzopyrazolyl group, a benzimidazolyl group, a pyridopyrrolyl group, a pyridopyrazolyl group, a pyridoimidazolyl group, a pyrimidopyrrolyl group, a pyrimidopyrazolyl group, a pyrimidoimidazolyl group, a pyrazinopyrrolyl group, a pyrazinopyrazolyl group, a pyrazinoimidazolyl group, a pyridazinopyrrolyl group, a pyridazinopyrazolyl group, and a pyridazinoimidazolyl group; R ｃｎ１ , R ｃｎ２ each independently represents H, F, Cl, Br, I, a cyano group, OH, =O, a methyl group, an ethyl group, a propyl group, an isopropyl group, a cyclopropyl group, a cyclohexyl group, a cyclopentyl group, a cyclobutyl group, or 【Chemistry 10】 wherein the methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclohexyl, cyclopentyl, and cyclobutyl groups are optionally selected from H, F, Cl, Br, I, OH, ═O, cyano, NH ２ , C １－４ Alkyl group, halogen-substituted C １－４ C substituted with alkyl or hydroxyl groups １－４ C substituted with alkyl or cyano groups １－４ Alkyl group, C １－４ Alkoxy group or C ３－６ is further substituted with 0 to 4 substituents selected from cycloalkyl groups; Ring C1 is a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, an oxetanyl group, an oxacyclopentyl group, an oxacyclohexyl group, an azetidinyl group, an azacyclopentyl group, a piperidine, a morpholine, a piperazine, a 1,4-diazepanyl group, 【Chemistry 11】 selected from bicyclo[2.1.1]hexanyl, bicyclo[2.2.1]heptanyl, bicyclo[3.3.2]decanyl, bicyclo[2.2.2]octyl, bicyclo[3.2.1]octyl, bicyclo[3.3.3]undecyl, and adamantyl groups; R ｃ１ are each independently selected from H, F, Cl, Br, I, cyano, OH, =0, methyl, ethyl, propyl, isopropyl, cyclopropyl, methoxy or ethoxy, and the methyl, ethyl, propyl, isopropyl, cyclopropyl, methoxy or ethoxy groups are optionally selected from H, F, Cl, Br, I, OH, =0, cyano, NH ２ , C １－４ Alkyl group, halogen-substituted C １－４ C substituted with alkyl or hydroxyl groups １－４ C substituted with alkyl or cyano groups １－４ Alkyl group, C １－４ Alkoxy group or C ３－６ is further substituted with 0 to 4 substituents selected from cycloalkyl groups; One option is R ｃｎ１ and R ｃｎ２ together with the carbon atom to which they are attached form a substituted or unsubstituted azetidinyl group, azacyclopentyl group, piperidine or piperazine, which, when substituted, may optionally be H, F, Cl, Br, I, OH, ═O, a cyano group, NH ２ , C １－４ Alkyl group, halogen-substituted C １－４ C substituted with alkyl or hydroxyl groups １－４ C substituted with alkyl or cyano groups １－４ Alkyl group, C １－４ Alkoxy group or C ３－６ 6. The compound of claim 5, or a stereoisomer, tautomer, deuteride, solvate, prodrug, metabolite, pharma- ceutically acceptable salt, or co-crystal thereof, further substituted with 0 to 4 substituents selected from cycloalkyl groups.

7. The compound is selected from the compounds represented by the following general formula (II-1) or general formula (II-2): 【Chemistry 12】 R ａｎ is H, methyl group, CD ３ , ethyl, propyl, isopropyl, cyclopropyl, oxetanyl, oxacyclopentyl or oxacyclohexyl, wherein the methyl, ethyl, propyl, isopropyl, cyclopropyl, oxetanyl, oxacyclopentyl or oxacyclohexyl groups are optionally selected from the group consisting of H, F, Cl, Br, I, OH, ═O, cyano, NH ２ , a methyl group, an ethyl group, a propyl group, an isopropyl group, a vinyl group, a 1-propenyl group, a 2-propenyl group, an ethynyl group, a 1-propynyl group, a 2-propynyl group, 【Chemistry 13】 further substituted with 0 to 4 substituents selected from cyclopropyl, methoxy, ethoxy, and phenyl; R ａ Or R ｂ are each independently selected from H, F, Cl, Br, I, cyano, OH, ═O, methyl, ethyl, propyl, isopropyl, and cyclopropyl; One option is R ａｎ and R ａ form a pyridine ring together with the carbon atom to which they are attached, Ring C1 is a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, or 【Chemistry 14】 is selected from R ｃ１ are each independently selected from H, F, Cl, Br, I, cyano, OH, ═O, methyl, ethyl, propyl, isopropyl, and cyclopropyl; Ring C2 is selected from an azetidinyl group, an azacyclopentyl group, a piperidine or a piperazine; R ｃ２ are each independently H, F, Cl, Br, I, OH, ═O, a cyano group, or NH ２ , methyl, ethyl, propyl, isopropyl, cyclopropyl, methoxy, and ethoxy groups; m is selected from 0 or 1; n is selected from 0 or 1; r is selected from 0, 1, 2 or 3; s is selected from 0 or 1; 7. The compound of claim 6, or a stereoisomer, tautomer, deuteride, solvate, prodrug, metabolite, pharma- ceutically acceptable salt, or co-crystal thereof, wherein t is selected from 0, 1, 2, or 3.

8. The compound has the general formula (III): 【Chemistry 15】 2. The compound of claim 1, selected from the group consisting of the compounds shown in:

9. R ａｎ is H, C １－４ Alkyl group, C ３－６ cycloalkyl group, 3- to 6-membered heterocycloalkyl group, said alkyl group, cycloalkyl group or heterocycloalkyl group optionally being selected from H, halogen, OH, ═O, cyano group, NH ２ , C １－４ Alkyl group, C ２－４ Alkenyl group, C ２－４ Alkynyl group, -C ２－４ Alkynyl-C ３－６ Cycloalkyl groups, halogen-substituted C １－４ C substituted with alkyl or hydroxyl groups １－４ C substituted with alkyl or cyano groups １－４ Alkyl group, C １－４ Alkoxy group, C ３－６ is further substituted with 0-4 substituents selected from a cycloalkyl group, a phenyl group, a 3- to 6-membered heterocycloalkyl group, or a 5- to 6-membered heteroaryl group, said heterocycloalkyl group or heteroaryl group containing 1-3 heteroatoms selected from O, S, and N; R ａ Or R ｂ are each independently H, a halogen, a cyano group, OH, ═O, or C １－４ Alkyl group, C １－４ Alkoxy group, C ３－６ cycloalkyl groups, wherein the alkyl, alkoxy or cycloalkyl groups are optionally selected from H, halogen, OH, ═O, cyano, NH ２ , C １－４ Alkyl group, halogen-substituted C １－４ C substituted with alkyl or hydroxyl groups １－４ C substituted with alkyl or cyano groups １－４ Alkyl group, C １－４ Alkoxy group or C ３－６ is further substituted with 0 to 4 substituents selected from cycloalkyl groups; R １ is H, C １－４ Alkyl group or C ３－６ cycloalkyl groups, said alkyl or cycloalkyl groups being optionally selected from H, halogen, OH, ═O, cyano, NH ２ , C １－４ Alkyl group, halogen-substituted C １－４ C substituted with alkyl or hydroxyl groups １－４ C substituted with alkyl or cyano groups １－４ Alkyl group, C １－４ Alkoxy group or C ３－６ is further substituted with 0 to 4 substituents selected from cycloalkyl groups; R ２ａ , R ２ｂ , R ３ａ , R ３ｂ are each independently H, a halogen, a cyano group, OH, ═O, or C １－４ Alkyl group, C １－４ Alkoxy group or C ３－６ cycloalkyl groups, wherein the alkyl, alkoxy or cycloalkyl groups are optionally selected from H, halogen, OH, ═O, cyano, NH ２ , C １－４ Alkyl group, halogen-substituted C １－４ C substituted with alkyl or hydroxyl groups １－４ C substituted with alkyl or cyano groups １－４ Alkyl group, C １－４ Alkoxy group or C ３－６ is further substituted with 0 to 4 substituents selected from cycloalkyl groups; m is selected from 0, 1 or 2; 9. The compound of claim 8, or a stereoisomer, tautomer, deuteride, solvate, prodrug, metabolite, pharma- ceutically acceptable salt, or co-crystal thereof, wherein n is selected from 0, 1, or 2.

10. L is, 【Chemistry 16】 or a 5-membered heteroaryl group, the left side of L being connected to ring A, said heteroaryl group being optionally selected from H, halogen, OH, a cyano group, NH ２ , C １－４ Alkyl group, halogen-substituted C １－４ C substituted with alkyl or hydroxyl groups １－４ C substituted with alkyl or cyano groups １－４ Alkyl group, C １－４ further substituted with 0-2 substituents selected from alkoxy groups, said heteroaryl group containing 1-3 heteroatoms selected from O, S, N; R １ is selected from H, a methyl group, an ethyl group, a propyl group, an isopropyl group, or a cyclopropyl group, and the methyl group, the ethyl group, the propyl group, the isopropyl group, or the cyclopropyl group is optionally selected from H, F, Cl, Br, I, OH, ═O, a cyano group, NH ２ , C １－４ Alkyl group, halogen-substituted C １－４ C substituted with alkyl or hydroxyl groups １－４ C substituted with alkyl or cyano groups １－４ Alkyl group, C １－４ Alkoxy group or C ３－６ is further substituted with 0 to 4 substituents selected from cycloalkyl groups; R ｃｎ１ , R ｃｎ２ are each independently H, a halogen, a cyano group, OH, ═O, or C １－４ Alkyl group, C １－４ Alkoxy group, C ３－７ Monocycloalkyl group, C ４－１０ Fused cycloalkyl group, C ５～１０ C-membered spirocycloalkyl group ５－１０ a bridged cycloalkyl group, a 4- to 7-membered monoheterocycloalkyl group, a 4- to 10-membered condensed heterocycloalkyl group, a 5- to 10-membered spiroheterocycloalkyl group, a 5- to 10-membered bridged heterocycloalkyl group, or 【Chemistry 17】 wherein the alkyl, alkoxy, cycloalkyl or heterocycloalkyl group is optionally selected from H, halogen, OH, ═O, cyano, NH ２ , C １－４ Alkyl group, halogen-substituted C １－４ C substituted with alkyl or hydroxyl groups １－４ C substituted with alkyl or cyano groups １－４ Alkyl group, C １－４ Alkoxy group or C ３－６ is further substituted with 0-4 substituents selected from a cycloalkyl group, said heterocycloalkyl group containing 1-3 heteroatoms selected from O, S, N; Ring C1 is C ３－７ Monocycloalkyl group, C ４－１１ Fused cycloalkyl group, C ５～１１ C-membered spirocycloalkyl group ５－１２ a 4- to 7-membered bridged cycloalkyl group, a 4- to 11-membered monoheterocycloalkyl group, a 4- to 11-membered fused heterocycloalkyl group, a 5- to 11-membered spiroheterocycloalkyl group, or a 5- to 12-membered bridged heterocycloalkyl group, said heterocycloalkyl group containing 1 to 3 heteroatoms selected from O, S, and N; R ｃ１ are each independently H, a halogen, a cyano group, OH, ═O, or C １－４ Alkyl group, C １－４ Alkoxy group, C ３－６ cycloalkyl group or 3-6 membered heterocycloalkyl group, said alkyl group, alkoxy group, cycloalkyl group or heterocycloalkyl group optionally being selected from H, halogen, OH, ═O, cyano group, NH ２ , C １－４ Alkyl group, halogen-substituted C １－４ C substituted with alkyl or hydroxyl groups １－４ C substituted with alkyl or cyano groups １－４ Alkyl group, C １－４ Alkoxy group or C ３－６ is further substituted with 0-4 substituents selected from a cycloalkyl group, said heterocycloalkyl group containing 1-3 heteroatoms selected from O, S, N; One option is R ｃｎ１ and R ｃｎ２ together with the carbon atoms to which they are attached form a 4- to 7-membered monoheterocycloalkyl group, a 4- to 11-membered fused heterocycloalkyl group, a 5- to 11-membered spiroheterocycloalkyl group, or a 5- to 12-membered bridged heterocycloalkyl group, said heterocycloalkyl group optionally being selected from H, halogen, OH, ═O, a cyano group, NH ２ , C １－４ Alkyl group, halogen-substituted C １－４ C substituted with alkyl or hydroxyl groups １－４ C substituted with alkyl or cyano groups １－４ Alkyl group, C １－４ Alkoxy group or C ３－６ is further substituted with 0-4 substituents selected from a cycloalkyl group, said heterocycloalkyl group containing 1-3 heteroatoms selected from O, S, N; s is selected from 0, 1, and 2; 10. The compound of claim 9, or a stereoisomer, tautomer, deuteride, solvate, prodrug, metabolite, pharma- ceutically acceptable salt, or co-crystal thereof, wherein t is selected from 0, 1, 2, 3, or 4.

11. R ａｎ is selected from H, methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclohexyl, cyclopentyl, cyclobutyl, oxetanyl, oxacyclopentyl, oxacyclohexyl, azetidinyl, azacyclopentyl, piperidinyl or piperazinyl, and the methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclohexyl, cyclopentyl, cyclobutyl, oxetanyl, oxacyclopentyl, oxacyclohexyl, azetidinyl, azacyclopentyl, piperidinyl or piperazinyl group is optionally selected from H, F, Cl, Br, I, OH, ═O, cyano, NH ２ , C １－４ Alkyl group, C ２－４ Alkenyl group, C ２－４ Alkynyl group, -C ２－４ Alkynyl-C ３－６ Cycloalkyl groups, halogen-substituted C １－４ C substituted with alkyl or hydroxyl groups １－４ C substituted with alkyl or cyano groups １－４ Alkyl group, C １－４ Alkoxy group, C ３－６ is further substituted with 0-4 substituents selected from a cycloalkyl group, a phenyl group, a 3- to 6-membered heterocycloalkyl group, or a 5- to 6-membered heteroaryl group, said heterocycloalkyl group or heteroaryl group containing 1-3 heteroatoms selected from O, S, and N; R ａ Or R ｂ are each independently selected from H, F, Cl, Br, I, cyano, OH, =0, methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclohexyl, cyclopentyl, cyclobutyl, azetidinyl, azacyclopentyl, azacyclohexyl, piperidinyl, methoxy or ethoxy, and the methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclohexyl, cyclopentyl, cyclobutyl, azetidinyl, azacyclopentyl, azacyclohexyl, piperidinyl, methoxy or ethoxy groups are optionally selected from H, F, Cl, Br, I, OH, =0, cyano, NH ２ , C １－４ Alkyl group, halogen-substituted C １－４ C substituted with alkyl or hydroxyl groups １－４ C substituted with alkyl or cyano groups １－４ Alkyl group, C １－４ Alkoxy group or C ３－６ is further substituted with 0 to 4 substituents selected from cycloalkyl groups; L is, 【Chemistry 18】 The left side of L is connected to ring A, and the oxazolyl, thiazolyl, thienyl, furyl, pyrrolyl, pyrazolyl, triazolyl, or imidazolyl group is optionally selected from H, F, Cl, Br, I, OH, a cyano group, NH ２ , further substituted with 0 to 2 substituents selected from a methyl group, an ethyl group, a propyl group, an isopropyl group, a methoxy group, and an ethoxy group; R １ is selected from H, a methyl group, an ethyl group, a propyl group, and an isopropyl group; R ２ａ , R ２ｂ , R ３ａ , R ３ｂ are each independently selected from H, F, Cl, Br, I, cyano, OH, =0, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy or cyclopropyl, and the methyl, ethyl, propyl, isopropyl, methoxy, ethoxy or cyclopropyl groups are optionally selected from H, F, Cl, Br, I, OH, =0, cyano, NH ２ , C １－４ Alkyl group, halogen-substituted C １－４ C substituted with alkyl or hydroxyl groups １－４ C substituted with alkyl or cyano groups １－４ Alkyl group, C １－４ Alkoxy group or C ３－６ is further substituted with 0 to 4 substituents selected from cycloalkyl groups; R ｃｎ１ , R ｃｎ２ each independently represents H, F, Cl, Br, I, a cyano group, OH, =O, a methyl group, an ethyl group, a propyl group, an isopropyl group, a cyclopropyl group, a cyclohexyl group, a cyclopentyl group, a cyclobutyl group, an azetidinyl group, an azacyclopentyl group, an azacyclohexyl group, or 【Chemistry 19】 wherein the methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclohexyl, cyclopentyl, cyclobutyl, azetidinyl, azacyclopentyl, and azacyclohexyl groups are optionally selected from H, F, Cl, Br, I, OH, ═O, cyano, NH ２ , C １－４ Alkyl group, halogen-substituted C １－４ C substituted with alkyl or hydroxyl groups １－４ C substituted with alkyl or cyano groups １－４ Alkyl group, C １－４ Alkoxy group or C ３－６ is further substituted with 0 to 4 substituents selected from cycloalkyl groups; Ring C1 is a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, an oxetanyl group, an oxacyclopentyl group, an oxacyclohexyl group, an azetidinyl group, an azacyclopentyl group, piperidine, morpholine, piperazine, 1,4-diazepanyl group, a cyclopropyl-fused cyclopentyl, a cyclopentyl-fused cyclobutyl, a cyclopentyl-fused cyclopentyl, a cyclopentyl-fused cyclohexyl, a cyclopropyl-spiro-cyclopentyl, a cyclobutyl-spiro-cyclobutyl, a cyclobutyl-spiro-cyclopentyl, Cyclopentyl-spiro-cyclopentyl, cyclopentyl-spiro-cyclohexyl, cyclohexyl-spiro-cyclohexyl, cyclopropyl-fused azetidinyl, cyclopropyl-fused azacyclopentyl, cyclopropyl-fused azacyclohexyl, cyclobutyl-fused azetidinyl, cyclobutyl-fused azacyclopentyl, cyclobutyl-fused azacyclohexyl, cyclopentyl-fused azetidinyl, cyclopentyl-fused azacyclopentyl, cyclopentyl-fused azacyclohexyl, cyclohexyl-fused azetidinyl, cyclohexyl-fused azacyclopentyl, azacyclopentyl, cyclohexyl-fused azacyclohexyl, azetidinyl-fused azetidinyl, azetidinyl-fused azacyclopentyl, azetidinyl-fused azacyclohexyl, azacyclopentyl-fused azetidinyl, azacyclopentyl-fused azacyclopentyl, azacyclopentyl-fused azacyclohexyl, azacyclohexyl-fused azetidinyl, azacyclohexyl-fused azacyclopentyl, azacyclohexyl-fused azacyclohexyl, cyclobutyl-spiro-azetidinyl, cyclobutyl-spiro-azacyclopentyl, cyclobutyl- spiro-azacyclohexyl, cyclopentyl-spiro-azetidinyl, cyclopentyl-spiro-azacyclopentyl, cyclopentyl-spiro-azacyclohexyl, cyclohexyl-spiro-azetidinyl, cyclohexyl-spiro-azacyclopentyl, cyclohexyl-spiro-azacyclohexyl, azetidinyl-spiro-azetidinyl, azetidinyl-spiro-azacyclopentyl, azetidinyl-spiro-azacyclohexyl, azacyclopentyl-spiro-azetidinyl, azacyclopentyl-spiro-azacyclopentyl, azacyclopentyl-spiro-azacyclopentyl,azacyclopentyl-spiro-azacyclohexyl, azacyclohexyl-spiro-azetidinyl, azacyclohexyl-spiro-azacyclopentyl, azacyclohexyl-spiro-azacyclohexyl, oxetanyl group, oxacyclopentyl group, oxacyclohexyl group, cyclopropyl fused oxetanyl, cyclopropyl fused oxacyclopentyl, cyclopropyl fused oxacyclohexyl, cyclobutyl fused oxetanyl, cyclobutyl fused oxacyclopentyl, cyclobutyl fused oxacyclohexyl, cyclopentyl fused oxetanyl, Cyclopentyl-fused oxacyclopentyl, cyclopentyl-fused oxacyclohexyl, cyclohexyl-fused oxetanyl, cyclohexyl-fused oxacyclopentyl, cyclohexyl-fused oxacyclohexyl, azetidinyl-fused oxetanyl, azetidinyl-fused oxacyclopentyl, azetidinyl-fused oxacyclohexyl, azacyclopentyl-fused oxetanyl, azacyclopentyl-fused oxacyclopentyl, azacyclopentyl-fused oxacyclohexyl, azacyclohexyl-fused oxetanyl, azacyclohexyl-fused oxacyclopentyl , azacyclohexyl-fused oxacyclohexyl, cyclobutyl-spiro-oxetanyl, cyclobutyl-spiro-oxacyclopentyl, cyclobutyl-spiro-oxacyclohexyl, cyclopentyl-spiro-oxetanyl, cyclopentyl-spiro-oxacyclopentyl, cyclopentyl-spiro-oxacyclohexyl, cyclohexyl-spiro-oxetanyl, cyclohexyl-spiro-oxacyclopentyl, cyclohexyl-spiro-oxacyclohexyl, azetidinyl-spiro-oxetanyl, azetidinyl-spiro-oxacyclo pentyl, azetidinyl-spiro-oxacyclohexyl, azacyclopentyl-spiro-oxetanyl, azacyclopentyl-spiro-oxacyclopentyl, azacyclopentyl-spiro-oxacyclohexyl, azacyclohexyl-spiro-oxetanyl, azacyclohexyl-spiro-oxacyclopentyl, azacyclohexyl-spiro-oxacyclohexyl, bicyclo[2.1.1]hexanyl, bicyclo[2.2.1]heptanyl, bicyclo[3.3.2]decanyl, bicyclo[2.2.2]octyl, bicyclo[3.2.1]octyl,bicyclo[3.3.3]undecyl, adamantyl group, 【Chemistry 20】 is selected from R ｃ１ are each independently selected from H, F, Cl, Br, I, cyano, OH, =0, methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclohexyl, cyclopentyl, cyclobutyl, azetidinyl, azacyclopentyl, piperidinyl, piperazinyl, methoxy or ethoxy, and the methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclohexyl, cyclopentyl, cyclobutyl, azetidinyl, azacyclopentyl, piperidinyl, piperazinyl, methoxy or ethoxy groups are optionally selected from H, F, Cl, Br, I, OH, =0, cyano, NH ２ , C １－４ Alkyl group, halogen-substituted C １－４ C substituted with alkyl or hydroxyl groups １－４ C substituted with alkyl or cyano groups １－４ Alkyl group, C １－４ Alkoxy group or C ３－６ is further substituted with 0 to 4 substituents selected from cycloalkyl groups; One option is R ｃｎ１ and R ｃｎ２ together with the carbon atoms bonded thereto, represent a substituted or unsubstituted azetidinyl group, azacyclopentyl group, piperidine, piperazine, azetidinyl-fused cyclopropyl, azetidinyl-fused cyclobutyl, azetidinyl-fused cyclopentyl, azetidinyl-fused cyclohexyl, azacyclopentyl-fused cyclopropyl, azacyclopentyl-fused cyclobutyl, azacyclopentyl-fused cyclopentyl, azacyclopentyl-fused cyclohexyl, azacyclohexyl-fused cyclopropyl, azacyclohexyl-fused cyclobutyl, azacyclohexyl-fused cyclopentyl, azacyclohexyl-fused cyclohexyl, azetidinyl-fused azetidinyl, azetidinyl-fused azacyclopentyl, azetidinyl-fused azacyclohexyl, azacyclopentyl-fused azetidinyl, azacyclopentyl-fused azacyclopentyl, azacyclohexyl-fused aza Cyclohexyl, azacyclohexyl-fused azetidinyl, azacyclohexyl-fused azacyclopentyl, azacyclohexyl-fused azacyclohexyl, azetidinyl-spiro-azetidinyl, azetidinyl-spiro-azacyclopentyl, azetidinyl-spiro-azacyclohexyl, azacyclopentyl-spiro-azetidinyl, azacyclopentyl-spiro-azacyclopentyl, azacyclopentyl-spiro- azacyclohexyl, azacyclohexyl-spiro-azetidinyl, azacyclohexyl-spiro-azacyclopentyl, azacyclohexyl-spiro-azacyclohexyl, azacyclopentyl-spiro-cyclobutyl, azacyclopentyl-spiro-cyclopentyl, azacyclohexyl-spiro-cyclobutyl, azacyclohexyl-spiro-cyclopentyl, azacyclohexyl-spiro-cyclohexyl, 【Chemistry 21】 and optionally, when substituted, H, halogen, OH, =O, cyano group, NH ２ , C １－４ Alkyl group, halogen-substituted C １－４ C substituted with alkyl or hydroxyl groups １－４ C substituted with alkyl or cyano groups １－４ Alkyl group, C １－４ Alkoxy group or C ３－６ 11. The compound of claim 10, or a stereoisomer, tautomer, deuteride, solvate, prodrug, metabolite, pharma- ceutically acceptable salt, or co-crystal thereof, further substituted with 0 to 4 substituents selected from cycloalkyl groups.

12. R ａｎ is selected from H, a methyl group, an ethyl group, a propyl group, an isopropyl group, and a cyclopropyl group, and the methyl group, the ethyl group, the propyl group, the isopropyl group, and the cyclopropyl group are optionally selected from H, F, Cl, Br, I, OH, ═O, a cyano group, NH ２ , a methyl group, an ethyl group, a propyl group, an isopropyl group, a vinyl group, a 1-propenyl group, a 2-propenyl group, an ethynyl group, a 1-propynyl group, a 2-propynyl group, 【Chemical 22】 further substituted with 0 to 4 substituents selected from cyclopropyl, methoxy, ethoxy, and phenyl; R ａ Or R ｂ are each independently selected from H, F, Cl, Br, I, cyano, OH, =O, methyl, ethyl, propyl, isopropyl, and cyclopropyl, and the methyl, ethyl, propyl, isopropyl, or cyclopropyl groups are optionally selected from H, F, Cl, Br, I, OH, =O, cyano, NH ２ , C １－４ Alkyl group, halogen-substituted C １－４ C substituted with alkyl or hydroxyl groups １－４ C substituted with alkyl or cyano groups １－４ Alkyl group, C １－４ Alkoxy group or C ３－６ is further substituted with 0 to 4 substituents selected from cycloalkyl groups; R ｃｎ１ , R ｃｎ２ each independently represents H, F, Cl, Br, I, a cyano group, OH, =O, a methyl group, an ethyl group, a propyl group, an isopropyl group, a cyclopropyl group, a cyclohexyl group, a cyclopentyl group, a cyclobutyl group, or 【Chemistry 23】 wherein the methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclohexyl, cyclopentyl, and cyclobutyl groups are optionally selected from H, F, Cl, Br, I, OH, ═O, cyano, NH ２ , C １－４ Alkyl group, halogen-substituted C １－４ C substituted with alkyl or hydroxyl groups １－４ C substituted with alkyl or cyano groups １－４ Alkyl group, C １－４ Alkoxy group or C ３－６ is further substituted with 0 to 4 substituents selected from cycloalkyl groups; Ring C1 is a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, an oxetanyl group, an oxacyclopentyl group, an oxacyclohexyl group, an azetidinyl group, an azacyclopentyl group, piperidine, morpholine, piperazine, 1,4-diazepanyl group, a cyclopropyl-fused cyclopentyl, a cyclopentyl-fused cyclobutyl, a cyclopentyl-fused cyclopentyl, a cyclopentyl-fused cyclohexyl, 【Chemistry 24】 selected from bicyclo[2.1.1]hexanyl, bicyclo[2.2.1]heptanyl, bicyclo[3.3.2]decanyl, bicyclo[2.2.2]octyl, bicyclo[3.2.1]octyl, bicyclo[3.3.3]undecyl, and adamantyl groups; R ｃ１ are each independently selected from H, a methyl group, an ethyl group, a propyl group, an isopropyl group, a cyclopropyl group, a methoxy group, or an ethoxy group, and the methyl group, the ethyl group, the propyl group, the isopropyl group, the cyclopropyl group, the methoxy group, or the ethoxy group is optionally selected from H, F, Cl, Br, I, OH, ═O, a cyano group, NH ２ , C １－４ Alkyl group, halogen-substituted C １－４ C substituted with alkyl or hydroxyl groups １－４ C substituted with alkyl or cyano groups １－４ Alkyl group, C １－４ Alkoxy group or C ３－６ is further substituted with 0 to 4 substituents selected from cycloalkyl groups; One option is R ｃｎ１ and R ｃｎ２ together with the carbon atoms bonded to them form a substituted or unsubstituted azetidinyl group, azacyclopentyl group, piperidine, piperazine, azacyclopentyl-spiro-cyclobutyl, azacyclopentyl-spiro-cyclopentyl, azacyclohexyl-spiro-cyclobutyl, azacyclohexyl-spiro-cyclopentyl, azacyclohexyl-spiro-cyclohexyl, and optionally, when substituted, H, F, Cl, Br, I, OH, ═O, a cyano group, NH ２ , C １－４ Alkyl group, halogen-substituted C １－４ C substituted with alkyl or hydroxyl groups １－４ C substituted with alkyl or cyano groups １－４ Alkyl group, C １－４ Alkoxy group or C ３－６ 12. The compound of claim 11, or a stereoisomer, tautomer, deuteride, solvate, prodrug, metabolite, pharma- ceutically acceptable salt, or co-crystal thereof, further substituted with 0 to 4 substituents selected from cycloalkyl groups.

13. Ring A is 【Chemistry 25】 is selected from L is, 【Chemistry 26】 and its left side is connected to ring A; R ａ Or R ｂ are each independently H, F, Cl, Br, I, a cyano group, OH, ═O, or CF ３ , a methyl group, an ethyl group, a propyl group, an isopropyl group, a cyclopropyl group; R ２ａ , R ２ｂ , R ３ａ , R ３ｂ are each independently selected from H; R ｃｎ１ , R ｃｎ２ each independently represents H, a methyl group, an ethyl group, a propyl group, an isopropyl group, a cyclopropyl group, a cyclohexyl group, a cyclopentyl group, a cyclobutyl group, or 【Chemical 27】 wherein the methyl, ethyl, propyl, isopropyl, cyclopropyl, cyclohexyl, cyclopentyl, and cyclobutyl groups are optionally selected from H, F, Cl, Br, I, OH, ═O, cyano, NH ２ , C.F. ３ , further substituted with 0 to 4 substituents selected from methyl, ethyl, propyl, isopropyl, cyclopropyl, methoxy, or ethoxy groups; Ring C1 is a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cyclopentyl-fused cyclobutyl group, or 【Chemistry 28】 is selected from R ｃ１ are each independently selected from H, F, and Cl; One option is R ｃｎ１ and R ｃｎ２ together with the carbon atoms bonded to them form a substituted or unsubstituted azetidinyl group, azacyclopentyl group, piperidine, piperazine, azacyclopentyl-spiro-cyclobutyl, azacyclopentyl-spiro-cyclopentyl, azacyclohexyl-spiro-cyclobutyl, azacyclohexyl-spiro-cyclopentyl, azacyclohexyl-spiro-cyclohexyl, and optionally, when substituted, H, F, Cl, Br, I, OH, ═O, a cyano group, NH ２ , C.F. ３ , further substituted with 0 to 4 substituents selected from methyl, ethyl, propyl, isopropyl, cyclopropyl, methoxy, or ethoxy groups; m is selected from 0 or 1; n is selected from 0 or 1; s is selected from 0 or 1; 13. The compound of claim 12, or a stereoisomer, tautomer, deuteride, solvate, prodrug, metabolite, pharma- ceutically acceptable salt, or co-crystal thereof, wherein t is selected from 0, 1, or 2.

14. The compound of claim 1, or a stereoisomer, tautomer, deuteride, solvate, prodrug, metabolite, pharma- ceutically acceptable salt, or co-crystal thereof, wherein the compound is selected from one of the structures shown in Table S-1 or Table S-2.

15. 15. A pharmaceutical composition comprising a compound according to any one of claims 1 to 14 or a stereoisomer, tautomer, deuteride, solvate, prodrug, metabolite, pharma- ceutically acceptable salt or co-crystal thereof, and a pharma- ceutically acceptable carrier, preferably the pharmaceutical composition comprises 1 to 1500 mg of the compound according to any one of claims 1 to 14 or a stereoisomer, deuteride, solvate, prodrug, metabolite, pharma- ceutically acceptable salt or co-crystal thereof.

16. Use of a compound according to any one of claims 1 to 15 or a stereoisomer, tautomer, deuterated form, solvate, prodrug, metabolite, pharma- ceutically acceptable salt or co-crystal thereof in the manufacture of a medicament for the treatment of a disease associated with the inhibition of the METTL3 enzyme.

17. 17. The application according to claim 16, characterized in that the disease is selected from cancer.

18. 15. A method for treating a disease in a mammal, said method comprising administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 14 or a stereoisomer, deuterated form, solvate, prodrug, metabolite, pharma- ceutically acceptable salt or co-crystal thereof, wherein the therapeutically effective amount is preferably 1 to 1500 mg, and wherein the disease is preferably cancer.

Images